[go: up one dir, main page]

WO2009055783A2 - Anti-pcsk9 and methods for treating lipid and cholesterol disorders - Google Patents

Anti-pcsk9 and methods for treating lipid and cholesterol disorders Download PDF

Info

Publication number
WO2009055783A2
WO2009055783A2 PCT/US2008/081311 US2008081311W WO2009055783A2 WO 2009055783 A2 WO2009055783 A2 WO 2009055783A2 US 2008081311 W US2008081311 W US 2008081311W WO 2009055783 A2 WO2009055783 A2 WO 2009055783A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloride
antibody
antigen
cdr
pcsk9
Prior art date
Application number
PCT/US2008/081311
Other languages
French (fr)
Other versions
WO2009055783A3 (en
Inventor
Joseph A. Hedrick
Frederick James Monsma, Jr.
Tatyana Churakova
Diane Hollenbaugh
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/739,761 priority Critical patent/US8598320B2/en
Priority to CA2703712A priority patent/CA2703712A1/en
Priority to CN2008801235736A priority patent/CN102232088A/en
Priority to EP08841231.7A priority patent/EP2205639B1/en
Priority to JP2010531314A priority patent/JP2011501952A/en
Priority to AU2008316587A priority patent/AU2008316587B2/en
Priority to BRPI0818765A priority patent/BRPI0818765A8/en
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to MX2010004454A priority patent/MX2010004454A/en
Priority to NZ584902A priority patent/NZ584902A/en
Publication of WO2009055783A2 publication Critical patent/WO2009055783A2/en
Publication of WO2009055783A3 publication Critical patent/WO2009055783A3/en
Priority to IL205323A priority patent/IL205323A0/en
Priority to US14/094,560 priority patent/US20140161798A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the field of the present invention relates to methods and compositions for treating disorders of cholesterol homeostasis by administering an anti-PCSK9 antibody or antigen- binding fragment thereof,
  • Atherosclerotic coronary heart disease represents the major cause for death and cardiovascular morbidity in the western world.
  • Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes metlitus, family history, male gender, cigarette smoke, high serum cholesterol, high low density lipoprotein (LDL) cholesterol levels and low high density lipoprotein (HDL) cholesterol levels.
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • a total cholesterol level in excess of about 225-250 mg/dl is associated with significant elevation of risk of CHD.
  • HMG-CoA reductase inhibiting drugs Antagonize HfVIG-CoA reductase and cholesterol synthesis in the iiver and increase the number of hepatic LDL receptors on the DCi- surface to enhance uptake and catabolism of LDL, A drawback of such an approach is that these drugs commonly suffer from a disadvantageous side-effect profile, including, for example, liver toxicity.
  • An alternate approach is to modulate the LDL receptor pathway directly.
  • PCSK9 Cpr ⁇ proteln convertase subtilisin/kexin type 9 is a serine protease family member that binds to ana regulates LDL receptor expression on the surface of celts.
  • Inhibition of the LDL receptor ⁇ PCSK9 interaction is an attractive approach to the treatment of cholesterol disorders. Inhibition of interactions between large proteins (i.e., protein- protein interactions or PPI) by the use of antibodies or small molecule inhibitors is, however, generally regarded as being particularly difficult and challenging. Large proteins such as PCSK9, with a mofecuSar weight of about 74 KDa 1 and LDLR 5 with a molecular weight of about 160 KDa (glycosylated on cell surface; 115 KDa in immature form), are likely to exhibit extensive intermolecular contacts over a large area. The existence of extensive contacts makes it unlikely that a given antibody or small molecule inhibitor will successfully block their binding.
  • the present invention surprisingly has overcome the technical difficuities associated with the blocking of intermolecuJar interactions between large proteins and has demonstrated that blockage of the PCSK9-LDLR interaction with an antibody or peptide is possible. As discussed in detail herein, this, in turn, provides a novel method by which to treat cholesterol disorders.
  • the present invention provides, in part, a method for reducing total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total cholesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio, in a subject (e.g., a human), comprising administering, to said subject, a therapeutically effective amount of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody, polyclonal antibody or recombinant antibody) or EGF-A polypeptide that binds specifically to PCSK9 which antibody or fragment or polypeptide inhibits binding between PCSK9 and LDL receptor; optionally in association with a further chemotherapeutic agent (e.g., ezetimibe and/or simvastatin).
  • an antibody or antigen-binding fragment thereof e.g., monoclonal antibody, polyclonal antibody or recombinant antibody
  • EGF-A polypeptide that binds specifically to PCSK9 which antibody or fragment or poly
  • the present invention further provides, in part, a method for treating or preventing hypercholesterolemia, hyperlipidernia, hypertriglyceridaemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma, in an subject, comprising administering, to said subject, a therapeutically effective amount of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody, polyclonal antibody or recombinant antibody) or EGF-A polypeptide that binds specifically to PCSK9, which antibody or fragment or polypeptide inhibits binding between PC-SK9 and LDL receptor; optionally in association with a further therapeutic agent (e.g., ezetimibe and/or simvastatin), fn an embodiment of the invention, the antibody or fragment or EGF-A polypeptide binds specifically to a PCSK9 catalytic domain or to a domain of PCSK9 which interacts with an LDL receptor EGF-A domain.
  • the present invention also provides, in part, a pharmaceutical composition
  • a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody, polyclonal antibody or recombinant antibody) or EGF-A polypeptide which binds specifically to PCSK9, which antibody or fragment or polypeptide inhibits binding between PCSK9 and LDL receptor, and a pharmaceutically acceptable carrier; optionally in association with a further chemotherapeutic agent (e.g., ezetimibe and/or simvastatin).
  • an antibody or antigen-binding fragment thereof e.g., monoclonal antibody, polyclonal antibody or recombinant antibody
  • EGF-A polypeptide which binds specifically to PCSK9, which antibody or fragment or polypeptide inhibits binding between PCSK9 and LDL receptor
  • a pharmaceutically acceptable carrier optionally in association with a further chemotherapeutic agent (e.g., ezetimibe and/or simvastatin).
  • the present invention also provides an isolated polypeptide comprising an amino acid sequence comprising about 90% or more amino acid sequence similarity to a fragment of the human LDL receptor which fragment consists of amino acids beginning at about amino acid position 314 and ending at about amino acid position 355 of said receptor wherein said polypeptide; wherein said polypeptide optionally comprises one or more properties selected from the group consisting of: (i) binds to PCSK9; (ii) competes with LDL receptor or an anti-PCSK9 antibody or antigen-binding fragment thereof for binding to PCSK9; (iii) reduces total cholesterol level when administered to an animal; (iv) reduces low density lipoprotein cholesteroi level when administered to an animal; (v) reduces apolipoprotein B level when administered to an animal; (vi) reduces total cholesterol/high density lipoprotein ratio when administered to an animal; and (vii) reduces low density lipoprotein/high density lipoprotein ratio when administered to an animal; or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier.
  • the polypeptide consists of the amino acid sequence of SEQ ID NO: 3; or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier.
  • the present invention provides an isolated antibody or antigen-binding fragment thereof comprising one or more members selected from the group consisting of: (i) CDR-HI 5 CDR-H2 and CDR-H3 of the variable region the 11B5 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 10; (ii) CDR-H1 , CDR-H2 and CDR-H3 of the variable region the 75B9 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 18; (iii) CDR-H1, CDR-H2 and CDR-H3 of the variable region the 77D10 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 26; (iv) CDR-Hl 5 CPR-H2 and CDR-H3 of the variable region the 29C10 heavy chain immunoglobulin which comprises the
  • the present invention also provides an isolated antibody or antigen-binding fragment thereof comprising one or more members selected from the group consisting of: (i) HCDR1 comprising the amino acid sequence G F N I K D T Y M H(SEQIDNO: 11), HCDR2 comprising the amino acid sequence R I D P A N G H T E Y D P K F Q D(SEQ ID NO: 12) and HCDR3 comprising the amino acid sequence s Y F G S i F A Y (SEQ ID NO: 13); (it) HCDR1 comprising the amino acid sequence G F N I K D T Y i H(SEQ IDNO: 19), HCDR2 comprising the amino acid sequence R i D P A N G H T E Y D P K F Q G (SEQ ID NO: 20) and HCDR3 comprising the amino acid sequences Y Y G S I F A Y (SEQ ID NO: 21); (iii) HCDR1 comprising the amino acid sequence G F N I K D ⁇
  • LCDR1 comprising the amino acid sequence R A s Q D I s N Y L N(SEQID NO: 39), LCDR2 comprising the amino acid sequence Y s s R L H s (SEQIDNO: 40) and LCDR3 comprising the amino acid sequence Q Q G K T L P L T (SEQID NO: 41);
  • LCDR1 comprising the amino acid sequence R S S Q S L V Y S D G N T Y L H (SEQ ID NO: 47), LCDR2 comprising the amino acid sequence R v S N R F s (SEQ ID NO: 48) and LCDR3 comprising the amino acid sequence L Q S T H F P P T (SEQ ID NO: 49); and
  • LCDR1 comprising the amino acid sequence K A S Q N V G T N v v (SEQ ID NO: 55), LCDR2 comprising the amino acid sequence s A S Y R Y s (SEQ ID NO: 56) and LCDR3 comprising the amino acid sequence
  • the present Invention provides an isolated antibody or antigen-binding fragment thereof of claim xxx comprising one or more members selected from the group consisting of: (a) an immunoglobulin heavy chain comprising the amino acid sequence: E V Q L Q Q S G A E L V K P G A S V T L S C T A S G F M I K D T Y M H W V N Q R P E Q G L V W I G R I D P A M G H T E Y E P K F Q D K A T I T T D T S S N T A Y L K L S S L T S G D T A V Y Y C A R S;
  • compositions comprising any of the antibodies or polypeptides of the present invention association with a further chemotherapeutic agent, e.g., a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor, in an embodiment of the invention, the further chemotherapeutic agent is ezettmibe, lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin.
  • a further chemotherapeutic agent e.g., a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a coronary vasodilator, a di
  • diacetolol hydrochloride diacetolol hydrochloride, dilevalol hydrochloride, exaprolof hydrochloride, flestofol sulfate, metatol hydrochloride, metoprofol 2-Propanoi, metoprolol tartrate, pamatoiol sulfate, penbutofof sulfate, practoloi, tiprenolol hydrochloride or toiamolol.
  • Embodiments of the invention also include those wherein the antibody or fragment is a humanized antibody, a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti-idiotypic antibody, a humanized antibody, a bispecific antibody, a cameltzed single domain antibody, a diabody, an scfv, an scfv dimer, a dsfv, a (dsfv) 2 , a dsFv-dsfv ⁇ a bispecific ds diabody, an Fv.
  • the antibody or fragment is a humanized antibody, a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti-idiotypic antibody, a humanized antibody, a
  • the antibody or antigen-binding fragment thereof is linked to an immunoglobulin constant region, e.g., a K light chain, ⁇ 1 heavy chain, ⁇ 2 heavy chain, ⁇ 3 heavy chain or ⁇ 4 heavy chain.
  • the present invention also provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of the present invention in association with a pharmaceutically acceptable carrier.
  • the present invention also provides a method for reducing total cholesterol ievel; low density lipoprotein cholesterol level; realizeipoprotein B level; total cholesterol/high density lipoprotein ratio; or low density lipoprotein/high density lipoprotein ratio; or for treating hypercholesterolemia; hyperfipidemia; hypertriglyceridaemia; sitosteroiemia; atherosclerosis; arteriosclerosis; coronary heart disease; vascular inflammation; or xanthoma, in a subject, comprising administering, to said subject, a therapeutically effective amount of any polypeptide or antibody or antigen-binding fragment thereof of the present invention as set forth herein; or pharmaceutical composition thereof; optionally, in association with a further chemotherapeutic agent, e.g., as set forth herein.
  • a further chemotherapeutic agent e.g., as set forth herein.
  • the present invention also provides a method for producing an antibody or antigen-binding fragment therof of claim 1 comprising introducing one or more polynucleotides into one or more host cells; which polynucleotides encodes and direct expression of said heavy and/or light chain immunoglobulins; and growing said host cells under conditions whereby said heavy and light chain immunoglobulins are expressed; e.g.. wherein said polynucleotide encoding and directing expression of said light chain and said polynucleotide encoding and directing expression of said heavy chain are in separate host ceJSs.
  • the present invention includes methods and compositions for an innovative method lor treating cholesterol disorders.
  • the methods and compositions of the present invention are useful for treating cholesterol disorders by modulating the LDL receptor pathway.
  • the methods and compositions of the present invention antagonize the interaction between PCSK9 and LDLR and thereby lead to increased clearance of LDL from the bloodstream,
  • the present invention provides a method for targeting and blocking this interaction, thus, leading to a beneficial effect with regard to blood cholesterol levels.
  • low density lipoprotein receptor includes any such receptor, e.g., human LDLR along with any allelic variant thereof, in one embodiment of the invention, full-length LDLR comprises the following amino acid sequence (see e.g., GenBank NM_G00527.2);
  • a soluble LDLR fragment comprises the following amino acid sequence (Yamamoto ef a/., Cell (1984) 39:27 - 38):
  • the EGF-A domain of LDL receptor comprises the amino acid sequence (SEQ ID NO: 3)
  • the term ''subject includes any animal, e.g., a mammal such as a human.
  • PCSK9 The present invention includes compositions and methods comprising antibodies and antigen-binding fragment thereof which bind specifically to PCSK9, for example, human PCSK9.
  • specific PCSK9 polypeptide sequences or antigenic fragments thereof from various species set forth below may be used as an antigen:
  • the present invention also provides methods for reducing total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total chotesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio, in a subject, by administering, to the subject, a polypeptide comprising an LDL receptor EGF-A domain optionally in association with a further chemotherapeut ⁇ c agent (e.g., as set forth herein) or a pharmaceutical composition thereof which composes a pharmaceutically acceptable carrier.
  • a polypeptide comprising an LDL receptor EGF-A domain optionally in association with a further chemotherapeut ⁇ c agent (e.g., as set forth herein) or a pharmaceutical composition thereof which composes a pharmaceutically acceptable carrier.
  • the EGF-A domain of LDL receptor binds to PCSK9 and, without being bound by any particular theory or mechanism, may reduce the activity of PCSK9 by competing with the full, endogenous LDL receptor for binding to PCSK9
  • the EGF-A domain comprises or consists of the following amino acid sequence
  • human LDL receptor comprises the following amino acid sequence:
  • EGF-A domain is underscored and in bold faced text. See also Genbank accession nos.: NP_000518, EAW84170, BAD92646.1 or AAF24515.1.
  • the present invention also comprises an isolated polypeptide comprising or consisting of an EGF-A polypeptide, for example, in a pharmaceutical composition which includes a pharmaceutically acceptable carrier.
  • the present invention also provides such a polypeptide optionally fused to any other heterologous polypeptide which is not naturally contiguous with the other, immediately adjacent LDL receptor sequences as well as methods of treatments comprising administration of the fused polypeptide e.g., as discussed herein, Any such polypeptide may be referred to herein as an "EGF-A polypeptide" and a polynucleotide encoding an EGF-A polypeptide may be referred to as an "EGF-A polynucleotide".
  • the EGF-A polynucleotide comprises the following nucleotide sequence:
  • the present invention also includes fusions which include the
  • the fused polypeptides of the invention may be conveniently constructed, for example, by insertion of a polynucleotide of the invention or fragment thereof into an expression vector.
  • the fusions of the invention may include tags which facilitate purification or detection. Such tags include glutathtone-S-transferase (GST), hexahistidine (His6) tags, maltose binding protein (MBP) tags, haemagglutinin (HA) tags, cellulose binding protein (CBP) tags and myc tags.
  • Detectable tags such as 32 P 1 35 S 5 3 H 1 14 C, 18 F, 125 I 1 131 I 1 11301 In, 76 Br, 67 Ga, " 111 Tc, 1 23 S, 111 In and 68 Ga may also be used to label the polypeptides and polynucleotides of the invention. Methods for constructing and using such fusions are very conventional and well known in the art. Any isolated polynucleotide encoding such an EGF-A polypeptide of the present invention also forms part of the present invention along with any vector comprising such a polynucleotide and a host cell (e.g., bacterial host cell or eukaryotic cell) comprising such a vector.
  • a host cell e.g., bacterial host cell or eukaryotic cell
  • promoter Such polynucleotides operably associated with an expression control sequence (e.g., a promoter) also form part of the present invention.
  • a "promoter” or “promoter sequence” is a DNA regulatory region capable of binding an RNA polymerase in a cell (e.g., directly or through other promoter- bound proteins or substances) and initiating transcription of a coding sequence.
  • a promoter sequence is, in general, bounded at its 3' terminus by the transcription initiation site and extends upstream (5 1 direction) to include the minimum number of bases or elements necessary to initiate transcription at any level.
  • a transcription initiation site (conveniently defined, for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
  • the promoter may be operably associated with other expression control sequences, including enhancer and repressor sequences or with a nucleic acid of the invention. Promoters which may be used to control gene expression include, but are not limited to, cytomegalovirus (CMV) promoter (U.S. Patent Nos.
  • CMV cytomegalovirus
  • a coding sequence is "under the control of”, “functionally associated with” or “operably associated with” transcriptional and translational control sequences in a cell or other expression system when the sequences direct RNA polymerase mediated transcription of the coding sequence into RNA, preferably mRNA, which then may be RNA spliced (if it contains introns) and, optionally, translated into a protein encoded by the coding sequence.
  • express and expression mean allowing or causing the information in a gene, RNA or DNA sequence to become manifest; for example, producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene.
  • a DNA sequence is expressed in or by a cell to form an "expression product” such as an RNA (e.g., mRNA) or a protein.
  • the expression product itself may also be said to be “expressed” by the cell.
  • the term 'Vector 51 includes a vehicle (e.g., a plasmid) by which a DNA or RNA sequence can be introduced into a host cell, so as to transform the host and, optionally, promote expression and/or replication of the introduced sequence.
  • Vectors that can be used in this invention include plasm ids, viruses, bacteriophage, integratable DNA fragments, and other vehicles that may facilitate introduction of the nucleic acids into the genome of the host.
  • Plasmids are the most commonly used form of vector but all other forms of vectors which serve a similar function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et ai, Cloning Vectors: A Laboratory Manual, 1985 and Supplements, Elsevier, N. Y., and Rodriguez et al. (eds.), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, 1988, Buttersworth, Boston, MA.
  • expression system includes ⁇ for example, a host cell and compatible vector which, under suitable conditions, can express a protein or nucleic acid which is carried by the vector and introduced to the host cell.
  • Common expression systems include E. co ⁇ host cells and plasmid vectors, insect host cells and Baculovirus vectors, and mammalian host cells and vectors.
  • Prokaryotic host-vector systems include a wide variety of vectors for many different species.
  • a representative vector for amplifying DNA is pBR322 or many of its derivatives ⁇ e.g., pUC18 or 19
  • Vectors that can be used to express the EGF-A polypeptides include, but are not limited to, those containing the lac promoter (pUC ⁇ series); trp promoter (pBR322-frp); Spp promoter (the pfN-s ⁇ r ⁇ s); Sambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540).
  • the present invention comprises methods of expression an EGF-A polypeptide of the present invention comprising introducing a vector comprising a polynucleotide encoding said polypeptide (e.g., operably associated with an expression control sequence such as a promoter) into a suitable host ceil and propagating (e.g., growing in a suitable liquid growth medium) the host cell under conditions which are suitable to expression of the polypeptide from the polynucleotide in the vector.
  • a vector comprising a polynucleotide encoding said polypeptide (e.g., operably associated with an expression control sequence such as a promoter) into a suitable host ceil and propagating (e.g., growing in a suitable liquid growth medium) the host cell under conditions which are suitable to expression of the polypeptide from the polynucleotide in the vector.
  • a vector comprising a polynucleotide encoding said polypeptide (e.g., operably associated with an expression control sequence such as
  • such a polypeptide must bind to PCSK9 or a functional fragment thereof; or inhibit binding of PCSK9 and LDL receptor or any functional fragment of either; or must exhibit the ability to reduce total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total choiesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio in a subject, such as an acceptable animal model (e.g., a mammal such as a dog, primate, rabbit, mouse or rat) or a human.
  • an acceptable animal model e.g., a mammal such as a dog, primate, rabbit, mouse or rat
  • the term "host cell” includes any cell of any organism that is selected, modified, transfected, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression or replication, by the cell, of a gene, a DNA or RNA sequence or a protein.
  • isolated polynucleotide or “isolated polypeptide” include a polynucleotide (e.g., RNA or DNA molecule, or a mixed polymer) or a polypeptide, respectively, which are partiaily or fully separated from other components that are normally found in cells or in recombinant DNA expression systems. These components include, but are not limited to, celi membranes, cell walls, ribosomes, polymerases, serum components and extraneous genomic sequences.
  • An isolated polynucleotide or polypeptide will, in an embodiment of the invention, be an essentially homogeneous composition of molecules but may contain some heterogeneity.
  • the present invention contemplates any superficial or slight modification to the amino acid or nucleotide sequences which correspond to the EGF-A polypeptides and polynucleotides of the invention.
  • sequence conservative variants of the nucleic acids which encode the EGF-A polypeptides of the invention are those in which a change of one or more nucleotides in a given codon results in no alteration in the amino acid encoded at that position.
  • Function- conservative variants of the EGF-A polypeptides of the invention are also contemplated by the present invention.
  • “Function-conservative variants” are those in which one or more amino acid residues in an EGF-A polypeptide have been changed without altering the overall conformation and/or function of the polypeptide (e.g., ability to bind to PCSK9 or inhibit binding of PCSK9 and an LDL receptor or fragment thereof), including, but, by no means limited to, replacement of an amino acid with one having similar properties.
  • Amino acids with similar properties are well known in the art. For example, polar/hydrophilic amino acids which may be interchangeable include asparagine.
  • nonpolar/hydrophobic amino acids which may be interchangeable include glycine, alanine, valine, leucine, isoieucine, proline, tyrosine, phenylalanine, tryptophan and methionine
  • acidic amino acids which may be interchangeable include aspartic acid and glutamic acid and baste amino acids which may be Interchangeable include histidine, lysine and arginine.
  • the present invention includes polynucleotides encoding EGF-A (e.g., SEQ ID NO: 9) and functional fragments thereof as well as nucleic acids which hybridize to the polynucleotides.
  • the nucleic acids hybridize under low stringency conditions, under moderate stringency conditions or under high stringency conditions.
  • a nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook, eta!., supra).
  • Typical low stringency hybridization conditions are 55 0 C, 5X SSC, 0.1% SDS, 0.25% milk, and no formamide at 42 0 C; or 30% formamide, 5X SSC, 0.5% SDS at 42 0 C.
  • Typical moderate stringency hybridization conditions are similar to the low stringency conditions except the hybridization is carried out in 40% formamide, with 5X or 6X SSC at 42 0 C.
  • High stringency hybridization conditions are similar to low stringency conditions except the hybridization conditions are carried out in 50% formamide, 5X or 6X SSC and, optionally, at a higher temperature (e.g., higher than 42 0 C: 57 0 C, 59 0 C, 60 0 C, 62 0 C, 63 0 C, 65 0 C or 68 0 C).
  • SSC is 0.15M NaCI and 0.015M Na-citrate.
  • Hybridization requires that the two nucleic acids contain complementary sequences, although, depending on the stringency of the hybridization, mismatches between bases are possible.
  • the appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art.
  • such a polynucleotide encodes a polypeptide that must bind to PCSK9 or a functional fragment thereof: or inhibit binding of PCSK9 and LDL receptor or any functional fragment of either; or must exhibit the ability to reduce total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total cholesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio in a subject, such as an acceptable animal model (e.g., a mammas such as a dog, primate, rabbit, mouse or rat) or a human.
  • an acceptable animal model e.g., a mammas such as a dog, primate, rabbit, mouse or rat
  • pofynucleotides comprising nucleotide sequences and polypeptides comprising amino acid sequences which are at least about 70% identical, preferably at least about 80% identical, more preferably at least about 90% identical and most preferably at least about 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to a reference nucleotide sequence (SEQ ID NO: 9) or reference amino acid sequence (SEQ ID NO; 3), when the comparison is performed by a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences.
  • Polypeptides comprising amino acid sequences which are at least about 70% similar, preferably at least about 80% similar, more preferably at least about 90% similar and most preferably at least about 95% similar (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to the reference EGF-A amino acid sequence of SEQ ID NO: 3, when the comparison is performed with a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences, are also included in the present invention.
  • Sequence identity refers to exact matches between the nucleotides or amino acids of two sequences which are being compared.
  • Sequence similarity refers to both exact matches between the amino acids of two polypeptides which are being compared in addition to matches between nonidenticai, biochemically related amino acids. Biochemically related amino acids which share similar properties and may be interchangeable are discussed above.
  • BLAST ALGORITHMS Attschul, S.F., etai, (1990) J. MoI. Biol. 215:403- 410; Gish, W,, et ai., (1993) Nature Genet 3:266-272; Madden, T.L., et ai, (1996) Meth. Enzymol. 266:131-141; Altschuf, S.F., etai., (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et ai., (1997) Genome Res. 7:649-656; Wootton, J.
  • the present invention includes methods and compositions comprising anti-PCSK9 antibodies and antigen-binding fragments thereof.
  • anti-PCSK9 antibody or the like includes any antibody that binds specifically to PCSK9 (e.g., human PCSK9).
  • the anti-PCSK9 antibodies and antigen-binding fragments thereof used in the present invention include antibodies and fragments which were raised against or bind to the whole PCSK9 protein as well as antibodies raised against or bind to particular short epitopes within PCSK9, e.g., the catalytic domain of PCSK9 or a portion thereof (e.g., binding to an VFAQSIPWNLER epitope (SEQ ID NO: 8)) or a C-terminal domain of PCSK9 (i.e., C- terminal relative to the cat domain of PCSK9)-having amino acids SRSGKRRGERMEA (amino acids 490-502 of SEQ ID NO: 4).
  • the anti- PCSK9 antibody or antigen-binding fragment thereof binds to the domain of PCSK9 which interacts with the EGF-A domain of the LDL receptor.
  • Specific isolated mouse anti-human PCSK9 antibody immunoglobulin sequences of the present invention are set forth below. CDR sequences for each immunoglobulin chain are underscored.
  • HCDR1 G F N I K D T Y M H (SEQ ID NO: 11)
  • HCDR2 R I D p A H G H T E Y D P K F Q D (SEQ ID NO: 12)
  • HCDR3 S Y F G S I F A Y (SEQ ID NO: 13)
  • the present invention includes isolated polypeptides (e.g., antibodies and antigen- binding fragments thereof) comprising one or more (e.g., 3) CDRs taken from the light and/or heavy chain immunoglobulin set forth above as defined by the convention set forth in Kabai "Sequences of Proteins of lmmunologicai Interest" (National Institutes of Health, Befhesda, Md,, 1987 and 1991 ⁇ or in Chotbia et aL J. MoL Bioi, 196:901 (1987); Nature 342:878 (1989 ⁇ ; and J. MoI. Biol. 186:651 (1989) (Kabat or Chothsa ⁇ or Al-Lazikani et aL, J. Mot.
  • isolated polypeptides e.g., antibodies and antigen- binding fragments thereof
  • one or more (e.g., 3) CDRs taken from the light and/or heavy chain immunoglobulin set forth above as defined by the convention set forth in Ka
  • the invention includes any antibody or antigen-binding fragment thereof comprising one or more of the light chain and/or heavy chain immunoglobulin CDRs set forth above, in an embodiment of the invention, the antibody or fragment comprises all 3 light chain and/or ail 3 heavy chain CDRs, e.g., in the order specified above.
  • Embodiments of the invention include anfi-PCSK9 antibodies and antigen-binding fragments thereof, e.g., as set forth above wherein, the antibodies or fragments are monoclonal antibodies, camelized single domain antibodies, polyclonal antibodies, bi ⁇ pecific antibodies, chimeric antibodies, recombinant antibodies, anti-idiotypic antibodies, humanized antibodies, bispecific antibodies, diabodies, single chain antibodies, disulfide Fvs (dsfv), Fvs, Fabs, Fab's, F(ab ! )aS and domain antibodies.
  • the term antibody covers, but is not limited to, monoclonal antibodies, polyclonal antibodies, muitispecific antibodies (e.g., bispecific antibodies).
  • antigen-binding fragment of an antibody encompasses a fragment or a derivative of an antibody, typically including at least a portion of the antigen-binding or variable regions (e.g., one or more CDRs) of the parental antibody, that retains at least some of the binding specificity of the parental antibody.
  • antibody antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab') 2 , and Fv fragments; dsFv; (dsFv) 2 , ds diabodies; dsFv-dsFv'; single-chain antibody molecules, e.g., sc-Fv, sc-Fv dimers (bivalent diabodies); bispecific diabodies; and muitispecific antibodies formed from antibody fragments.
  • the present invention includes anti-PCSK9 antibodies and antigen-binding fragments thereof which binds specifically to PCSK9, for example, human PCSK9.
  • an antibody or fragment that binds specifically to human PCSK9 binds preferentially to human PCSK9 as compared to that of rat, mouse or chimp PCSK9.
  • Preferential binding to human PCSK9 means binding with an affinity which is greater than that of rat, mouse or chimp PCSK9 binding to any degree (e.g., 1%, 10%, 50%, 100%, or 10X higher affinity).
  • an anti-human PCSK9 antibody binds to human PCSK9 without any detectable binding to any other species of PCSK9 (e.g., no detectable binding to a mouse or rat PCSK9).
  • Specific anti- PCSK9 binding refers to binding of the antibody to PCSK9 or an antigenic fragment thereof with a Kd at least about 100-fold higher than that of any other protein that might be bound and a minimum Kd of about 500 nM.
  • Any suitable method for generating antibodies may be used.
  • a recipient may be immunized with PCSK9 or an immunogenic fragment thereof.
  • Any suitable method of immunization can be used. Such methods can include adjuvants, other immunostimuiants, repeated booster immunizations, and the use of one or more immunization routes.
  • Any suitable source of PCSK9 can be used as the immunogen for the generation of the antibodies and fragments of the compositions and methods disclosed herein.
  • Such forms include, but are not limited whole protein, peptide(s), and epitopes generated through recombinant, synthetic, chemicai or enzymatic degradation means known in the art.
  • Any form of the antigen can be used to generate the antibody that is sufficient to generate a biologically active antibody.
  • the eliciting antigen may be a single epitope, multiple epitopes, or the entire protein alone or in combination with one or more immunogenictty enhancing agents known in the art.
  • the eliciting antigen may be an isolated full-length protein, a ceil surface protein (e.g., immunizing with DCis transfected with at least a portion of the antigen), or a soluble protein fragment.
  • Monoclonal antibodies may be prepared from various mammalian hosts, such as mice, rats, other rodents, humans, other primates, etc. Description of techniques for preparing such monoclonal antibodies may be found in, eg., Stites etai.
  • monoclonal antibodies may be obtained by a variety of techniques familiar to researchers skilled in the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell.
  • DNA sequences that encode a monoclonal antibody or an antigen binding fragment thereof may be isolated by screening a DfMA library from human B cells according, e.g., to the general protocol outlined by Huse et ai. (1989) Science 246:1275-1281 ,
  • polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covendingiy or non-covalently, a substance that provides for a detectable signal.
  • labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like.
  • Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752;
  • mice which produce human immunoglobulins when immunized with an given antigen are also available in the art. See e.g., Lonberg, N., et al. t (1994) Nature 368(6474): 856-859; Lonberg, N. (1994) Handbook of Experimental Pharmacology
  • a "Fab fragment" is comprised of one light chain and the C H 1 and variable regions of one heavy chain.
  • the heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.
  • An "Fc" region contains two heavy chain fragments comprising the C H 1 and
  • C H 2 domains of an antibody The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the C H 3 domains.
  • a "Fab 1 fragment” contains one light chain and a portion of one heavy chain that contains the V H domain and the CH 1 domain and also the region between the C H 1 and
  • a "F(ab')2 fragment” contains two light chains and two heavy chains containing a portion of the constant region between the C H 1 and C H 2 domains, such that an interchain disulfide bond is formed between the two heavy chains, A F(ab') 2 fragment thus is composed of two Fab ! fragments that are held together by a disulfide bond between the two heavy chains.
  • Disulfide stabilized Fv fragments and “dsFv” include molecules having a variable heavy chain (V H ) and/or a variable light chain (V L ) which are linked by a disulfide bridge.
  • the Tv region comprises the variable regions from both the heavy and light chains, but lacks the constant regions.
  • single-chain Fv or "scFv” antibody refers to antibody fragments comprising the V H and V L domains of an antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the V H and V L chains to pair and form a binding site (e.g., 5-12 residues long).
  • a "domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain.
  • two or more V H regions are covaJently joined with a peptide linker to create a bivalent domain antibody.
  • the two V H regions of a bivalent domain antibody may target the same or different antigens.
  • a "bivalent antibody” comprises two antigen-binding sites. In some instances, the two binding sites have the same antigen specificities.
  • bivalent antibodies may be bispecific,
  • the present invention comprises scfv dinners and dsfv dimers, each of which scfv and dsfv moieties may have a common or different antigen binding specificity.
  • a (dsfv) £ comprises three peptide chains: two V H moieties linked by a peptide linker and bound by disulfide bridges to two V L moieties.
  • a bispecific ds dsabody comprises a VH 1 - VL 2 (tethered by a peptide linker) linked, by a disulfide bridge between the VH 1 and VLi, to a VL 1 -VH 2 moiety (also tethered by a peptide linker),
  • a bispecific dsfv-dsfv' also comprises three peptide chains: a VH 1 -VH 2 moiety wherein the heavy chains are linked by a peptide (inker (e.g., a long flexible linker) and are bound to VL t and VL 2 moieties, respectively, by disulfide bridges; wherein each disulfide paired heavy and light chain has a different antigen specificity
  • an scfv dimer (a bivalent diabody) comprises a V H - V L moiety wherein the heavy and Sight chains are
  • a bispecific diabody comprises VH 1 -VL 2 moiety ⁇ linked by a peptide linker) associated with a VLrVH 2 ⁇ linked by a peptide linker), wherein the VHi and VLi coordinate and the VH 2 and VL 2 coordinate and each coordinated set has diverse antigen specificities.
  • the term "monoclonal antibody”, as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of antibodies directed against ⁇ or specific for) different epitopes.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made recombinantiy or by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
  • the "monoclonal antibodies 1 ' may also be isolated from phage antibody libraries using the techniques described in Clackson et a!. (1991 ) Nature 352: 624-628 and Marks et a!. (1991 ) J. MoL Biol. 222: 581 -597, for example. See also Presta (2005) J. Allergy Clin. Immunol.
  • Monoclonel antibodies include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or Sight chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, white the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et aL, (1984) Proc. Natl Acad, Sci.USA 81 : 6851-6855).
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or Sight chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, white the remainder of the chain(s) is identical with or homologous to corresponding sequence
  • variable domains are obtained from an antibody from an experimental animal (the "parental antibody 3 '), such as a mouse, and the constant domain sequences are obtained from human antibodies, so that the resulting chimeric antibody wiSl be less likely to elicit an adverse Immune response in a human subject than the parental mouse antibody.
  • a recombinant antibody or antigen-binding fragment thereof of the invention is, in an embodiment of the invention, an antibody which is produced recombinantly, e.g., expressed from a polynucleotide which has been introduced into an organism (e.g., a plasmid containing a polynucleotide encoding the antibody or fragment transformed into a bacterial cell (e.g., E.coli) or a mammalian cell (e.g., CHO cell)), followed by isolation of the antibody or fragment from the organism.
  • the present invention comprises methods for expressing any antibody or antigen-binding fragment theref or polypeptide of the present invention.
  • an embodiment of the present invention comprises a process for producing an immunoglobulin molecule or an immunologically functional immunoglobulin fragment comprising at least the variable domains of the immunoglobulin heavy and/or light chains, in a host cell (e.g., a single host cell), such as a CHO cell (e.g.. . .
  • CHO-K1 or DXB11 cell comprising the steps of (i) transforming said host cell with a first polynucleotide encoding at least the variable domain of the immunoglobulin heavy chain and a second polynucleotide encoding at least the variable domain of the immunoglobulin light chain, and (ii) independently expressing said first polynucleotide and said second polynucleotide so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed host cell.
  • the polynucleotides are operably linked to a promoter such as a CMV promoter.
  • the present invention also comprises a process for producing an immunoglobulin molecule or an immunologically functional immunoglobulin fragment comprising introducing transforming a first haplo ⁇ d yeast host cell (e.g., Pichia such as Pichia pasioris) with a first polynucleotide encoding at ieast the variable domain of the immunoglobulin heavy chain or fight chain and transforming a second haptotd yeast host cell (e.g., Pichia such as Pichia pastoris) with a second polynucleotide encoding the other chain, atowlng the hapfoid ceils to form polyploids, such as diploids, (e.g., via mating), selecting the polyploids from the haploids, and growing the polyploids under conditions wherein the heavy and light chains are expressed in the polyploids and, optionally, secreted into the culture medium.
  • a first haplo ⁇ d yeast host cell e.g., Pichia such as Pi
  • polynucleotides introduced into a host cell remain ectopic whereas in another embodiment of the invention, the polynucleotide is integrated into the chromosomal DNA of the host cell.
  • a method for producing an antibody or fragment further comprises isolating the chains that are expressed from the host eell and/or culture medium.
  • the present invention also includes camelized single domain antibodies. See, e.g., Muyldermans etai. (2001) Trends Biochem. ScL 26:230; Reichmann etal. (1999) J. Immunol. Methods 231 : 25; WO 94/04678; WO 94/25591 ; U.S. Pat. No. 6,005,079, which are hereby incorporated by reference in their entireties).
  • Camelidae (camels, dromedaries and llamas) comprise IgG antibodies in which are devoid of light chains and therefore called 'heavy-chain 4 IgGs or HCAb (for heavy-chain antibody).
  • HCAbs typically have a molecular weight of -95 kDa since they consist only of the heavy-chain variable domains. Although the HCAbs are devoid of light chains, they have an authentic antigen-binding repertoire (Hamers-Casterman etal., Nature (1993) 363:446-448; Nguyen et al., k ⁇ v. Immunol. (2001) 79:261-296; Nguyen et ai, Immunogenetics. (2002) 54:39-47).
  • the present invention provides single domain antibodies comprising two V H domains with modifications such that single domain antibodies are formed.
  • diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V H ) connected to a light chain variable domain (V L ) in the same polypeptide chain (V N -V L or Vt- V H ).
  • V H heavy chain variable domain
  • V L light chain variable domain
  • humanized antibody refers to forms of antibodies that contain sequences from both human and non-human ⁇ e.g., mouse or rat) antibodies.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially ail of the hypervariable loops (CDRs) correspond to those of a non-human immunoglobulin, and ail or substantially ail of the framework (FR) regions are those of a human immunoglobulin sequence.
  • CDRs hypervariable loops
  • FR framework
  • An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also called CDRs, Several public sources for human framework sequence are available including, e.g., V-base (IvIRC Center for Protein Engineering),
  • the humanized antibody may optionally comprise at least a portion of a human immunoglobulin constant region (Fc),
  • an embodiment of the invention includes humanized anti-PCSK9 (e.g., anti-human PCSK9) antibodies comprising the specific mouse immunoglobulin CDRs and human immunoglobulin framework regions which are set forth herein, e.g., fused to a human immunoglobulin constant region.
  • humanized anti-PCSK9 e.g., anti-human PCSK9 antibodies comprising the specific mouse immunoglobulin CDRs and human immunoglobulin framework regions which are set forth herein, e.g., fused to a human immunoglobulin constant region.
  • HCDR1 comprising the amino acid sequence G F N i K D T Y M H(SEQ ID NO: 11), HCDR2 comprising the amino acid sequence R I D P A N G H T E Y D P K F Q D(SEQ ID NO: 12) and HCDR3 comprising the amino acid sequence S Y F G s I F A Y (SEQ ID NO: 13);
  • HCDR1 comprising the amino acid sequence G F N I K D T Y I H(SEQIDNO: 19
  • HCDR2 comprising the amino acid sequence R I D P A N G H T E Y D P K F Q G (SEQ ID NO: 20) and HCDR3 comprising the amino acid sequence s Y Y G S I F A Y (SEQ ID NO: 21);
  • HCDR1 comprising the amino acid sequence G F N I K D Y Y I H (SEQ ID NO: 27), HCDR2 comprising the amino acid sequence w I D P E N G D T
  • HCDR1 comprising the amino acid sequence G F N I K D T Y I H (SEQ ID NO: 35), HCDR2 comprising the amino acid sequence K i D p A N G Y T K Y A P N F Q G (SEQ ID NO: 36) and HCDR3 comprising the amino acid sequence G Y Y P. Y Y S L D Y (SEQ IP NO: 37);
  • HCDR 1 comprising the amino acid sequence G F T F S N H D K A(SEQIDNO: 43), HCDR2 comprising the amino add sequence s i T p s G G T T Y Y R D S E G (SEQ ID NO; 44) and HCDR3 comprising the amino acid sequence Q N Y Y D G s Y Y Y G L Y Y F D Y (SEQ ID NO: 45);
  • HCDR1 comprising the amino acid sequence G Y T F T D Y Y M M(SEQIDNO: 51), HCD R2 com prising the amino acid sequence D I N P N ISF G G A I Y M Q K F K G (SEQ JD NO: 52) and HCDR3 comprising the amino acid sequence G i I T E i A E D F (SEQ ID NO: 53);
  • LCDR1 comprising the amino acid sequence S A S S S V S Y L Y (SEQ ID NO: 15), LCDR2 comprising the amino acid sequence R s s H R A s (SEQ ID NO: 16) and LCDR3 comprising the amino acid sequence H Q Y Q S Y P F T (SEQ ID NO: 17);
  • LCDR1 comprising the amino acid sequence s A S S S V S Y L F (SEQ lDNO: 23), LCDR2 comprising the amino acid sequence R T s Y L A S (SEQ SD NO: 24) and LCDR3 comprising the amino acid sequence H Q Y H T Y P P T (SEQ ID NO: 25);
  • LCDR1 comprising the amino acid sequence R A S G N I H S Y L A (SEQlD NO: 31), LCDR2 comprising the amino acid sequence N A K T L F D (SEQiDNO: 32) and LCDR3 comprising the amino acid sequence Q H F w N T P
  • LCDR 1 comprising the amino acid sequence R A S Q D I S N Y L N(SEQID NO: 39), LCDR2 comprising the amino acid sequence Y s S R L H s (SEQIDNO: 40) and LCDR3 comprising the amino acid sequence Q Q G K T L P L T (SEQ ID NO: 41);
  • LCDR 1 comprising the amino acid sequence R S S Q S L V Y S D G N T Y L H (SEQ ID NO: 47), LCDR2 comprising the amino acid sequence R v s N R F S (SEQ ID NO: 48) and LCDR3 comprising the amino acid sequence L Q S T H F P P T (SEQ ID NO: 49); or (xii) LCDR1 comprising the amino acid sequence K A S Q N VG T N V V (SEQID NO: 55), LCDR2 comprising the amino acid sequence S A S Y R Y S (SEQiD NO: 56) and LCDR3 comprising the amino acid sequence Q Q Y K T Y P Y T (SEQiD NO: 57).
  • the present invention also includes isolated polypeptides comprising the amino acid sequences of the immunoglobulin chains set forth herein along with isolated polynucleotides encoding said polypeptides, vectors comprising the polynucleotides and isolated host ceils comprising the polynucleotides and vectors (e.g., CHO ceils, bacterial celis such as E.
  • Methods for making the polypeptides are also included: comprising introducing a polynucleotide or vector into a host cell and culturing the host ceil under condition whereby the polypeptide can be expressed and, optionally, secreted and, optionally, isolating the polypeptide.
  • the present invention provides methods for treating or preventing disorders of cholesterol or lipid homeostasis and disorders associated therewith, e.g., hypercholesterolemia, hyperlipidemia, hypertrigiycehdaemia, sitosterofemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation and xanthoma by administering a therapeutically effective amount of an anti-PCSK9 antibody (e.g., as set forth herein) or antigen-binding fragment thereof or an EGF-A polypeptide.
  • an anti-PCSK9 antibody e.g., as set forth herein
  • hypercholesterolemia includes, e.g., familial and non-familial hypercholesterolemia.
  • Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevation of serum cholesterol bound to low density lipoprotein (LDL).
  • Familial hypercholesterolemia includes both heterozygous FHC and homozygous FHC.
  • Hyperlipidemia is an elevation of lipids in the bloodstream. These lipids include cholesterol, cholesterol esters, phospholipids and triglycerides. Hyperlipidemia includes for example, type I, Ha, Mb 1 Ml, IV and V. Sitosterolemia is a rare inherited plant sterol storage disease. In general, the metabolic defect in the affected patient causes hyperabsorption of sitosterol from the gastrointestinal tract, decreased hepatic secretion of sitosterol with subsequent decreased elimination, and altered cholesterol synthesis.
  • Atherosclerosis includes hardening of arteries associated with deposition of fatty substances, cholesterol, cellular waste products, caicium and fibrin in the inner lining of an artery. The buildup that results is called plaque.
  • Arteriosclerosis includes the diffuse build-up and deposition of calcium in artery walls which leads to hardening.
  • the present invention also provides methods for improving blood cholesterol markers associated with increased risk of heart disease. These markers include high total cholesterol, high LDL, high total cholesterol to HDL ratio and high LDL to HDL ratio.
  • a total cholesterol of less than 200 mg/dL is considered desirable, 200- 239 mg/dL is considered borderline high and 240 mg/dL and above is considered high.
  • a blood LDL ievef of less than 100 mg/dL is considered optimal; 100- 129 mg/dL is considered near optimal/above optimal, 130-159 mg/dL is considered borderline high, 160-189 mg/dL is considered high and 190 mg/dL and above is considered very high.
  • HDL levels considered normal are at least 35 - 40 mg/dL.
  • Another indicator of heart disease risk is the ratio of total cholesterol to HDL.
  • a very low risk of heart disease correlates with a ratio of ⁇ 3,4 (men) or ⁇ 3.3
  • a low risk is associated with a ratio of 4.0 (men) or 3.8 (women)
  • an average risk is associated with a ratio of 5.0 (men) or 4.5 (women)
  • a moderate risk is associated with a ratio of 9,5 (men) or 7.0 (women)
  • a high risk is associated with a ratio of >23 (men) or >11 (women).
  • a further indicator of heart disease risk is the ratio of LDL to HDL.
  • anti-PCSK9 antibodies and antigen-binding fragments thereof or EGF-A polypeptides of the invention are formulated into a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier.
  • the anti-PCSK9 antibodies and antigen-binding fragments thereof or EGF-A polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the antibody or fragment is combined in admixture with a pharmaceutically acceptable carrier.
  • Carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; tow molecular weight polypeptides; proteins, such as serum atoumin, gelatin or immunoglobulins; hydrophsfc polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutam ⁇ ne, asparagine.
  • arginine or lysine monosaccharides. disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterfoils such as sodium; and/or nonionic surfactants such as TweenTM, PluronicsTM or PEG.
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitutlon.
  • Therapeutic or pharmaceutical compositions or formulations herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • a parenteral route e.g., intravenous, subcutaneous, intraarterial, intratumoral, intramuscular, intraperitoneal.
  • Dosages and desired anti-PCSK9 or EGF-A polypeptide concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug Development, Yacobi etai., Eds., Pergamon Press, New York 1989, pp. 42 96.
  • a therapeutically effective dosage or amount of anti-PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptides is administered to the subject.
  • a therapeutically effective dosage is a dosage sufficient to decrease total serum cholesterol, decrease blood LDL levels or increase biood HDL levels to any degree whatsoever
  • a therapeutically effective dosage of anti- PCSK9 antibody or antigen-binding fragment thereof e.g., as set forth herein
  • for treatment of hypercholesterolemia, hyperlipidemia, hypertriglyceridaemia, sitosterolem ⁇ a, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma or for treatment of any blood marker of heart disease risk is about 0.1 mg/kg (body weight)/week to about 1.0 mg/kg/week.
  • a therapeutically effective dosage of soluble PCSK9 EGF-A polypeptide is, in an embodiment of the invention, about 0.25 mg/kg/week to about 25 mg/kg/week.
  • administration and dosage of an agent is done according to the schedule listed in the product information sheet of the agents, in the Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th Ed); Medical Economics Company; ISBN: 1563634457; 57th edition (November 2002), as well as therapeutic protocols well known in the art.
  • a physician or clinician may monitor the blood cholesterol levels in a subject being treated or about to be treated with an anti-PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptide and make adjustments to the subject's treatment regimen as needed to reach a positive medical outcome.
  • the present invention provides methods and compositions for treating disorders of lipid and cholesterol metabolism (e.g., any set forth herein) by administration of an anti- PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptide.
  • the antibodies may, in an embodiment of the invention, be provided or administered in association with any additional or further chemotherapeutic agent.
  • the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin- converting enzyme (ACE) inhibitor, a coronary vasodilator, a diuretic or an adrenergic stimulant.
  • the further therapeutic agent is a cholesterol lowering medication such as an HMG-CoA reductase inhibitor.
  • Cardiovascular agents which may used in connection with the present invention include those for treatment or prevention of lipid and/or cholesterol disorders or hypertension and other cardiovascular disorders and diseases. Disorders of lipid or cholesterol metabolism may be caused or aggravated by hypertension. Hypertension is defined as persistently high blood pressure. Generally, adults are classified as being hypertensive when systolic blood pressure is persistently above 140 mmHg or when diastolic blood pressure is above 90 mmHg. Long-term risks for cardiovascular mortality increase in a direct relationship with persistent blood pressure. Examples of antihypertensive agents which may be used in the present invention include e.g., calcium channel blockers, angiot ⁇ nsin-converting enzyme (ACE) inhibitors.
  • ACE angiot ⁇ nsin-converting enzyme
  • angiotensin-l f receptor antagonists diuretics, adrenergic Mockers including beta- adrenergic receptor blockers and alpha-acfrenergic receptor blockers or diuretics.
  • Other cardiac drugs that may be provided in association with an anti-PCSK9 antibody or antigen-binding fragment thereof includes anti-anginal agents, such as adrenergic stimulants or coronary vasodilators and HMG-CoA reductase inhibitors.
  • HIVIG-CQA reductase inhibitors inhibit the HMG-CoA reductase enzyme and, thus, reduce production of cholesterol in the body of a subject.
  • HMG-CoA reductase inhibitors include, e.g., lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin and simvastatin
  • Adrenergic blockers include those compounds which are ⁇ -receptor inhibitors and/or ⁇ -receptor inhibitors.
  • Adrenergic blockers which are ⁇ -receptor inhibitors include a class of drugs that antagonize the cardiovascular effects of catecholamines in hypertension, angina pectoris, and cardiac arrhythmias
  • ⁇ -adrenergic receptor blockers include, but are not limited to, bunoioi hydrochloride (1(2H)-Naphthalenone, 5-[3-(1 ,1- dtmethylethyl)amino]-2-hydroxypropoxy]-3 i 4-dihydro-, hydrochloride, CAS RN 31969-05-8 which can be obtained from Parke-Davis); acebutoiol ( ⁇ N-[3-Acetyl-4-[2-hydroxy-3-[(1 methylethyf)amino]propoxy]phenyl]- butanamide, or ( ⁇ )-3'-Acety
  • Atenolol such as benzeneacetamide 4- [2'-hydroxy-3'-((1-methylethyl)amino]propoxy]- , for example, TENORMIN ® I. V.
  • carteolol hydrochloride such as 5-[3-[(1 ,1 - dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-2 ⁇ 1 H)-quinolinone monohydrochloride, for example, Cartrol ® Filmtab ® Tablets available from Abbott; Celiprotol hydrochloride ⁇ 3-[3-Acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxyl]phenyl3-1 ,1- diethylurea monohydrochloride, CAS RN 57470-78-7, also see in US Patent No.
  • cetamolol hydrochloride (Acetamide, 2-[2-[3-[(1 ,1 -dimethylethyl)amino]-2- hydroxypropoxy]-phenoxy]-N-methyl-,monohydrochloride, CAS RN 77590-95-5, see also US Patent No.
  • labetalol hydrochloride such as 5-[1-hydroxy-2-[(1-methyl-3- phenylpropyl) amino] ethyl]salicylamtde monohydrochloride, for example, NORMODYNE ® Tablets available from Schering; esmolol hydrochloride ( ( ⁇ )-Methyl p-[2-hydroxy-3- (isopropylamino) propoxy] hydrocinnamate hydrochloride, for example, BREVIBLOC ® Injection available from Baxter); levobetaxoiol hydrochloride (such as (S)-1-[p-[2- (cyclopropyImethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride, for example, BETAXONTM Ophthalmic Suspension available from Alcon); ievobunoSol hydrochloride (such as (-)-5-[3-(
  • nadolol such as 1-(tert-butylamino)-3 ⁇ [(5,6,7,8- tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol, for example, Nadolol Tablets available from Mylan
  • practolol Acetamide, N-[4-[2-hydroxy-3-[1-methylethyl)amino]- propoxy]phenyl]-, CAS RN 6673-35-4, see also US Patent No3,408,387)
  • propranolol hydrochloride (1-(lsopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride CAS RN 318-98-9
  • sotalol hydrochloride such as d,l-N-[4-[1-hydroxy-2-[(1- methy(ethyl ⁇ amino]e
  • cicfoproloi hydrochloride such 2-Propanof, 1-[4-[2- (cyciopropylmethoxy)ethoxy]phenoxy] ⁇ 3-[1 -methylethyl)amino]-, hydrochloride, A.A.S, RN 63686-79-3); and dexpropranolol hydrochloride (2-Propanol, 1-[1-methylethyl)-amino]-3- ⁇ 1-naphthalenyloxy)-hydrochloride (CAS RN 13071-11-9); diacetolol hydrochloride (Acetamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methyl-ethyl)amino]propoxy][phenyl]- ,monohydrochloride CAS RN 69796-04-9);diIevaloi hydrochloride (Benzamide, 2-hydroxy- 5-[1 -hydroxy-2-[1
  • Adrenergic receptors which are ⁇ -receptor inhibitors act to block vasoconstriction induced by endogenous catecholamines. The resulting fall in peripheral resistance leads to a fall in mean blood pressure. The magnitude of this effect is dependent upon the degree of sympathetic tone at the time the antagonist is administered.
  • Suitable adrenergic receptors which are ⁇ -receptor inhibitors include, but are not limited to, fenspiride hydrochloride (which may be prepared as disclosed in US Patent No. 3,399,192 herein incorporated by reference); proroxan (CAS RN 33743-96-3); alfuzosin hydrochloride (CAS RN : 81403-68-1); and labetatol hydrochloride as described above or combinations thereof.
  • Adrenergic blockers with a and ⁇ receptor inhibitor activity which may be used with the present invention include, but are not Simited to, bretylium tosylate (CAS RN : 61-75- 6); dihydroergtamine mesylate (such as ergotaman-3 1 , 6 !
  • labetalol such as 5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl]salicyfamide monohydrochloride, for example, NORMODYNE ® Tablets available from Schering
  • bretylium tosylate Benzenemethanaminium, 2-bromo-N-ethyI- N.N-dimethyh salt with 4-methylbenzenesulfonic acid (1 :1) CAS RN 61-75-6
  • phentolamine mesylate Phenol, 3-f[(4,5-dihydro-1H-imidazol-2-yl)methyl](4- methylphenyl)amino]-, monomethanesulfonate (salt) CAS RN 65-28-1
  • solypertine tartrate 5H-1 ,3-Dioxoio[4,5-f]indoie, 7-[2-[4-(2-methoxyphenyl)
  • An angiotensin system inhibitor is an agent that interferes with the function, synthesis or catabolism of angiotensin II.
  • agents which may be used in the present invention include but are not limited to angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, angiotensin M receptor antagonists, agents that activate the catabolism of angiotensin fl and agents that prevent the synthesis of angiotensin I from which angiotensin Il is ultimately derived.
  • ACE angiotensin-converting enzyme
  • Angiotensin II antagonists include but are not limited to angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, angiotensin M receptor antagonists, agents that activate the catabolism of angiotensin fl and agents that prevent the synthesis of angiotensin I from which angiotensin Il is ultimately derived.
  • ACE angiotensin-converting enzyme
  • Angiotensin M receptor antagonists agents that
  • Angiotensin I and angiotensin fl are synthesized by the enzymatic renin-angiotensin pathway.
  • the synthetic process is initiated when the enzyme renin acts on angiotensinogen, a pseudoglobulin in blood plasma, to produce the cecapeptide angiotensin L
  • Angiotensin f is converted by angiotensin-converting enzyme (ACE) to angiotensin II.
  • ACE angiotensin-converting enzyme
  • Angiotensin ll receptor antagonists are compounds which interfere with the activity of angiotensin Ii by binding to angiotensin lf receptors and interfering with its activity
  • Angiotensin Il receptor antagonists which may be used In the present invention are well known and include peptide compounds and non-peptide compounds.
  • angiotensin Jl receptor antagonists include: candesartan cilexet ⁇ (1H- Benz ⁇ rnidazole-7-carboxyIic acid, 2-ethoxy-1 -[[2'-(1 H-tetrazol-5-yl)[1 , 1 '-biphenyl]-4- yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl ⁇ oxy]ethyl ester ) CAS RN 145040-37-5); telmisartan( [i ,1'-Biphenyl]-2-carrboxylic acid, 4'-[(1 l 4'-dimethyl-2 l -propyl[2,6 l -bi-1 H- benzimidazol]-1 '-yl)methyl]- CAS RN 144701 -48-4); candesartan (1 H-Benzimidazoie-7- carboxylic acid, 2-ethoxy-1-[[2
  • Angiotensin-converting enzyme is an enzyme which catalyzes the conversion of angiotensin I to angiotensin II.
  • ACE inhibitors which may be used in the present invention include amino acids and derivatives thereof, peptides, including di and tri peptides and antibodies to ACE which intervene renin-angiotensin system by inhibiting the activity of ACE thereby reducing or eliminating the formation of pressor substance angiotensin N.
  • ACE inhibitors have been used medically to treat hypertension, congestive heart failure, myocardial infarction and renal disease.
  • Suitable ACE inhibitors include, but are not limited to, benazepril hydrochloride (such as 3-[[1-(ethoxycarbonyl)-3-phenyl-(1S)- propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1 -acetic acid rnonohydrochloride, for example, LOTREL ® Capsules available from Novartis); captoprii (such as 1-[(2S)-3-mercapto-2-methyfpropionyt]-L-proIine» for example, CAPTOPRIL Tablets available from Mylan); fosinoprii (such as L-proline, 4-cyclohexyl-1-[[[2-methyl-1- (1-oxopropoxy) propoxy] (4-phenylbutyl) phosphinyl] acetyl]-, sodium salt, trans -..for example, yON
  • perindopril 1 H-lndole-2-carboxylic acid 1 -[(2S)-2-[[(1 S)-1 -(ethoxycarbonyl)butyl]amino]-1 - oxopropyl]octahydro-, (2S,3aS,7aS)- CAS RN 82834-16-0); quinapril hydrochloride (3- Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1- oxopropyl]-1 ) 2,3,4-tetrahydro-, monohydrochloride, (3S)- CAS RN 82586-55- ); quinaprilat (3-lsoquinolinecarboxylic acid, 2-[(2S)-2-[[(1 S)-1 -(ethoxycarbonyl)butyl]amino]-1
  • Calcium channel blockers are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders such as hypertension, angina, and cardiac arrhythmias (Fteckenstein, Or. Res. V. 52 (suppi, 1), p, 13-16 (1983); Fleckenstetn, Experimental Facts an ⁇ Therapeutic Prospects, John Wiley, New York (1983); McCaIL D., Curr, Praci Cardiol, v. 10, p, 1-11 (1985)).
  • cardiovascular disorders such as hypertension, angina, and cardiac arrhythmias (Fteckenstein, Or. Res. V. 52 (suppi, 1), p, 13-16 (1983); Fleckenstetn, Experimental Facts an ⁇ Therapeutic Prospects, John Wiley, New York (1983); McCaIL D., Curr, Praci Cardiol, v. 10, p, 1-11 (1985)).
  • Calcium channel blockers are a heterogeneous group of drugs that prevent or stow the entry of calcium into ceils by regulating cellular calcium channels (Remington, The Science and Practice of Pharmacy, Nineteenth Edition, Mack Publishing Company, Eaton, PA, p. 963 (1995)).
  • Calcium channel blockers useful in the present invention include but are not limited to, the besylate saft of amlod ⁇ pine (such as 3- ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chk)rophenyl)-1 ,4-dihydro-6-methyl-3,5- pyridinedicarboxylate benzenesulphonate, for example, NORVASG ® available from Pfizer); cfent ⁇ azem maleate (1 ,5-Benzothiazepin-4(5H)-one, 3 ⁇ (acetyloxy)-8-chloro-5-[2- (dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyI)-(2S-cis)-, (Z)-2-butenedioate (1 :1), see also U.S.
  • amlod ⁇ pine such as 3- ethyl-5-methyl-2-(2-a
  • Patent No. 4,567,195 isradipine (3,5-Pyridinedicarboxylic acid, 4-(4- benzofurazanyl)-1,4-dihydro-2,6-dirnethyl-,methyl 1-methylethyl ester, ( ⁇ )-4(4- benzofurazany)l-1,4-dihydro-2,6-dimethyl-3,5-pyndinedicarboxylate, see also US Patent 4,466,972); nimodipine (such as is isopropyl (2 - methoxyethyl) 1 , 4- dihydro - 2, 6 - dimethyl - 4 - (3 - nitrophenyl) - 3, 5 - pyridine - dicarboxylate, for example, NIMOTOP ® available from Bayer); felodipine (such as ethyl methyl 4-(2,3-dichlorophenyl)-1 ,4-dihydro- 2,6-d ⁇ methyl-3,5
  • Cardiovascular agents of the present invention which also act as "anti-anginal agents" are useful in the present invention.
  • Angina includes those symptoms that occur when myocardial oxygen availability is insufficient to meet myocardial oxygen demand.
  • Non-limiting examples of these agents include: ranolazine (hydrochforidel -Piperazineacetamide, N-(2,6-dimethylphenyl ⁇ -4-[2-hydroxy-3- ⁇ 2- rnethoxyphenoxy)propyll-, dihydrochloride CAS RN 95635-56-6); betaxolol hydrochloride (2-Pr ⁇ panol, 1-[4-[2 (cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-, hydrochloride CAS RN 63659-19-8); bui ⁇ prozine hydrochloride (Methanone, [4- [3(dibutytemino)propoxy]phenyl](2-ethy
  • Coronary vasodilators may act to reduce angina systems by increasing the oxygen supply to the heart.
  • Coronary vasodilators useful in the present invention include, but are not limited to, diltiazem hydrochloride (such as 1 ,5-Benzothiazepin- 4(5H)-one,3-(acetyloxy)-5[2-(dimethylamino)ethyl]-2 ! -3-dihydro-2(4-methoxyphenyl)- !
  • (+)-cis for example, TIAZAC ® Capsules available from Forest
  • isosorbide dinitrate such as 1 ,4:3,6-dianhydro-D-glucitol 2,5-dinitrate, for example, iSORDIL ® TITRADOSE ® Tablets available from Wyeth-Ayerst
  • sosorbide mononitrate such as 1 ,4:3,6-dianhydro-D-glucitol,5-nitrate, an organic nitrate, for example, Ismo ® Tablets available from Wyeth-Ayerst
  • nitroglycerin such as 2,3 propanetriol trinitrate, for example, NiTROSTAT ® Tablets available from Parke-Davis
  • verapamil hydrochloride such as benzeneacetonitrile, ( ⁇ )-(alpha)[3[[2-(3,4 dimethoxyphenyl)ethyl]methylamino]propy
  • mi ⁇ flazine hydrochloride (1 - Piperazineacetamide, 3 ⁇ (aminocarbonyl)-4-[4,4-b!s(4 ⁇ fluorophenyl)butyt]-N-(2,6- dichlorophenyl)-, dihydrochSoride CAS RN 83898-67-3); mixidine (Benzeneethanamine, 3,4-dimethoxy-N-(1 -methyl-2-pyrrolid ⁇ nylidene)- Pyrrolidine, 2- [(3,4-dimethoxyphenethyl)imino]-1 -methyl- 1 -Methyl-2-[(3,4 ⁇ dimethoxyphenethyl)imino]pyrrolidine CAS RN 27737-38-8); molsidomine (1 ,2,3- Oxadiazolium, 5-[(ethoxycarbonyl)amino]-3-(4-rnorphoiinyl)-, inner salt CAS
  • hydrochloride CAS RN 6452-73- 9 pentrinitrol (1 ,3-Propanediol, 2 ! 2-bis[(nitrooxy)methyl]-, mononitrate (ester) CAS RN 1607-17-6); verapamil (Benzeneacetonitriie, ,aIpha.-[3-[[2-(3,4- dimethoxyphenyI)ethyl]methylamino]propyl]-3, 4-dimethoxy-. alpha. -(1-methylethyl)- CAS RN 52-53-9),
  • diuretic includes compounds that increase the excretion of solutes (mainly NaCI) and water.
  • the primary goal of diuretic therapy is to reduce extracellular fluid volume in order to lower blood pressure or rid the body of excess interstitial fluid (edema).
  • diuretics which may be used within the scope of this invention include althiazide (which may be prepared as disclosed in British Patent No. 902,658); benzthiazide (which may be prepared as disclosed in U.S. Patent No. 3,108,097); buthiazide (which may be prepared as disclosed in British Patent Nos. 861,367): chlorothiazide (which may be prepared as disclosed in U.S. 2,809,194); spironolactone (CAS Number 52-01-7); and triamterene (CAS Number 396-01-0).
  • Adrenergic stimulants useful as cardiovascular agents in the present invention include, but are not limited to, guanfacine hydrochloride (such as N-amk-ino-2-(2»6- dlchlorophenyl) acetam ⁇ de hydrochlonde s for example, TENEX ® Tablets available from Robins); methyldopa-hydrochtorothiazide (such as levo-3-(3,4-dihydroxyphenyl)-2 ⁇ methylalanine ) combined with Hydrochlorothiazide (such as 6-chloro-3,4 ⁇ dihydro-2 H - 1 ,2 f 4-benzothiadiazine ⁇ 7- sulfonamide 1 ,1 -dioxide, for example, the combination as, for example, ALDORIL ® Tablets avaiiable from Merck); methyldopa-chlorothiazide (such as 6- chloro-2 H -1 » 2, 4-benzothiadiazine
  • the anti-PCSK9 antibodies and antigen-binding fragments thereof and EGF-A polypeptides may also be administered in association with any azetidinone which inhibits intestinal cholesterol absorption.
  • azetidinones include ezetimibe
  • chemotherapeutic agents that may be administered in association with an anti-PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptide include fish oil, eicosaepenanoic acid, docosahexanoic acid, linoleic acid, niacin, fibrates such as fenofibrate, gemfibrozil and bile add sequestrants such as cholestyramine, colestipol and colesevelam.
  • chemofherapeutic agents include althiaz ⁇ de (2H-1 ,2,4-Benzothiadiazine-7- sulfonamide, 6-chloro-3,4-dihydro-3-[(2-propenylthio)methyl]-, 1 ,1 -dioxide CAS RN 5588- 16-9); benzthiazide (2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chIoro-3- [[(phenylmethyl)thio]methyl]-.
  • the present invention further provides a method for identifylng a substance which is a PCSK9 inhibitor or an inhibitor of PCSK9/LDL receptor binding or an inhibitor of PCSK9/EGF-A domain binding; or a substance which reduces total cholesterol level, low density lipoprotein cholesterol ievei, apolipoprotein B level, total cholesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio; or a substance which treats or prevents hypercholesterolemia, hyperlipidemia, hypertriglyceridaemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma in a subject comprising contacting PCSK9 polypeptide or a functional fragment thereof and a polypeptide comprising LDL receptor EGF-A domain (e.g., SEQ ID NO; 3) and a sample to be tested for the presence of said substance; wherein said substance is identified if less binding of PCSK9 and the polypeptide comprising LDL receptor EGF-A
  • An embodiment of the invention further comprises a negative-control assay wherein said PCSK9 and EGF-A polypeptides are contacted with a substance known not to inhibit binding of PCSK9 and LDL receptor or EGF-A domain thereof wherein the assay is determined to be operating property if more binding of the PCSK9 and LDL receptor or EGF-A domain thereof is observed than in the present of an inhibitor of said binding.
  • An embodiment of the invention further comprises a positive-control assay wherein said PCSK9 and EGF-A polypeptides are contacted with a substance known to inhibit binding of PCSK9 and LDL receptor or EGF-A domain thereof wherein the assay is determined to be operating properly if less binding of the PCSK9 and LDL receptor or EGF-A domain thereof is observed than in the present of an inhibitor of said binding.
  • Binding of the substance can be determined using any of several methods known in the art.
  • Example 1 Soluble EGF-A domain of the LDL receptor or anti-PCSK9 antibody blocks the LDLR-PCSK9 interaction
  • a soluble peptide encoding the EGF-A domain of the human LDL receptor as well as various anti-PCSK9 antibodies are shown to block interactions between PCSK9 and the receptor.
  • PCSK9 carrylng a C-terminal FLAG tag was purified from HEK293 cells stably expressing PCSK9. Purity was estimated, by silver staining, at greater than >90%.
  • Anti-PCSK9-catalytic domain antibody was purchased from Cayman Chemical (Rabbit anti-murine-PCSK9 polyclonal antibody, Cayman Chemical; Ann Arbor, Mi; Cat.# 10008811). This rabbit anti-mouse/human PCSK9-catalytic domain antibody recognizes an epitope with the following amino acid sequence: VFAQSiPWNLER (SEQ ID NO: 8).
  • a rabbit anti- human PCSK9 C-terminal domain antibody (which binds specifically to SRSGKRRGERMEA (amino acids 490-502 of SEQ ID NO: 4)) and a rabbit anti-human PCSK9 whole protein antibody were also used.
  • Soluble EGF-A domain peptide was synthetically generated using standard methods. 2.5 ng of purified, C-terminaliy FLAG tagged PCSK9 (2.5 ng/2.5 ul/well of a ProxiPlate-384 Plus (Perk ⁇ n-Eimer; Waitham, Mass) in 2.5 microliters of buffer (25 mM HEPES.
  • a donor/acceptor bead mixture (AlphaScreen Histidine Detection Kit, Perkin-Elmer; Waitharn, Mass.; Cat. #6760619C) was added and alphaScreen signal was detected using the 2103 En Vision Multilabel Plate Reader (Perkin-Elmer; Waltham, Mass).
  • the donor/acceptor bead mixture was prepared in dark conditions by adding 10 ul Nickel-Acceptor bead and 10 ui SA-Donor bead to 2.2 ml buffer for one 384-well piate and incubated in dark at room temperature for at least 2 hours,
  • Example 2 Artt ⁇ -PCSKi antibody treatment of cells leads to enhanced LDL uptake. Incubation of cells with soluble PCSK9 leads to a decrease in the ability of the cells to absorb and clear low density lipoprotein (LDL) from the medium.
  • LDL low density lipoprotein
  • This example demonstrates that inhibition of PCSK9 with an anti-PCSK9 antibody antagonizes this effect of PCSK9 and leads to increased levels of LDL uptake and clearance.
  • the uptake assays were performed as follows: HepG2 ceils at 10,000 cells/well in
  • DiI-LDL was removed afterwards, the cells were fixed with Prefer fixative (glyoxal, ethanol, buffer; Anatech LTD.; Hayward, CA; cat# 414) for 20 minutes, then the cells were washed with PBS two times and DiI-LDL uptake into the cells was read using a fluorescence intensity reader Analyst.
  • Prefer fixative glyoxal, ethanol, buffer; Anatech LTD.; Hayward, CA; cat# 414
  • Table 4 sli ⁇ wiTuptake of dit-labeted LDL by human HepG2 liver ceils treated with the indicated amounts of purified, recombinant PCSK9 (control) or PCSK9 in the presence of either polyclonal antibody raised against the catalytic domain peptide (anti-CAT) or antibody raised against the whole protein (anti-all).
  • PCSK9-de ⁇ endent uptake of LDL by the cells increased in a manner dependent upon the presence of anti-PCSK9 antibody in the mixture. Higher numbers indicated greater LDL uptake and preservation of LDLR despite the presence of PCSK9.
  • the 75B9, 77D10, 11B5, 22D11, 1F11/1G11 and 29C 10 anti-PCSK9 antibodies were characterized.
  • the antibodies were found to effectively inhibit interaction between PCSK9 and the LDL receptor as well as inhibit PCSK9-mediated LDL receptor degradation.
  • the antibodies were found to inhibit PCSK9 and, thereby increase the levels of LDL receptor present.
  • the antibodies neutralized the in vivo cholesterol increase observed when exogenous PCSK9 was added.
  • the 75B9, 77D10, 1165, 22011, 1F11/1G11 and 29C10 antibodies were evaluated in an in-cell western assay for their ability to inhibit the degradation of the LDL receptor by PCSK9 in HepG2 ceils.
  • Alphascreen binding assays An Amplified Luminescent Proximity Homogeneous Assay (ALPHA, Perkin-Elmer;
  • the antibodies tested inhibited PCSK9/LDL receptor interaction with various potencies (expressed in terms of IC 5G and % inhibition relative to the assay performed with no antibody added).
  • mice Male C57BL/6] mice were injected, intraperitoneal, with 400 ⁇ g of anti- human PCSK9 Antibody, 1 F11/1 G11.
  • Time-4 hours Mice were terminated and plasma and liver samples were collected.
  • Plasma lipoprotein profiles of individual mice were determined by fast protein liquid chromatography (FPLC) with a Pharmacia Superose 6 column.
  • FPLC fraction cholesterol levels were determined using Wako Cholesterol Enzymatic colorimetric method.
  • Protein levels of Liver LDL Receptor were determined by Western Blot. 40 ⁇ g of each liver homogenate was separated on an Invitrogen 4-12% NuPAGE gei s transferred to PVDF membrane and incubated with goat anti-mouse LDL receptor antibody (rabbit anti-GAPDH antibody was used as a control for equal loading). Membranes were then incubated with corresponding HRP-linked antibodies and visualization was accomplished with high performance chemiluminescence film. Band intensities were quantified using tmageQuant 5.2 software.
  • LDL receptor levels were expressed in Arbitrary Units (AU) as a ratio of LDL receptor band intensity to GAPDH band intensity.
  • AU Arbitrary Units
  • the results of the LDL receptor measurements are set forth in tables 7 and 8 below. Two separate analyses of the data are presented.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.

Description

Antϊ-PCSK9 and Methods for Treating Lipid and Cholesterol Disorders
This application claims the benefit of U.S. patent application no. 60/982,922, filed October 26, 2007, which is herein incorporated by reference in its entirety.
Field of the invention
The field of the present invention relates to methods and compositions for treating disorders of cholesterol homeostasis by administering an anti-PCSK9 antibody or antigen- binding fragment thereof,
Background of the Invention
Atherosclerotic coronary heart disease (CHD) represents the major cause for death and cardiovascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes metlitus, family history, male gender, cigarette smoke, high serum cholesterol, high low density lipoprotein (LDL) cholesterol levels and low high density lipoprotein (HDL) cholesterol levels. In general, a total cholesterol level in excess of about 225-250 mg/dl is associated with significant elevation of risk of CHD.
A variety of clinical studies have demonstrated that elevated levels of total cholesterol or LDL cholesterol promote human atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total cholesterol and LDL cholesterol.
One method for lowering LDL cholesterol levels is by administration of HMG-CoA reductase inhibiting drugs. These drugs antagonize HfVIG-CoA reductase and cholesterol synthesis in the iiver and increase the number of hepatic LDL receptors on the ceii- surface to enhance uptake and catabolism of LDL, A drawback of such an approach is that these drugs commonly suffer from a disadvantageous side-effect profile, including, for example, liver toxicity. An alternate approach is to modulate the LDL receptor pathway directly.
PCSK9 Cprøproteln convertase subtilisin/kexin type 9) is a serine protease family member that binds to ana regulates LDL receptor expression on the surface of celts.
Inhibition of the LDL receptor~PCSK9 interaction is an attractive approach to the treatment of cholesterol disorders. Inhibition of interactions between large proteins (i.e., protein- protein interactions or PPI) by the use of antibodies or small molecule inhibitors is, however, generally regarded as being particularly difficult and challenging. Large proteins such as PCSK9, with a mofecuSar weight of about 74 KDa1 and LDLR5 with a molecular weight of about 160 KDa (glycosylated on cell surface; 115 KDa in immature form), are likely to exhibit extensive intermolecular contacts over a large area. The existence of extensive contacts makes it unlikely that a given antibody or small molecule inhibitor will successfully block their binding.
Summary of the Invention
The present invention surprisingly has overcome the technical difficuities associated with the blocking of intermolecuJar interactions between large proteins and has demonstrated that blockage of the PCSK9-LDLR interaction with an antibody or peptide is possible. As discussed in detail herein, this, in turn, provides a novel method by which to treat cholesterol disorders.
The present invention provides, in part, a method for reducing total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total cholesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio, in a subject (e.g., a human), comprising administering, to said subject, a therapeutically effective amount of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody, polyclonal antibody or recombinant antibody) or EGF-A polypeptide that binds specifically to PCSK9 which antibody or fragment or polypeptide inhibits binding between PCSK9 and LDL receptor; optionally in association with a further chemotherapeutic agent (e.g., ezetimibe and/or simvastatin). In an embodiment of the invention, the antibody or fragment or EGF-A polypeptide binds specifically to a PCSK9 catalytic domain or to a domain of PCSK9 which interacts with an LDL receptor EGF-A domain.
The present invention further provides, in part, a method for treating or preventing hypercholesterolemia, hyperlipidernia, hypertriglyceridaemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma, in an subject, comprising administering, to said subject, a therapeutically effective amount of an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody, polyclonal antibody or recombinant antibody) or EGF-A polypeptide that binds specifically to PCSK9, which antibody or fragment or polypeptide inhibits binding between PC-SK9 and LDL receptor; optionally in association with a further therapeutic agent (e.g., ezetimibe and/or simvastatin), fn an embodiment of the invention, the antibody or fragment or EGF-A polypeptide binds specifically to a PCSK9 catalytic domain or to a domain of PCSK9 which interacts with an LDL receptor EGF-A domain.
The present invention also provides, in part, a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof (e.g., monoclonal antibody, polyclonal antibody or recombinant antibody) or EGF-A polypeptide which binds specifically to PCSK9, which antibody or fragment or polypeptide inhibits binding between PCSK9 and LDL receptor, and a pharmaceutically acceptable carrier; optionally in association with a further chemotherapeutic agent (e.g., ezetimibe and/or simvastatin). The present invention also provides an isolated polypeptide comprising an amino acid sequence comprising about 90% or more amino acid sequence similarity to a fragment of the human LDL receptor which fragment consists of amino acids beginning at about amino acid position 314 and ending at about amino acid position 355 of said receptor wherein said polypeptide; wherein said polypeptide optionally comprises one or more properties selected from the group consisting of: (i) binds to PCSK9; (ii) competes with LDL receptor or an anti-PCSK9 antibody or antigen-binding fragment thereof for binding to PCSK9; (iii) reduces total cholesterol level when administered to an animal; (iv) reduces low density lipoprotein cholesteroi level when administered to an animal; (v) reduces apolipoprotein B level when administered to an animal; (vi) reduces total cholesterol/high density lipoprotein ratio when administered to an animal; and (vii) reduces low density lipoprotein/high density lipoprotein ratio when administered to an animal; or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier. In an embodiment of the invention, the polypeptide consists of the amino acid sequence of SEQ ID NO: 3; or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier. The present invention provides an isolated antibody or antigen-binding fragment thereof comprising one or more members selected from the group consisting of: (i) CDR-HI5 CDR-H2 and CDR-H3 of the variable region the 11B5 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 10; (ii) CDR-H1 , CDR-H2 and CDR-H3 of the variable region the 75B9 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 18; (iii) CDR-H1, CDR-H2 and CDR-H3 of the variable region the 77D10 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 26; (iv) CDR-Hl5 CPR-H2 and CDR-H3 of the variable region the 29C10 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 34; (V) CDR-H1, CDR-H2 and CDR-H3 of the variable region the 22D11 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 42; (vi) CDR-H1 , CDR-H2 and CDR-H3 of the variable region the 1 F11/1G11 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 50; (vii) CDR-H1 , CDR-H2 and CDR-H3 of the variable region the 11 B5 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 14; (viii) CDR-H1 , CDR-H2 and CDR-H3 of the variable region the 75B9 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 22; (ix) CDR-H1, CDR-H2 and CDR-H3 of the variable region the 77D10 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 30; (x) CDR-H1, CDR-H2 and CDR-H3 of the variable region the 29C10 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 38; (xi) CDR-H 1 , CDR-H2 and CDR-H3 of the variable region the 22D11 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 46; and (xii) CDR-H 1 , CDR-H2 and CDR-H3 of the variable region the 1 F11/1 G11 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 54. The present invention also provides an isolated antibody or antigen-binding fragment thereof comprising one or more members selected from the group consisting of: (i) HCDR1 comprising the amino acid sequence G F N I K D T Y M H(SEQIDNO: 11), HCDR2 comprising the amino acid sequence R I D P A N G H T E Y D P K F Q D(SEQ ID NO: 12) and HCDR3 comprising the amino acid sequence s Y F G S i F A Y (SEQ ID NO: 13); (it) HCDR1 comprising the amino acid sequence G F N I K D T Y i H(SEQ IDNO: 19), HCDR2 comprising the amino acid sequence R i D P A N G H T E Y D P K F Q G (SEQ ID NO: 20) and HCDR3 comprising the amino acid sequences Y Y G S I F A Y (SEQ ID NO: 21); (iii) HCDR1 comprising the amino acid sequence G F N I K D Ύ Y i H (SEQ ID NO: 27), HCDR2 comprising the amino acid sequence W I D P E N G D T E Y A P K F Q G fSEQ ID NO: 28) and HCDR3 comprising the amino acid sequence Y Y R Y D D G T /,τ F P Y (SEQ ID NO: 29); (iv) HCDR 1 comprising the amino acid sequence G F N I K D T Y I H(SEQlDNO; 35), HCDR2 comprising the amino acid sequence w I D P A N G Y T K Y A P N F Q G (SEQ ID NO: 36) and HCDR3 comprisjng the amino acid sequence G Y Y R Y Y S L D Y (SEQ ID NO: 37); (v) HCDRI comprising the amino acid sequence G P T F s N H D M A (SEQ (D NO: 43) s HCDR2 comprising the amino acid sequence s i T p s G G T T Y Y R D S V E G (SEQ [D NO: 44) and HCDR3 comprising the amino acid sequence Q M Y Y D G S Y Y Y G L Y Y F D Y (SEQ ID NO: 45); (vi) HCDR1 comprising the amino acid sequence G Y T F T D Y Y M n (SEQ ID NO: 51), HCDR2 comprising the amino acid sequence D I N P N N G G A I Y N Q K F K G (SEQ ID NO: 52) and HCDR3 comprising the amino acid sequence G I I T E I A E D F (SEQ (D NO: 53); (vii) LCDR1 comprising the amino acid sequence S A S S S V S Y L Y(SEQ ID NO: 15), LCDR2 comprising the amino acid sequence R s S H R A s (SEQ ID NO: 16) and LCDR3 comprising the amino acid sequence H Q Y Q S Y P P T (SEQ ID NO: 17); (viii) LCDR1 comprising the amino acid sequence s A S S SV S Y L F (SEQ ID NO: 23), LCDR2 comprising the amino acid sequence R T s Y L A s (SEQ ID NO: 24) and LCDR3 comprising the amino acid sequence H Q Y H T Y P P T (SEQ ID NO: 25); (ix) LCDR1 comprising the amino acid sequence R A S G N I H S Y L A (SEQ ID NO: 31), LCDR2 comprising the amino acid sequence N A K T L P D (SEQ (D NO: 32) and LCDR3 comprising the amino acid sequence Q H F w N T p W T (SEQ ID NO: 33);
(x) LCDR1 comprising the amino acid sequence R A s Q D I s N Y L N(SEQID NO: 39), LCDR2 comprising the amino acid sequence Y s s R L H s (SEQIDNO: 40) and LCDR3 comprising the amino acid sequence Q Q G K T L P L T (SEQID NO: 41); (xi) LCDR1 comprising the amino acid sequence R S S Q S L V Y S D G N T Y L H (SEQ ID NO: 47), LCDR2 comprising the amino acid sequence R v S N R F s (SEQ ID NO: 48) and LCDR3 comprising the amino acid sequence L Q S T H F P P T (SEQ ID NO: 49); and (xii) LCDR1 comprising the amino acid sequence K A S Q N V G T N v v (SEQ ID NO: 55), LCDR2 comprising the amino acid sequence s A S Y R Y s (SEQ ID NO: 56) and LCDR3 comprising the amino acid sequence Q Q Y K T Y P Y T (SEQ ID NO: 57).
Furthermore, the present Invention provides an isolated antibody or antigen-binding fragment thereof of claim xxx comprising one or more members selected from the group consisting of: (a) an immunoglobulin heavy chain comprising the amino acid sequence: E V Q L Q Q S G A E L V K P G A S V T L S C T A S G F M I K D T Y M H W V N Q R P E Q G L V W I G R I D P A M G H T E Y E P K F Q D K A T I T T D T S S N T A Y L K L S S L T S G D T A V Y Y C A R S
Y F G S I F A Y W G Q G T L V T V Ξ A (SEQ ID NO: 10); (b) an immunoglobulin light chain comprising the amino acid sequence: Q I V L T Q S P A
Figure imgf000007_0001
Figure imgf000008_0001
include, e.g., compositions comprising any of the antibodies or polypeptides of the present invention association with a further chemotherapeutic agent, e.g., a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor, in an embodiment of the invention, the further chemotherapeutic agent is ezettmibe, lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin. rivastatin, simvastatin, an azetidinone, bunolol hydrochloride, acebutoloi, alprenolol hydrochloride, atenolol, carteolol hydrochloride, celiproiol hydrochloride; cetamolol hydrochloride, fabetalol hydrochloride, esmolol hydrochloride, levobetaxolol hydrochloride, levobunolol hydrochloride, nadolol, practoloi, propranolol hydrochloride, sotalol hydrochloride, timolol, timolol maleate, btsoprotoi; bisoprolol fumarate, nebivaiol, cicloprolol hydrochloride, dexpropranolol hydrochloride. diacetolol hydrochloride, dilevalol hydrochloride, exaprolof hydrochloride, flestofol sulfate, metatol hydrochloride, metoprofol 2-Propanoi, metoprolol tartrate, pamatoiol sulfate, penbutofof sulfate, practoloi, tiprenolol hydrochloride or toiamolol. Embodiments of the invention also include those wherein the antibody or fragment is a humanized antibody, a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti-idiotypic antibody, a humanized antibody, a bispecific antibody, a cameltzed single domain antibody, a diabody, an scfv, an scfv dimer, a dsfv, a (dsfv)2, a dsFv-dsfv\ a bispecific ds diabody, an Fv. an Fab, an Fab', an F(ab')2, or a domain antibody. In an embodiment of the invention, the antibody or antigen-binding fragment thereof is linked to an immunoglobulin constant region, e.g., a K light chain, γ1 heavy chain, γ2 heavy chain, γ3 heavy chain or γ4 heavy chain. The present invention also provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of the present invention in association with a pharmaceutically acceptable carrier.
The present invention also provides a method for reducing total cholesterol ievel; low density lipoprotein cholesterol level; apoiipoprotein B level; total cholesterol/high density lipoprotein ratio; or low density lipoprotein/high density lipoprotein ratio; or for treating hypercholesterolemia; hyperfipidemia; hypertriglyceridaemia; sitosteroiemia; atherosclerosis; arteriosclerosis; coronary heart disease; vascular inflammation; or xanthoma, in a subject, comprising administering, to said subject, a therapeutically effective amount of any polypeptide or antibody or antigen-binding fragment thereof of the present invention as set forth herein; or pharmaceutical composition thereof; optionally, in association with a further chemotherapeutic agent, e.g., as set forth herein. The present invention also provides a method for producing an antibody or antigen-binding fragment therof of claim 1 comprising introducing one or more polynucleotides into one or more host cells; which polynucleotides encodes and direct expression of said heavy and/or light chain immunoglobulins; and growing said host cells under conditions whereby said heavy and light chain immunoglobulins are expressed; e.g.. wherein said polynucleotide encoding and directing expression of said light chain and said polynucleotide encoding and directing expression of said heavy chain are in separate host ceJSs.
Brief Description of the Figures Figure 1. Mouse anti-human PCSK9 antibody mature variable region amino acid sequences. CDRs are underscored.
Detailed Description of the Invention
The present invention includes methods and compositions for an innovative method lor treating cholesterol disorders. The methods and compositions of the present invention are useful for treating cholesterol disorders by modulating the LDL receptor pathway. Specifically, the methods and compositions of the present invention antagonize the interaction between PCSK9 and LDLR and thereby lead to increased clearance of LDL from the bloodstream, In spite of formidable technical difficulties associated with blocking PPIs, the present invention provides a method for targeting and blocking this interaction, thus, leading to a beneficial effect with regard to blood cholesterol levels.
The term low density lipoprotein receptor (LDLR) includes any such receptor, e.g., human LDLR along with any allelic variant thereof, in one embodiment of the invention, full-length LDLR comprises the following amino acid sequence (see e.g., GenBank NM_G00527.2);
Figure imgf000010_0001
In an embodiment of the invention, a soluble LDLR fragment comprises the following amino acid sequence (Yamamoto ef a/., Cell (1984) 39:27 - 38):
Figure imgf000010_0002
Sn an embodiment of the invention, the EGF-A domain of LDL receptor comprises the amino acid sequence
Figure imgf000010_0003
(SEQ ID NO: 3)
The term ''subject" includes any animal, e.g., a mammal such as a human.
PCSK9 The present invention includes compositions and methods comprising antibodies and antigen-binding fragment thereof which bind specifically to PCSK9, for example, human PCSK9. In some embodiments of the invention, specific PCSK9 polypeptide sequences or antigenic fragments thereof from various species set forth below may be used as an antigen:
Figure imgf000011_0003
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000012_0001
Figure imgf000012_0002
EGF-A
The present invention also provides methods for reducing total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total chotesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio, in a subject, by administering, to the subject, a polypeptide comprising an LDL receptor EGF-A domain optionally in association with a further chemotherapeutϊc agent (e.g., as set forth herein) or a pharmaceutical composition thereof which composes a pharmaceutically acceptable carrier. The EGF-A domain of LDL receptor binds to PCSK9 and, without being bound by any particular theory or mechanism, may reduce the activity of PCSK9 by competing with the full, endogenous LDL receptor for binding to PCSK9 For example, in an embodiment of the invention, the EGF-A domain comprises or consists of the following amino acid sequence
Figure imgf000012_0003
In an embodiment of the invention, human LDL receptor comprises the following amino acid sequence:
Figure imgf000013_0001
The EGF-A domain is underscored and in bold faced text. See also Genbank accession nos.: NP_000518, EAW84170, BAD92646.1 or AAF24515.1.
The present invention also comprises an isolated polypeptide comprising or consisting of an EGF-A polypeptide, for example, in a pharmaceutical composition which includes a pharmaceutically acceptable carrier. The present invention also provides such a polypeptide optionally fused to any other heterologous polypeptide which is not naturally contiguous with the other, immediately adjacent LDL receptor sequences as well as methods of treatments comprising administration of the fused polypeptide e.g., as discussed herein, Any such polypeptide may be referred to herein as an "EGF-A polypeptide" and a polynucleotide encoding an EGF-A polypeptide may be referred to as an "EGF-A polynucleotide". For example, in an embodiment of the invention, the EGF-A polynucleotide comprises the following nucleotide sequence:
Figure imgf000013_0002
As discussed above, the present invention also includes fusions which include the
EGF-A polypeptides and polynucleotides of the present invention and a second polypeptide or polynucleotide moiety, which may be referred to as a "tag". The fused polypeptides of the invention may be conveniently constructed, for example, by insertion of a polynucleotide of the invention or fragment thereof into an expression vector. The fusions of the invention may include tags which facilitate purification or detection. Such tags include glutathtone-S-transferase (GST), hexahistidine (His6) tags, maltose binding protein (MBP) tags, haemagglutinin (HA) tags, cellulose binding protein (CBP) tags and myc tags. Detectable tags such as 32P1 35S5 3H1 14C, 18F, 125I1 131I1 11301In, 76Br, 67Ga, "111Tc, 123S, 111In and 68Ga may also be used to label the polypeptides and polynucleotides of the invention. Methods for constructing and using such fusions are very conventional and well known in the art. Any isolated polynucleotide encoding such an EGF-A polypeptide of the present invention also forms part of the present invention along with any vector comprising such a polynucleotide and a host cell (e.g., bacterial host cell or eukaryotic cell) comprising such a vector. Such polynucleotides operably associated with an expression control sequence (e.g., a promoter) also form part of the present invention. In general, a "promoter" or "promoter sequence" is a DNA regulatory region capable of binding an RNA polymerase in a cell (e.g., directly or through other promoter- bound proteins or substances) and initiating transcription of a coding sequence. A promoter sequence is, in general, bounded at its 3' terminus by the transcription initiation site and extends upstream (51 direction) to include the minimum number of bases or elements necessary to initiate transcription at any level. Within the promoter sequence may be found a transcription initiation site (conveniently defined, for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. The promoter may be operably associated with other expression control sequences, including enhancer and repressor sequences or with a nucleic acid of the invention. Promoters which may be used to control gene expression include, but are not limited to, cytomegalovirus (CMV) promoter (U.S. Patent Nos. 5,385,839 and 5,168.062), the SV40 early promoter region (Benoist, et ai, (1981) Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., (1980) Cell 22:787-797), the herpes thymidine kinase promoter (Wagner, et ai, (1981) Proc. Natl. Acad. Sci. USA 78:1441-1445), the regulatory sequences of the metallothionern gene (Brinster, et a!,, (1982) Nature 296:39- 42); prokaryotic expression vectors such as the β-factamase promoter (Vilia-Komaroff, et ai... (1978) Proc, Natl. Acad. Sci, USA 75:3727-3731), or the fac promoter (DøBoβr, et a!.. (1983) Proc. Natl. Acad. Sci. USA 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American (1980) 242:74-94; and promoter elements from yeast or other fungi such as the GaI 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter or the alkaline phosphatase promoter.
A coding sequence is "under the control of", "functionally associated with" or "operably associated with" transcriptional and translational control sequences in a cell or other expression system when the sequences direct RNA polymerase mediated transcription of the coding sequence into RNA, preferably mRNA, which then may be RNA spliced (if it contains introns) and, optionally, translated into a protein encoded by the coding sequence.
The terms "express" and "expression" mean allowing or causing the information in a gene, RNA or DNA sequence to become manifest; for example, producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene. A DNA sequence is expressed in or by a cell to form an "expression product" such as an RNA (e.g., mRNA) or a protein. The expression product itself may also be said to be "expressed" by the cell. The term 'Vector51 includes a vehicle (e.g., a plasmid) by which a DNA or RNA sequence can be introduced into a host cell, so as to transform the host and, optionally, promote expression and/or replication of the introduced sequence.
Vectors that can be used in this invention include plasm ids, viruses, bacteriophage, integratable DNA fragments, and other vehicles that may facilitate introduction of the nucleic acids into the genome of the host. Plasmids are the most commonly used form of vector but all other forms of vectors which serve a similar function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et ai, Cloning Vectors: A Laboratory Manual, 1985 and Supplements, Elsevier, N. Y., and Rodriguez et al. (eds.), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, 1988, Buttersworth, Boston, MA.
The term "expression system" includes^ for example, a host cell and compatible vector which, under suitable conditions, can express a protein or nucleic acid which is carried by the vector and introduced to the host cell. Common expression systems include E. coϋ host cells and plasmid vectors, insect host cells and Baculovirus vectors, and mammalian host cells and vectors.
Prokaryotic host-vector systems include a wide variety of vectors for many different species. A representative vector for amplifying DNA is pBR322 or many of its derivatives {e.g., pUC18 or 19), Vectors that can be used to express the EGF-A polypeptides include, but are not limited to, those containing the lac promoter (pUC~series); trp promoter (pBR322-frp); Spp promoter (the pfN-sβrϊβs); Sambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius eta!., "Expression Vectors Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", in Rodriguez and Denhardt (eds.) Vectors; A Survey of Molecular Cloning Vectors and Their Uses, 1988, Buttersworth, Boston, pp. 205-236. Many polypeptides can be expressed, at high levels, in an E.coit/T7 expression system as disclosed in U.S. Patent Nos. 4,952,496, 5,693,489 and 5,869,320 and in Davanioo, P., et al., (1984) Proc. Natl. Acad. Sci. USA 81 : 2035- 2039; Studier, F. W., etal., (1986) J. MoL Bioi. 189: 113-130; Rosenberg, A. H., et al., (1987) Gene 56: 125-135; and Dunn, J. J., et al., (1988) Gene 68: 259.
The present invention comprises methods of expression an EGF-A polypeptide of the present invention comprising introducing a vector comprising a polynucleotide encoding said polypeptide (e.g., operably associated with an expression control sequence such as a promoter) into a suitable host ceil and propagating (e.g., growing in a suitable liquid growth medium) the host cell under conditions which are suitable to expression of the polypeptide from the polynucleotide in the vector. Also part of the present invention is any isolated polypeptide with about 90% or more amino acid sequence similarity or identity to that of SEQ ID NO: 3. In an embodiment of the invention, such a polypeptide must bind to PCSK9 or a functional fragment thereof; or inhibit binding of PCSK9 and LDL receptor or any functional fragment of either; or must exhibit the ability to reduce total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total choiesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio in a subject, such as an acceptable animal model (e.g., a mammal such as a dog, primate, rabbit, mouse or rat) or a human.
In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook, era/., 1989"); DNA Cloning: A Practical Approach, Volumes I and Il (D.N. Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & SJ. Higgins eds. (1985)); Transcription And Translation (B.D. Hames & SJ. Higgins, eds. (1984)); Animal Cell Culture (RJ. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); B. Perbal, A Practical Guide To Molecular Cloning (1984); FM Ausubel. Θtai (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, inc. (1994). The term "host cell" includes any cell of any organism that is selected, modified, transfected, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression or replication, by the cell, of a gene, a DNA or RNA sequence or a protein. The terms "isolated polynucleotide" or "isolated polypeptide" include a polynucleotide (e.g., RNA or DNA molecule, or a mixed polymer) or a polypeptide, respectively, which are partiaily or fully separated from other components that are normally found in cells or in recombinant DNA expression systems. These components include, but are not limited to, celi membranes, cell walls, ribosomes, polymerases, serum components and extraneous genomic sequences.
An isolated polynucleotide or polypeptide will, in an embodiment of the invention, be an essentially homogeneous composition of molecules but may contain some heterogeneity.
The present invention contemplates any superficial or slight modification to the amino acid or nucleotide sequences which correspond to the EGF-A polypeptides and polynucleotides of the invention. In particular, the present invention contemplates sequence conservative variants of the nucleic acids which encode the EGF-A polypeptides of the invention. "Sequence-conservative variants" of an EGF-A polynucleotide sequence are those in which a change of one or more nucleotides in a given codon results in no alteration in the amino acid encoded at that position. Function- conservative variants of the EGF-A polypeptides of the invention are also contemplated by the present invention. "Function-conservative variants" are those in which one or more amino acid residues in an EGF-A polypeptide have been changed without altering the overall conformation and/or function of the polypeptide (e.g., ability to bind to PCSK9 or inhibit binding of PCSK9 and an LDL receptor or fragment thereof), including, but, by no means limited to, replacement of an amino acid with one having similar properties. Amino acids with similar properties are well known in the art. For example, polar/hydrophilic amino acids which may be interchangeable include asparagine. glutamϊne, serine, cysteine, threonine, Sysine, arginine, histidine, aspartic acid and glutamic acid; nonpolar/hydrophobic amino acids which may be interchangeable include glycine, alanine, valine, leucine, isoieucine, proline, tyrosine, phenylalanine, tryptophan and methionine; acidic amino acids which may be interchangeable include aspartic acid and glutamic acid and baste amino acids which may be Interchangeable include histidine, lysine and arginine. The present invention includes polynucleotides encoding EGF-A (e.g., SEQ ID NO: 9) and functional fragments thereof as well as nucleic acids which hybridize to the polynucleotides. In an embodiment of the invention, the nucleic acids hybridize under low stringency conditions, under moderate stringency conditions or under high stringency conditions. A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook, eta!., supra). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. Typical low stringency hybridization conditions are 550C, 5X SSC, 0.1% SDS, 0.25% milk, and no formamide at 420C; or 30% formamide, 5X SSC, 0.5% SDS at 420C. Typical moderate stringency hybridization conditions are similar to the low stringency conditions except the hybridization is carried out in 40% formamide, with 5X or 6X SSC at 420C. High stringency hybridization conditions are similar to low stringency conditions except the hybridization conditions are carried out in 50% formamide, 5X or 6X SSC and, optionally, at a higher temperature (e.g., higher than 420C: 570C, 590C, 600C, 620C, 630C, 650C or 680C). In general, SSC is 0.15M NaCI and 0.015M Na-citrate. Hybridization requires that the two nucleic acids contain complementary sequences, although, depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the higher the stringency under which the nucleic acids may hybridize. For hybrids of greater than 100 nucleotides in length, equations for calculating the melting temperature have been derived (see Sambrook. et ai, supra, 9.50-9.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucieotide determines its specificity (see Sambrook, etai, supra). In an embodiment of the invention, such a polynucleotide encodes a polypeptide that must bind to PCSK9 or a functional fragment thereof: or inhibit binding of PCSK9 and LDL receptor or any functional fragment of either; or must exhibit the ability to reduce total cholesterol level, low density lipoprotein cholesterol level, apolipoprotein B level, total cholesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio in a subject, such as an acceptable animal model (e.g., a mammas such as a dog, primate, rabbit, mouse or rat) or a human. Also included in the present invention are pofynucleotides comprising nucleotide sequences and polypeptides comprising amino acid sequences which are at least about 70% identical, preferably at least about 80% identical, more preferably at least about 90% identical and most preferably at least about 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to a reference nucleotide sequence (SEQ ID NO: 9) or reference amino acid sequence (SEQ ID NO; 3), when the comparison is performed by a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences. Polypeptides comprising amino acid sequences which are at least about 70% similar, preferably at least about 80% similar, more preferably at least about 90% similar and most preferably at least about 95% similar (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to the reference EGF-A amino acid sequence of SEQ ID NO: 3, when the comparison is performed with a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences, are also included in the present invention.
Sequence identity refers to exact matches between the nucleotides or amino acids of two sequences which are being compared. Sequence similarity refers to both exact matches between the amino acids of two polypeptides which are being compared in addition to matches between nonidenticai, biochemically related amino acids. Biochemically related amino acids which share similar properties and may be interchangeable are discussed above.
The following references regarding the BLAST algorithm are herein incorporated by reference: BLAST ALGORITHMS: Attschul, S.F., etai, (1990) J. MoI. Biol. 215:403- 410; Gish, W,, et ai., (1993) Nature Genet 3:266-272; Madden, T.L., et ai, (1996) Meth. Enzymol. 266:131-141; Altschuf, S.F., etai., (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et ai., (1997) Genome Res. 7:649-656; Wootton, J. C1 et ai., (1993) Comput Chem, 17:149-163; Hancock, JM, et al.t (1994) Comput. Appi. BϊoscL 10:67-70; ALIGNMENT SCORING SYSTEMS: Dayhoff, M.O., et ai, "A model of evolutionary change in proteins." in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppi. 3, M.O. Dayhoff (ed.), PP- 345-352, Natl. Biomed. Res. Found., Washington, DC; Schwartz, R. M., et ai., "Matrices for detecting distant relationships." in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3." M.O. Dayhoff {ed.), pp. 353-358, Natl. Biomed. Res. Found.. Washington DC; Affschul, S.F., (1991) J. MoI. Biol. 219:555-565; States, D.J., et at, (1991) Methods 3:66-70: Henskoff, S., etai., (1992) Proc. Natl Acad. Set. USA 89:10915-10919; Altschul. S. F., et ai., (1993) J. MoI. Evol. 36:290-300; ALIGNMENT STATISTICS: Karlϊn, S., etal., (1990) Proc. Natl, Acad. Sci. USA 87:2264-2268; Karlrn, S., θtal,, (1993) Proc. Natl, Acad. ScL USA 90:5873-5877; Dembo, A., etal., (1994) Ann. Prob.22:2022-2039; and Altschul, S.F. "Evaluating the statistical significance of multiple distinct local alignments." in Theoretical and Computational Methods in Genome Research (S. Suhai, ed.}, (1997) pp.1-14, Plenum, New York,
Antibodies
The present invention includes methods and compositions comprising anti-PCSK9 antibodies and antigen-binding fragments thereof. The term anti-PCSK9 antibody or the like includes any antibody that binds specifically to PCSK9 (e.g., human PCSK9). The anti-PCSK9 antibodies and antigen-binding fragments thereof used in the present invention include antibodies and fragments which were raised against or bind to the whole PCSK9 protein as well as antibodies raised against or bind to particular short epitopes within PCSK9, e.g., the catalytic domain of PCSK9 or a portion thereof (e.g., binding to an VFAQSIPWNLER epitope (SEQ ID NO: 8)) or a C-terminal domain of PCSK9 (i.e., C- terminal relative to the cat domain of PCSK9)-having amino acids SRSGKRRGERMEA (amino acids 490-502 of SEQ ID NO: 4). In an embodiment of the invention, the anti- PCSK9 antibody or antigen-binding fragment thereof binds to the domain of PCSK9 which interacts with the EGF-A domain of the LDL receptor. Specific isolated mouse anti-human PCSK9 antibody immunoglobulin sequences of the present invention are set forth below. CDR sequences for each immunoglobulin chain are underscored.
11 B5 immunoglobulin heavy chain B V Q L Q Q S G A E L V K P G A S V T L S C T A S G F N I K D T Y
M__H W V N Q R P E Q G L V W I G R I D P A N G H T E Y D P K F Q D
K A T I T T D T S S N T A Y L H L S S L T S G D T A V Y Y C A R S Y F G S I F A Y W G Q G T L V T V S A
(SEQ ID NO: 10)
HCDR1: G F N I K D T Y M H (SEQ ID NO: 11)
HCDR2: R I D p A H G H T E Y D P K F Q D (SEQ ID NO: 12)
HCDR3: S Y F G S I F A Y (SEQ ID NO: 13)
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
The present invention includes isolated polypeptides (e.g., antibodies and antigen- binding fragments thereof) comprising one or more (e.g., 3) CDRs taken from the light and/or heavy chain immunoglobulin set forth above as defined by the convention set forth in Kabai "Sequences of Proteins of lmmunologicai Interest" (National Institutes of Health, Befhesda, Md,, 1987 and 1991 } or in Chotbia et aL J. MoL Bioi, 196:901 (1987); Nature 342:878 (1989}; and J. MoI. Biol. 186:651 (1989) (Kabat or Chothsa} or Al-Lazikani et aL, J. Mot. Biol. 273: 927-948 (1997}. Thus, the invention includes any antibody or antigen-binding fragment thereof comprising one or more of the light chain and/or heavy chain immunoglobulin CDRs set forth above, in an embodiment of the invention, the antibody or fragment comprises all 3 light chain and/or ail 3 heavy chain CDRs, e.g., in the order specified above. Embodiments of the invention include anfi-PCSK9 antibodies and antigen-binding fragments thereof, e.g., as set forth above wherein, the antibodies or fragments are monoclonal antibodies, camelized single domain antibodies, polyclonal antibodies, biεpecific antibodies, chimeric antibodies, recombinant antibodies, anti-idiotypic antibodies, humanized antibodies, bispecific antibodies, diabodies, single chain antibodies, disulfide Fvs (dsfv), Fvs, Fabs, Fab's, F(ab!)aS and domain antibodies. Thus, the term antibody covers, but is not limited to, monoclonal antibodies, polyclonal antibodies, muitispecific antibodies (e.g., bispecific antibodies). The term antigen-binding fragment of an antibody encompasses a fragment or a derivative of an antibody, typically including at least a portion of the antigen-binding or variable regions (e.g., one or more CDRs) of the parental antibody, that retains at least some of the binding specificity of the parental antibody. Examples of antibody antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; dsFv; (dsFv)2, ds diabodies; dsFv-dsFv'; single-chain antibody molecules, e.g., sc-Fv, sc-Fv dimers (bivalent diabodies); bispecific diabodies; and muitispecific antibodies formed from antibody fragments.
The present invention includes anti-PCSK9 antibodies and antigen-binding fragments thereof which binds specifically to PCSK9, for example, human PCSK9. in an embodiment of the invention an antibody or fragment that binds specifically to human PCSK9 binds preferentially to human PCSK9 as compared to that of rat, mouse or chimp PCSK9. Preferential binding to human PCSK9 means binding with an affinity which is greater than that of rat, mouse or chimp PCSK9 binding to any degree (e.g., 1%, 10%, 50%, 100%, or 10X higher affinity). In an embodiment of the invention, an anti-human PCSK9 antibody binds to human PCSK9 without any detectable binding to any other species of PCSK9 (e.g., no detectable binding to a mouse or rat PCSK9). Specific anti- PCSK9 binding refers to binding of the antibody to PCSK9 or an antigenic fragment thereof with a Kd at least about 100-fold higher than that of any other protein that might be bound and a minimum Kd of about 500 nM.
Any suitable method for generating antibodies may be used. For example, a recipient may be immunized with PCSK9 or an immunogenic fragment thereof. Any suitable method of immunization can be used. Such methods can include adjuvants, other immunostimuiants, repeated booster immunizations, and the use of one or more immunization routes. Any suitable source of PCSK9 can be used as the immunogen for the generation of the antibodies and fragments of the compositions and methods disclosed herein. Such forms include, but are not limited whole protein, peptide(s), and epitopes generated through recombinant, synthetic, chemicai or enzymatic degradation means known in the art. Any form of the antigen can be used to generate the antibody that is sufficient to generate a biologically active antibody. Thus, the eliciting antigen may be a single epitope, multiple epitopes, or the entire protein alone or in combination with one or more immunogenictty enhancing agents known in the art. The eliciting antigen may be an isolated full-length protein, a ceil surface protein (e.g., immunizing with ceiis transfected with at least a portion of the antigen), or a soluble protein fragment.
Any suitable method can be used to elicit an antibody with the desired biologic properties to inhibit PCSK9. Monoclonal antibodies (mAbs) may be prepared from various mammalian hosts, such as mice, rats, other rodents, humans, other primates, etc. Description of techniques for preparing such monoclonal antibodies may be found in, eg., Stites etai. (eds.) BASIC AND CLINICAL IMMUNOLOGY {4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) ANTIBODIES: A LABORATORY MANUAL CSH Press; Goding (1986) MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, NY. Thus, monoclonal antibodies may be obtained by a variety of techniques familiar to researchers skilled in the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell. See Kohler and Milstein (1976) Eur, J. Immunol. 6:511-519, Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. See, e.g., Doyle etai. (eds. 1994 and periodic supplements) CELL AND TISSUE CULTURE: LABORATORY PROCEDURES, John Wiley and Sons, New York, NY. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences that encode a monoclonal antibody or an antigen binding fragment thereof by screening a DfMA library from human B cells according, e.g., to the general protocol outlined by Huse et ai. (1989) Science 246:1275-1281 ,
Other suitable techniques involve selection of libraries of antibodies in phage or similar vectors. See, e.g., Huse et ai. supra; and Ward etai. (1989) Nature 341 :544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covaientiy or non-covalently, a substance that provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like.
Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752;
3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabtlly U.S. Patent No. 4,816,567; and Queen et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033; or made in transgenic mice, see
Mendez et al (1997) Nature Genetics 15:146-156.
Mice which produce human immunoglobulins when immunized with an given antigen are also available in the art. See e.g., Lonberg, N., et al.t (1994) Nature 368(6474): 856-859; Lonberg, N. (1994) Handbook of Experimental Pharmacology
113:49-101 ; Lonberg, N., etai., (1995) Intern. Rev. Immunol. 13:65-93, and Harding, F., et al, (1995) Ann. N. Y Acad. Sci 764:536-546); Taylor, L., et aL, (1992) Nucleic Acids
Research 20:6287-6295; Chen, J., et ai., (1993) International immunology 5: 647-656;
Tuaitlon, et aL, (1993) Proc. Natl. Acad. Sci USA 90:3720-3724; Choi, et ai, (1993) Nature Genetics 4:117-123; Chen, J., et ai, (1993) EMBO J. 12: 821- 830; Tuaϋion, et ai,
(1994) J Immunol. 152:2912-2920; Lonberg, etai,, (1994) Nature 368(6474): 856-859;
Lonberg, N. (1994) Handbook of Experimental Pharmacology 113:49-101 ; Taylor, L, et ai, (1994) International Immunology 6: 579-591 ; Lonberg, N., et ai, (1995) Intern. Rev.
Immunol. Vol. 13: 65-93; Harding, F., et ai, (1995) Ann. N.Y Acad. Sci 764:536-546; Fishwild, D., et ai., (1996) Nature Biotechnology 14: 845-851 and Hardings et ai, (1995)
Annals NY Acad. Sci. 764:536-546. See further, U.S. Patent Nos. 5,545,806; 5,569,825;
5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661 ,016; 5,814,318; 5,874, 299; 5,770,429 and 5,545,807; and International Patent Application Publication Nos. WO 98/24884; WO
94/25585; WO 93/12227; WO 92/22645 and WO 92/03918. A "Fab fragment" is comprised of one light chain and the CH 1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.
An "Fc" region contains two heavy chain fragments comprising the CH1 and
CH2 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.
A "Fab1 fragment" contains one light chain and a portion of one heavy chain that contains the VH domain and the CH 1 domain and also the region between the CH1 and
CH2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab' fragments to form a F(abr) 2 motecule. A "F(ab')2 fragment" contains two light chains and two heavy chains containing a portion of the constant region between the CH 1 and CH2 domains, such that an interchain disulfide bond is formed between the two heavy chains, A F(ab') 2 fragment thus is composed of two Fab! fragments that are held together by a disulfide bond between the two heavy chains.
"Disulfide stabilized Fv fragments" and "dsFv" include molecules having a variable heavy chain (VH) and/or a variable light chain (VL) which are linked by a disulfide bridge.
The Tv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions.
The term "single-chain Fv" or "scFv" antibody refers to antibody fragments comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the VH and VL chains to pair and form a binding site (e.g., 5-12 residues long). For a review of scFv, see Pluckthun (1994) THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES, vol. 113, Rosenburg and Moore eds. Springer- Verlag, New York, pp. 269-315. See also, International Patent Application Publication No. WO 88/01649 and U.S. Pat. Nos. 4,946, 778 and 5,260,203. A "domain antibody" is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more VH regions are covaJently joined with a peptide linker to create a bivalent domain antibody. The two VH regions of a bivalent domain antibody may target the same or different antigens. A "bivalent antibody" comprises two antigen-binding sites. In some instances, the two binding sites have the same antigen specificities. However, bivalent antibodies may be bispecific, For example, the present invention comprises scfv dinners and dsfv dimers, each of which scfv and dsfv moieties may have a common or different antigen binding specificity. In an embodiment of the invention, a (dsfv)£ comprises three peptide chains: two VH moieties linked by a peptide linker and bound by disulfide bridges to two VL moieties. In an embodiment of the invention, a bispecific ds dsabody comprises a VH1- VL2 (tethered by a peptide linker) linked, by a disulfide bridge between the VH1 and VLi, to a VL1-VH2 moiety (also tethered by a peptide linker), In an embodiment of the invention, a bispecific dsfv-dsfv' also comprises three peptide chains: a VH1-VH2 moiety wherein the heavy chains are linked by a peptide (inker (e.g., a long flexible linker) and are bound to VLt and VL2 moieties, respectively, by disulfide bridges; wherein each disulfide paired heavy and light chain has a different antigen specificity, in an embodiment of the invention, an scfv dimer (a bivalent diabody) comprises a VH- VL moiety wherein the heavy and Sight chains are bound to by a peptide linker and dimerized with another such moiety such that VHs of one chain coordinate with the VLs of another chain and form two identical binding sites. In an embodiment of the invention a bispecific diabody comprises VH1-VL2 moiety {linked by a peptide linker) associated with a VLrVH2 {linked by a peptide linker), wherein the VHi and VLi coordinate and the VH2 and VL2 coordinate and each coordinated set has diverse antigen specificities.
The term "monoclonal antibody", as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of antibodies directed against {or specific for) different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made recombinantiy or by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal antibodies1' may also be isolated from phage antibody libraries using the techniques described in Clackson et a!. (1991 ) Nature 352: 624-628 and Marks et a!. (1991 ) J. MoL Biol. 222: 581 -597, for example. See also Presta (2005) J. Allergy Clin. Immunol. 116:731. Monoclonel antibodies include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or Sight chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, white the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et aL, (1984) Proc. Natl Acad, Sci.USA 81 : 6851-6855). For example, variable domains are obtained from an antibody from an experimental animal (the "parental antibody3'), such as a mouse, and the constant domain sequences are obtained from human antibodies, so that the resulting chimeric antibody wiSl be less likely to elicit an adverse Immune response in a human subject than the parental mouse antibody.
A recombinant antibody or antigen-binding fragment thereof of the invention is, in an embodiment of the invention, an antibody which is produced recombinantly, e.g., expressed from a polynucleotide which has been introduced into an organism (e.g., a plasmid containing a polynucleotide encoding the antibody or fragment transformed into a bacterial cell (e.g., E.coli) or a mammalian cell (e.g., CHO cell)), followed by isolation of the antibody or fragment from the organism. The present invention comprises methods for expressing any antibody or antigen-binding fragment theref or polypeptide of the present invention. For example, an embodiment of the present invention comprises a process for producing an immunoglobulin molecule or an immunologically functional immunoglobulin fragment comprising at least the variable domains of the immunoglobulin heavy and/or light chains, in a host cell (e.g., a single host cell), such as a CHO cell (e.g... CHO-K1 or DXB11 cell), comprising the steps of (i) transforming said host cell with a first polynucleotide encoding at least the variable domain of the immunoglobulin heavy chain and a second polynucleotide encoding at least the variable domain of the immunoglobulin light chain, and (ii) independently expressing said first polynucleotide and said second polynucleotide so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed host cell. \n an embodiment of the invention, the polynucleotides are operably linked to a promoter such as a CMV promoter. The present invention also comprises a process for producing an immunoglobulin molecule or an immunologically functional immunoglobulin fragment comprising introducing transforming a first haploϊd yeast host cell (e.g., Pichia such as Pichia pasioris) with a first polynucleotide encoding at ieast the variable domain of the immunoglobulin heavy chain or fight chain and transforming a second haptotd yeast host cell (e.g., Pichia such as Pichia pastoris) with a second polynucleotide encoding the other chain, atowlng the hapfoid ceils to form polyploids, such as diploids, (e.g., via mating), selecting the polyploids from the haploids, and growing the polyploids under conditions wherein the heavy and light chains are expressed in the polyploids and, optionally, secreted into the culture medium.
In an embodiment of the invention, polynucleotides introduced into a host cell remain ectopic whereas in another embodiment of the invention, the polynucleotide is integrated into the chromosomal DNA of the host cell.
In an embodiment of the invention, a method for producing an antibody or fragment further comprises isolating the chains that are expressed from the host eell and/or culture medium. The present invention also includes camelized single domain antibodies. See, e.g., Muyldermans etai. (2001) Trends Biochem. ScL 26:230; Reichmann etal. (1999) J. Immunol. Methods 231 : 25; WO 94/04678; WO 94/25591 ; U.S. Pat. No. 6,005,079, which are hereby incorporated by reference in their entireties). Camelidae (camels, dromedaries and llamas) comprise IgG antibodies in which are devoid of light chains and therefore called 'heavy-chain4 IgGs or HCAb (for heavy-chain antibody). HCAbs typically have a molecular weight of -95 kDa since they consist only of the heavy-chain variable domains. Although the HCAbs are devoid of light chains, they have an authentic antigen-binding repertoire (Hamers-Casterman etal., Nature (1993) 363:446-448; Nguyen et al., kόv. Immunol. (2001) 79:261-296; Nguyen et ai, Immunogenetics. (2002) 54:39-47). In one embodiment, the present invention provides single domain antibodies comprising two VH domains with modifications such that single domain antibodies are formed.
As used herein, the term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VN-VL or Vt- VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodses are described more fully in, e.g., EP 404,097; WO 93/11161 ; and HolNger et al. (1993) Proc. Natl. Acad. ScL USA 90: 6444-6448. For a review of engineered antibody variants generally see Holliger and Hudson (2005) Nat. Biotechnoi. 23:1126-1136.
As used herein, the term "humanized antibody" refers to forms of antibodies that contain sequences from both human and non-human {e.g., mouse or rat) antibodies. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially ail of the hypervariable loops (CDRs) correspond to those of a non-human immunoglobulin, and ail or substantially ail of the framework (FR) regions are those of a human immunoglobulin sequence. An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also called CDRs, Several public sources for human framework sequence are available including, e.g., V-base (IvIRC Center for Protein Engineering), The humanized antibody may optionally comprise at feast a portion of a human immunoglobulin constant region (Fc), For example, an embodiment of the invention includes humanized anti-PCSK9 (e.g., anti-human PCSK9) antibodies comprising the specific mouse immunoglobulin CDRs and human immunoglobulin framework regions which are set forth herein, e.g., fused to a human immunoglobulin constant region. The following U.S. patents are herein incorporated by reference: 5,585,089, 5,693,761 , 5,693,762 and 6,180,370. For example, embodiments of the invention include those wherein any of the following groups of CDRs are included within a humanized antibody of the invention:
(i) HCDR1 comprising the amino acid sequence G F N i K D T Y M H(SEQ ID NO: 11), HCDR2 comprising the amino acid sequence R I D P A N G H T E Y D P K F Q D(SEQ ID NO: 12) and HCDR3 comprising the amino acid sequence S Y F G s I F A Y (SEQ ID NO: 13); (ϋ) HCDR1 comprising the amino acid sequence G F N I K D T Y I H(SEQIDNO: 19), HCDR2 comprising the amino acid sequence R I D P A N G H T E Y D P K F Q G (SEQ ID NO: 20) and HCDR3 comprising the amino acid sequence s Y Y G S I F A Y (SEQ ID NO: 21); (iii) HCDR1 comprising the amino acid sequence G F N I K D Y Y I H (SEQ ID NO: 27), HCDR2 comprising the amino acid sequence w I D P E N G D T E Y A P K F Q G (SEO ID NO: 28) and HCDR3 comprising the amino acid sequence Y Y R Y D D G T w F P Y (SEQ ID NO: 29);
(iv) HCDR1 comprising the amino acid sequence G F N I K D T Y I H (SEQ ID NO: 35), HCDR2 comprising the amino acid sequence K i D p A N G Y T K Y A P N F Q G (SEQ ID NO: 36) and HCDR3 comprising the amino acid sequence G Y Y P. Y Y S L D Y (SEQ IP NO: 37);
(v) HCDR 1 comprising the amino acid sequence G F T F S N H D K A(SEQIDNO: 43), HCDR2 comprising the amino add sequence s i T p s G G T T Y Y R D S E G (SEQ ID NO; 44) and HCDR3 comprising the amino acid sequence Q N Y Y D G s Y Y Y G L Y Y F D Y (SEQ ID NO: 45);
(vi) HCDR1 comprising the amino acid sequence G Y T F T D Y Y M M(SEQIDNO: 51), HCD R2 com prising the amino acid sequence D I N P N ISF G G A I Y M Q K F K G (SEQ JD NO: 52) and HCDR3 comprising the amino acid sequence G i I T E i A E D F (SEQ ID NO: 53);
(vis) LCDR1 comprising the amino acid sequence S A S S S V S Y L Y (SEQ ID NO: 15), LCDR2 comprising the amino acid sequence R s s H R A s (SEQ ID NO: 16) and LCDR3 comprising the amino acid sequence H Q Y Q S Y P F T (SEQ ID NO: 17); (viii) LCDR1 comprising the amino acid sequence s A S S S V S Y L F (SEQ lDNO: 23), LCDR2 comprising the amino acid sequence R T s Y L A S (SEQ SD NO: 24) and LCDR3 comprising the amino acid sequence H Q Y H T Y P P T (SEQ ID NO: 25); (ix) LCDR1 comprising the amino acid sequence R A S G N I H S Y L A (SEQlD NO: 31), LCDR2 comprising the amino acid sequence N A K T L F D (SEQiDNO: 32) and LCDR3 comprising the amino acid sequence Q H F w N T P w T (SEQiD NO: 33);
(x) LCDR 1 comprising the amino acid sequence R A S Q D I S N Y L N(SEQID NO: 39), LCDR2 comprising the amino acid sequence Y s S R L H s (SEQIDNO: 40) and LCDR3 comprising the amino acid sequence Q Q G K T L P L T (SEQ ID NO: 41);
(xi) LCDR 1 comprising the amino acid sequence R S S Q S L V Y S D G N T Y L H (SEQ ID NO: 47), LCDR2 comprising the amino acid sequence R v s N R F S (SEQ ID NO: 48) and LCDR3 comprising the amino acid sequence L Q S T H F P P T (SEQ ID NO: 49); or (xii) LCDR1 comprising the amino acid sequence K A S Q N VG T N V V (SEQID NO: 55), LCDR2 comprising the amino acid sequence S A S Y R Y S (SEQiD NO: 56) and LCDR3 comprising the amino acid sequence Q Q Y K T Y P Y T (SEQiD NO: 57).
The present invention also includes isolated polypeptides comprising the amino acid sequences of the immunoglobulin chains set forth herein along with isolated polynucleotides encoding said polypeptides, vectors comprising the polynucleotides and isolated host ceils comprising the polynucleotides and vectors (e.g., CHO ceils, bacterial celis such as E. coll and fungal cells such as S.cerevisiae and Pichia such as Pichia pasioris), Methods for making the polypeptides are also included: comprising introducing a polynucleotide or vector into a host cell and culturing the host ceil under condition whereby the polypeptide can be expressed and, optionally, secreted and, optionally, isolating the polypeptide.
Therapeutic Methods, Administration and Pharmaceutical Formulations
The present invention provides methods for treating or preventing disorders of cholesterol or lipid homeostasis and disorders associated therewith, e.g., hypercholesterolemia, hyperlipidemia, hypertrigiycehdaemia, sitosterofemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation and xanthoma by administering a therapeutically effective amount of an anti-PCSK9 antibody (e.g., as set forth herein) or antigen-binding fragment thereof or an EGF-A polypeptide.
The term hypercholesterolemia includes, e.g., familial and non-familial hypercholesterolemia. Familial hypercholesterolemia (FHC) is an autosomal dominant disorder characterized by elevation of serum cholesterol bound to low density lipoprotein (LDL). Familial hypercholesterolemia includes both heterozygous FHC and homozygous FHC.
Hyperlipidemia is an elevation of lipids in the bloodstream. These lipids include cholesterol, cholesterol esters, phospholipids and triglycerides. Hyperlipidemia includes for example, type I, Ha, Mb1 Ml, IV and V. Sitosterolemia is a rare inherited plant sterol storage disease. In general, the metabolic defect in the affected patient causes hyperabsorption of sitosterol from the gastrointestinal tract, decreased hepatic secretion of sitosterol with subsequent decreased elimination, and altered cholesterol synthesis.
Atherosclerosis includes hardening of arteries associated with deposition of fatty substances, cholesterol, cellular waste products, caicium and fibrin in the inner lining of an artery. The buildup that results is called plaque.
Arteriosclerosis includes the diffuse build-up and deposition of calcium in artery walls which leads to hardening.
The present invention also provides methods for improving blood cholesterol markers associated with increased risk of heart disease. These markers include high total cholesterol, high LDL, high total cholesterol to HDL ratio and high LDL to HDL ratio.
In general, a total cholesterol of less than 200 mg/dL is considered desirable, 200- 239 mg/dL is considered borderline high and 240 mg/dL and above is considered high. in general, a blood LDL ievef of less than 100 mg/dL is considered optimal; 100- 129 mg/dL is considered near optimal/above optimal, 130-159 mg/dL is considered borderline high, 160-189 mg/dL is considered high and 190 mg/dL and above is considered very high.
In general, HDL levels considered normal are at least 35 - 40 mg/dL. Another indicator of heart disease risk is the ratio of total cholesterol to HDL. In general, a very low risk of heart disease correlates with a ratio of <3,4 (men) or <3.3
(women); a low risk is associated with a ratio of 4.0 (men) or 3.8 (women), an average risk is associated with a ratio of 5.0 (men) or 4.5 (women), a moderate risk is associated with a ratio of 9,5 (men) or 7.0 (women) and a high risk is associated with a ratio of >23 (men) or >11 (women). A further indicator of heart disease risk is the ratio of LDL to HDL. In general, a very low risk is associated with a ratio of 1 (men) or 1.5 (women), an average risk is associated with a ratio of 3.6 (men) or 3.2 (women), a moderate risk is associated with a ratio of 6.3 (men) or 5.0 (women) and a high risk is associated with a ratio of 8 (men) or 6.1 (women). In an embodiment of the invention, anti-PCSK9 antibodies and antigen-binding fragments thereof or EGF-A polypeptides of the invention are formulated into a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier. For general information concerning formulations, see, e.g., Gilman, er a/., (eds.) (1990), The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.; Avis, er a/., (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, New York; Lteberman, era/., (eds.) (1990) Pharmaceutical Dosage Forms: Tablets Dekker, New York; and Lieberman, et a/., (eds.) (1990), Pharmaceutical Dosaae, Forms: Disperse Systems Dekker, New York, Kenneth A. Walters (ed.) (2002) Dermatologiesl and Transdermal Formulations (Drugs and the Pharmaceutical Sciences). Vol 119, Marcel Dekker.
The anti-PCSK9 antibodies and antigen-binding fragments thereof or EGF-A polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the antibody or fragment is combined in admixture with a pharmaceutically acceptable carrier. Carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; tow molecular weight polypeptides; proteins, such as serum atoumin, gelatin or immunoglobulins; hydrophsfc polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamϊne, asparagine. arginine or lysine; monosaccharides. disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterfoils such as sodium; and/or nonionic surfactants such as Tween™, Pluronics™ or PEG. The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitutlon. Therapeutic or pharmaceutical compositions or formulations herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The route of administration of the antibodies and antigen-binding fragments thereof of the invention are, in an embodiment of the invention, by a parenteral route (e.g., intravenous, subcutaneous, intraarterial, intratumoral, intramuscular, intraperitoneal).
Dosages and desired anti-PCSK9 or EGF-A polypeptide concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug Development, Yacobi etai., Eds., Pergamon Press, New York 1989, pp. 42 96.
When used to treat a disorder in a subject (e.g., as discussed herein), a therapeutically effective dosage or amount of anti-PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptides is administered to the subject. In an embodiment of the invention, a therapeutically effective dosage is a dosage sufficient to decrease total serum cholesterol, decrease blood LDL levels or increase biood HDL levels to any degree whatsoever, Sn an embodiment of the invention a therapeutically effective dosage of anti- PCSK9 antibody or antigen-binding fragment thereof (e.g., as set forth herein) for treatment of hypercholesterolemia, hyperlipidemia, hypertriglyceridaemia, sitosterolemϊa, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma or for treatment of any blood marker of heart disease risk (e.g., as discussed herein) is about 0.1 mg/kg (body weight)/week to about 1.0 mg/kg/week. A therapeutically effective dosage of soluble PCSK9 EGF-A polypeptide is, in an embodiment of the invention, about 0.25 mg/kg/week to about 25 mg/kg/week. When possible, administration and dosage of an agent (e.g., further therapeutic agents discussed herein) is done according to the schedule listed in the product information sheet of the agents, in the Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th Ed); Medical Economics Company; ISBN: 1563634457; 57th edition (November 2002), as well as therapeutic protocols well known in the art.
A physician or clinician may monitor the blood cholesterol levels in a subject being treated or about to be treated with an anti-PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptide and make adjustments to the subject's treatment regimen as needed to reach a positive medical outcome.
Further chemotherapeutrc agents
The present invention provides methods and compositions for treating disorders of lipid and cholesterol metabolism (e.g., any set forth herein) by administration of an anti- PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptide. The antibodies may, in an embodiment of the invention, be provided or administered in association with any additional or further chemotherapeutic agent. In an embodiment of the invention, the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin- converting enzyme (ACE) inhibitor, a coronary vasodilator, a diuretic or an adrenergic stimulant. In an embodiment of the invention, the further therapeutic agent is a cholesterol lowering medication such as an HMG-CoA reductase inhibitor.
Cardiovascular agents which may used in connection with the present invention include those for treatment or prevention of lipid and/or cholesterol disorders or hypertension and other cardiovascular disorders and diseases. Disorders of lipid or cholesterol metabolism may be caused or aggravated by hypertension. Hypertension is defined as persistently high blood pressure. Generally, adults are classified as being hypertensive when systolic blood pressure is persistently above 140 mmHg or when diastolic blood pressure is above 90 mmHg. Long-term risks for cardiovascular mortality increase in a direct relationship with persistent blood pressure. Examples of antihypertensive agents which may be used in the present invention include e.g., calcium channel blockers, angiotβnsin-converting enzyme (ACE) inhibitors. angiotensin-l f receptor antagonists, diuretics, adrenergic Mockers including beta- adrenergic receptor blockers and alpha-acfrenergic receptor blockers or diuretics. Other cardiac drugs that may be provided in association with an anti-PCSK9 antibody or antigen-binding fragment thereof includes anti-anginal agents, such as adrenergic stimulants or coronary vasodilators and HMG-CoA reductase inhibitors.
HIVIG-CQA reductase inhibitors inhibit the HMG-CoA reductase enzyme and, thus, reduce production of cholesterol in the body of a subject. HMG-CoA reductase inhibitors include, e.g., lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin and simvastatin
Figure imgf000038_0001
Adrenergic blockers include those compounds which are β-receptor inhibitors and/or α-receptor inhibitors. Adrenergic blockers which are β-receptor inhibitors include a class of drugs that antagonize the cardiovascular effects of catecholamines in hypertension, angina pectoris, and cardiac arrhythmias, β-adrenergic receptor blockers include, but are not limited to, bunoioi hydrochloride (1(2H)-Naphthalenone, 5-[3-(1 ,1- dtmethylethyl)amino]-2-hydroxypropoxy]-3i4-dihydro-, hydrochloride, CAS RN 31969-05-8 which can be obtained from Parke-Davis); acebutoiol (±N-[3-Acetyl-4-[2-hydroxy-3-[(1 methylethyf)amino]propoxy]phenyl]- butanamide, or (±)-3'-Acetyl-4'-[2-hydroxy -3- (isopropyfamino) propoxy] butyraniSide); acebυtolol hydrochloride (such as N-[3~acetyl-4-[2~hydroxy-3-[1-rnethyl- ethylβ)amino}propoxy]ρhenyl]-!monohydrocochloride. (±-r3*-Acetyl-4!-[2~hydrQxy-3- (isoρropylamtno)propøxy]butyramiide monohydrochlorfde, for example, SECTRAL® Capsules available from Wyeth-Ayerst); alprenolol hydrochloride (2-Propanol, 1-[(1- methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-,hydrochIoride, CAS RN 13707-88-5 see Netherlands Patent Application No. 6,605,692); atenolol (such as benzeneacetamide 4- [2'-hydroxy-3'-((1-methylethyl)amino]propoxy]- , for example, TENORMIN® I. V. Injection available from AstraZeneca); carteolol hydrochloride (such as 5-[3-[(1 ,1 - dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-2{1 H)-quinolinone monohydrochloride, for example, Cartrol® Filmtab® Tablets available from Abbott); Celiprotol hydrochloride {3-[3-Acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxyl]phenyl3-1 ,1- diethylurea monohydrochloride, CAS RN 57470-78-7, also see in US Patent No. 4,034,009); cetamolol hydrochloride (Acetamide, 2-[2-[3-[(1 ,1 -dimethylethyl)amino]-2- hydroxypropoxy]-phenoxy]-N-methyl-,monohydrochloride, CAS RN 77590-95-5, see also US Patent No. 4,059,622); labetalol hydrochloride (such as 5-[1-hydroxy-2-[(1-methyl-3- phenylpropyl) amino] ethyl]salicylamtde monohydrochloride, for example, NORMODYNE® Tablets available from Schering; esmolol hydrochloride ( (±)-Methyl p-[2-hydroxy-3- (isopropylamino) propoxy] hydrocinnamate hydrochloride, for example, BREVIBLOC® Injection available from Baxter); levobetaxoiol hydrochloride (such as (S)-1-[p-[2- (cyclopropyImethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride, for example, BETAXON™ Ophthalmic Suspension available from Alcon); ievobunoSol hydrochloride (such as (-)-5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)- naphthalenone hydrochloride, for example, BETAGAN® Liquifilm® with C CAP®
Compliance Cap available from Allergan); nadolol (such as 1-(tert-butylamino)-3~[(5,6,7,8- tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol, for example, Nadolol Tablets available from Mylan); practolol (Acetamide, N-[4-[2-hydroxy-3-[1-methylethyl)amino]- propoxy]phenyl]-, CAS RN 6673-35-4, see also US Patent No3,408,387); propranolol hydrochloride (1-(lsopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride CAS RN 318-98-9); sotalol hydrochloride (such as d,l-N-[4-[1-hydroxy-2-[(1- methy(ethyl}amino]ethyl]-phenyl]methane-sulfonamide monohydrochloride, for example, BETAPACE AF™ Tablets available from Berlex);timolol (2-Propanol. 1-[(1 ,1- dimethylethyl)amino]-3-[[4-4(4-morphoIinyl)-1 ,2,5-thiadiazof-3-yl3oxy3-,hemthydrate. (S)-, CAS RN 91524-16-2); timolol maleate (S)-1-[(1. 1-dimethylethyl) amsno]-3-[[4- (4- morpholinyl)-1 , 2, 5-thiadiazoI -3- yl] oxy]-2-propanol ( Z )-2-butenedioate (1 :1 ) salt, CAS RN 26921-17-5); bisoprolol (2-Propanot, 1-f4-[[2-(1-methylethoxy)ethoxy]- metbyl]phenoxyl]-3-[(1-methylethyl)amino]-, (±). CAS RN 66722-44-9); bisoproioi fumarate {such as (+}-1-[4-p-(1-Methylethoxy) ethoxy]methyl]phenoxy]-3-[(1 -rnethylethyl}amino3-2- propanol (E) -2-butenedϊoate (2:1) (salt), for example, 2EBETA™ Tablets available from Lederie Consumer); nebivaloi (2H-1-Benzopyran-2-methanoi, αα'- [iminobis(methylene)]bis[6-fluoro-3!4-dihydro-, CAS RN 99200-09-6 see also US Patent No. 4,654,362); cicfoproloi hydrochloride, such 2-Propanof, 1-[4-[2- (cyciopropylmethoxy)ethoxy]phenoxy]~3-[1 -methylethyl)amino]-, hydrochloride, A.A.S, RN 63686-79-3); and dexpropranolol hydrochloride (2-Propanol, 1-[1-methylethyl)-amino]-3- {1-naphthalenyloxy)-hydrochloride (CAS RN 13071-11-9); diacetolol hydrochloride (Acetamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methyl-ethyl)amino]propoxy][phenyl]- ,monohydrochloride CAS RN 69796-04-9);diIevaloi hydrochloride (Benzamide, 2-hydroxy- 5-[1 -hydroxy-2-[1 -methyl-3-phenylpropyl)amino]ethyl]-,rnonohydrochloride, CAS RN 75659-08-4); exaprolol hydrochloride (2-Propanol, 1-(2-cyclohexylphenoxy)-3-[(1- methylethyl)amino]-,hydrochloride CAS RN 59333-90-3); flestolol sulfate (Benzoic acid, 2- fturo-.3-[[2-[aminocarbonyl)amino]-i-dimethylethyl]aminol-2-hydroxypropyl esten (±)- sulfate (1:1) (salt), CAS RN 88844-73-9; metalol hydrochloride (Methanesulfonamide, N- [4-[1-hydroxy-2-(methyIamino)propyl]phenyl]-,monohydrochloride CAS RN 7701-65- 7);metoprolol 2-Propanol, 1 -[4-(2-methoxyethyl)phenoxy]-3-[1 -methylethyl)amino]-; CAS RN 37350-58-6);metoproloi tartrate {such as 2-Propanol, 1-[4-(2-methoxyethyI)phenoxy]- 3~[(1 -methylethyl)amino]-, for example, LOPRESSOR® available from Novartis); pamatolol sulfate (Carbamic acid, [2-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxyl]phenyl]-ethyl]- .methyl ester, (±) sulfate (salt) (2:1), CAS RN 59954-01-7); penbutolol sulfate (2-Propanol, 1-(2-cycloρentylρhenoxy)-3-[1 ,1-dimethylethyl)amino]1, (S)-, sulfate (2:1) (salt), CAS RN 38363-32-5); practolol (Acetamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]- propoxylphenyl]-, CAS RN 6673-35-4;) tiprenolol hydrochloride (Propanol, 1-[(1- methylethyl)amino]-3-t2-(methylthio)-phenoxy]-, hydrochloride, (±), CAS RN 39832-43-4); tolamolol (Benzamide, 4-[2-[[2-hydroxy-3-(2-methylphenoxy)-propyl]amino]ethoxyl]-, CAS RN 38103-61-6).
Adrenergic receptors which are α-receptor inhibitors act to block vasoconstriction induced by endogenous catecholamines. The resulting fall in peripheral resistance leads to a fall in mean blood pressure. The magnitude of this effect is dependent upon the degree of sympathetic tone at the time the antagonist is administered. Suitable adrenergic receptors which are α-receptor inhibitors include, but are not limited to, fenspiride hydrochloride (which may be prepared as disclosed in US Patent No. 3,399,192 herein incorporated by reference); proroxan (CAS RN 33743-96-3); alfuzosin hydrochloride (CAS RN : 81403-68-1); and labetatol hydrochloride as described above or combinations thereof. Adrenergic blockers with a and β receptor inhibitor activity which may be used with the present invention include, but are not Simited to, bretylium tosylate (CAS RN : 61-75- 6); dihydroergtamine mesylate (such as ergotaman-31, 6!,18-trione,9,-1G-dihydro-12'- hydroxy-2'-methyl-5'"(phenylmethyl)-,(5'(alpha})-, monomethanesuifonate, for example, DHE 45® injection available from Novartis); carvedilol (such as (±)-1-(Carbazol-4-yloxy)-3- [[2-(o-methoxyphenoxy)ethyl3aminoj-2-propanoi, for example, COREG® Tablets available from SmithKline Beecham);. labetalol (such as 5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl]salicyfamide monohydrochloride, for example, NORMODYNE® Tablets available from Schering); bretylium tosylate (Benzenemethanaminium, 2-bromo-N-ethyI- N.N-dimethyh salt with 4-methylbenzenesulfonic acid (1 :1) CAS RN 61-75-6); phentolamine mesylate (Phenol, 3-f[(4,5-dihydro-1H-imidazol-2-yl)methyl](4- methylphenyl)amino]-, monomethanesulfonate (salt) CAS RN 65-28-1); solypertine tartrate (5H-1 ,3-Dioxoio[4,5-f]indoie, 7-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1 :1) CAS RN 5591-43-5); zolertine hydrochloride (Piperazine, 1-phenyl-4-[2-(1H-tetrazol-5-yl)ethyt]-, monohydrochloride (8Cl, 9Cl) CAS RN 7241-94-3)
An angiotensin system inhibitor is an agent that interferes with the function, synthesis or catabolism of angiotensin II, These agents which may be used in the present invention include but are not limited to angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, angiotensin M receptor antagonists, agents that activate the catabolism of angiotensin fl and agents that prevent the synthesis of angiotensin I from which angiotensin Il is ultimately derived. The renin-angiotensin system is involved in the regulation of hemodynamics and water and electrolyte balance. Factors that lower blood volume, renal profusion, or the concentration of Na+ in plasma tend to activate the system, while factors that increase these parameters tend to suppress its function. Angiotensin I and angiotensin fl are synthesized by the enzymatic renin-angiotensin pathway. The synthetic process is initiated when the enzyme renin acts on angiotensinogen, a pseudoglobulin in blood plasma, to produce the cecapeptide angiotensin L Angiotensin f is converted by angiotensin-converting enzyme (ACE) to angiotensin II. The latter is an active pressor substance which has been implicated as a causative agent in several forms of hypertension in various mammalian species.
Angiotensin ll receptor antagonists are compounds which interfere with the activity of angiotensin Ii by binding to angiotensin lf receptors and interfering with its activity, Angiotensin Il receptor antagonists which may be used In the present invention are well known and include peptide compounds and non-peptide compounds. Non-limiting examples of angiotensin Jl receptor antagonists include: candesartan cilexetϋ (1H- Benzϊrnidazole-7-carboxyIic acid, 2-ethoxy-1 -[[2'-(1 H-tetrazol-5-yl)[1 , 1 '-biphenyl]-4- yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl}oxy]ethyl ester ) CAS RN 145040-37-5); telmisartan( [i ,1'-Biphenyl]-2-carrboxylic acid, 4'-[(1 l4'-dimethyl-2l-propyl[2,6l-bi-1 H- benzimidazol]-1 '-yl)methyl]- CAS RN 144701 -48-4); candesartan (1 H-Benzimidazoie-7- carboxylic acid, 2-ethoxy-1-[[2'-(1 H-tetrazol-5-yl)[1 ,1'-biphenyl]-4-yl]methyl]- CAS RN 139481-59-7); losartan potassium (IH-lrtιidazoIe-5-methanoi, 2-butyl-4-chloro-1-[[2'-(1 H- tetrazol-5-yl)[1 ,1 '-biphenyl]-4-yl]methyl]-, monopotassium lrbesartani ,3- Diazaspiro(4.4]non-1 -en-4-one, 2-butyl-3-[[2'-(1 H-tetrazol-5-yl)[1 ,1 '-biphenyl]-4-yl3methyl]- CAS RN 138402-11-6).
Angiotensin-converting enzyme (ACE), is an enzyme which catalyzes the conversion of angiotensin I to angiotensin II. ACE inhibitors which may be used in the present invention include amino acids and derivatives thereof, peptides, including di and tri peptides and antibodies to ACE which intervene renin-angiotensin system by inhibiting the activity of ACE thereby reducing or eliminating the formation of pressor substance angiotensin N. ACE inhibitors have been used medically to treat hypertension, congestive heart failure, myocardial infarction and renal disease. Suitable ACE inhibitors include, but are not limited to, benazepril hydrochloride (such as 3-[[1-(ethoxycarbonyl)-3-phenyl-(1S)- propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1 -acetic acid rnonohydrochloride, for example, LOTREL® Capsules available from Novartis); captoprii (such as 1-[(2S)-3-mercapto-2-methyfpropionyt]-L-proIine» for example, CAPTOPRIL Tablets available from Mylan); fosinoprii (such as L-proline, 4-cyclohexyl-1-[[[2-methyl-1- (1-oxopropoxy) propoxy] (4-phenylbutyl) phosphinyl] acetyl]-, sodium salt, trans -..for example, yONOPRIL® Tablets available from Bristol-Myers Squibb); moexipril hydrochloride (such as [3S-[2[R*(R*}],3R*]]-2-[2-[[1 - (Ethoxycarbonyl)-3- phenylpropyl]amino]-1-oxopropyl]-,1,2,3,4-tetrahydro-6,7-dimethoxy-3- isoquinolinecarboxylic acid, monohydrochloride, for example, UNIRETIC® Tablets available from Schwarz); perindopril erbumine ( such as 2S,3aS,7aS)-1 -[(S)-N-[(S)-1- Carboxybutyl]alanyl]hexahydro~2-indolinecarboxylte acid, 1 -ethyl ester, compound with tert-butylamine (1 :1), for example, ACEON® Tablets available from Soivay); quinapril (such as [3S-[2[R*(R*)]!3R*]]-2-[2-[[1-(βthoxycarbonyl)-3-phenylproρyl]amino]-1- oxopropyl}-1.2,3,4-tetrahydro-3-isoquinolinecarboxyfic acid, monohydrochloride, for example, ACCU RETIC® Tablets available from Parke-Davls): ramipni (such as 2-aza- bicyclo [3.3.G]-octane-3~carbGxylic acid derivative, for example, ALTACE® Capsules available from Monarch); enalapril maleate (such as (S)-1-[N -[1-(ethoxycarbonyl)-3- phenylpropyl]-L-afanyl]-L-proline, (Z)-2-butenedioate salt (1 :1)., for example, VASOTEC® Tablets available from Merck); iisinoprii (such as ( S )-1-[ N 2-(1-carboxy-3- phenylpropyl)-L-Iysyl]-L-ρroline clihydrate, for example, PRINZIDE® Tablets available from Merck); delapril (which may be prepared as disclosed in US Patent No. 4,385,051); and spiraprif (which may be prepared as disclosed in US Patent No. 4.470,972); benazeprilat (1 H-1-8enzazepine-1 -acetic acid, 3-[[(1S)-1-carboxy-3-phenylpropyl]amino]-2,3,4,5- tetrahydro-2-oxo-t (3S)- CAS RN 86541-78-8); delapril hydrochloride (Glycine, N-[(1S)-1 - (ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)-, monohydrochloride CAS RN 83435-67-0); fosinopril sodium (L-Proiine, 4-cyclohexyl-1- K(R)-[(1 S)-2-methyl-1 -(1 -oxopropoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-"! sodium salt, (4S)- CAS RN 88889-14-9); libenzapril (1 H-1 -Benzazepine-1 -acetic acid, 3-[[(1S)-5- amino-1-carboxypentyl]amino]-2,3,4>5-tetrahydro-2-oxo-, (3S)- CAS RN 109214-55-3); pentopril (1H-lndoJe-1-pentanoic acid, 2-carboxy-2,3-dihydro-.alpha.,.gamma.-dimethyl- .deita.-oxo-, .alpha.-ethyl ester, (.alpha.R!.gamma.R,2S)- CAS RN 82924-03-6); perindopril 1 H-lndole-2-carboxylic acid, 1 -[(2S)-2-[[(1 S)-1 -(ethoxycarbonyl)butyl]amino]-1 - oxopropyl]octahydro-, (2S,3aS,7aS)- CAS RN 82834-16-0); quinapril hydrochloride (3- Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1- oxopropyl]-1)2,3,4-tetrahydro-, monohydrochloride, (3S)- CAS RN 82586-55- ); quinaprilat (3-lsoquinolinecarboxylic acid, 2-[(2S)-2-[[(1 S)-1-carboxy-3- phenylpropyl]amino]-1-oxopropyl]-1 ,2,3,4-teirahydro-, (3S)- CAS RN 82768-85-2); spirapril hydrochioride (1 ,4-Dithia-7-azaspiro[4,4]nonane-8-carboxylic acid, 7-[(2S)-2- [[(1 S)-1 -(ethoxycarbonyI)-3-phenylpropyl]amino]-1 -oxopropyl]-, monohydrochloride, (8S)- CAS RN 94841-17-5); spiraprilat 1(,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7- [(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1 -oxopropyl]-, (8S)- CAS RN 83602-05- 5); teprotide (Bradykinin potentiator BPP9a CAS RN 35115-60-7); lisinopril (L-Protine, N2-[(iS)-1-carboxy-3-phenylpropyl]-L-lysyl- CAS RN 76547-98-3); zofenopril (L-Proiine, 1-[(2S)-3-(benzoytthio)-2-methyl-1-oxopropyl3-4-(phenylthio)-. calcium salt (2:1), (4S)- CAS RN 81938-43-4).
"Calcium channel blockers" are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders such as hypertension, angina, and cardiac arrhythmias (Fteckenstein, Or. Res. V. 52 (suppi, 1), p, 13-16 (1983); Fleckenstetn, Experimental Facts anύ Therapeutic Prospects, John Wiley, New York (1983); McCaIL D., Curr, Praci Cardiol, v. 10, p, 1-11 (1985)). Calcium channel blockers are a heterogeneous group of drugs that prevent or stow the entry of calcium into ceils by regulating cellular calcium channels (Remington, The Science and Practice of Pharmacy, Nineteenth Edition, Mack Publishing Company, Eaton, PA, p. 963 (1995)). Calcium channel blockers useful In the present invention include but are not limited to, the besylate saft of amlodϊpine (such as 3- ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chk)rophenyl)-1 ,4-dihydro-6-methyl-3,5- pyridinedicarboxylate benzenesulphonate, for example, NORVASG® available from Pfizer); cfentϊazem maleate (1 ,5-Benzothiazepin-4(5H)-one, 3~(acetyloxy)-8-chloro-5-[2- (dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyI)-(2S-cis)-, (Z)-2-butenedioate (1 :1), see also U.S. Patent No. 4,567,195); isradipine (3,5-Pyridinedicarboxylic acid, 4-(4- benzofurazanyl)-1,4-dihydro-2,6-dirnethyl-,methyl 1-methylethyl ester, (±)-4(4- benzofurazany)l-1,4-dihydro-2,6-dimethyl-3,5-pyndinedicarboxylate, see also US Patent 4,466,972); nimodipine (such as is isopropyl (2 - methoxyethyl) 1 , 4- dihydro - 2, 6 - dimethyl - 4 - (3 - nitrophenyl) - 3, 5 - pyridine - dicarboxylate, for example, NIMOTOP® available from Bayer); felodipine (such as ethyl methyl 4-(2,3-dichlorophenyl)-1 ,4-dihydro- 2,6-dϊmethyl-3,5-pyridinedicarboxylate, for example, PLENDIL® Extended-Release Tablets available from AstraZeneca LP); nilvadipine (3,5-Pyridinedicarboxylic acid, 2- cyano-1 ,4-dihydro-6-methyl-4-(3-nitrophenyl)-,3-methyl 5-(1-methylethyl) ester, also see US Patent No.3, 799,934); nifedipine (such as 3,5-pyridinedicarboxylic acid,1 ,4-dihydro- 2,6-dimethyl-4-(2-nitroρhenyl)-, dimethyl ester, for example, PROCARDIA XL® Extended Release Tablets available from Pfizer); diltiazem hydrochloride (such as 1 ,5- Benzothiazepin-4(5H)-one,3-(acetyloxy)-5[2-(dimethylamino)ethyl]-23-3-dihydro-2(4- methoxyphenyl)-, monohydrochloride, (+)-cis., for example, TIAZAC® Capsules available from Forest); verapamil hydrochloride (such as benzeneacetronitrile, (alpha)-[[3-[[2-{3,4- dimethoxyphenyl) ethyl] methylamino] propyI3-3,4-dimethoxy-(aIpha)-(1-methylethyl) hydrochloride, for example, ISOPTI N® SR Tablets available from Knoll Labs); teludipine hydrochloride (3,5-Pyridinedicarboxylic acid, 2-{(dimethylamino)methyl]-4-[2-[(1 E)-3-(1 , 1 - dimethylethoxy)~3-oxo-1-propenyl]phenyl]-1,4-dihydro-6-methyl-, diethyl ester, monohydrochforide) CAS RN 108700-03-4); belfosdil (Phosphonic add, [2-{2- phenoxyethyl)-1,3-propanediyl]bis-, tetrabutyl ester CAS RN 103486-79-9); fostedil (Phosphonic acid, [[4-(2-benzothiazolyl)phenyl]methyl]-, diethyl ester CAS RN 75889-62- 2).
Cardiovascular agents of the present invention which also act as "anti-anginal agents" are useful in the present invention. Angina includes those symptoms that occur when myocardial oxygen availability is insufficient to meet myocardial oxygen demand. Non-limiting examples of these agents include: ranolazine (hydrochforidel -Piperazineacetamide, N-(2,6-dimethylphenyl}-4-[2-hydroxy-3-{2- rnethoxyphenoxy)propyll-, dihydrochloride CAS RN 95635-56-6); betaxolol hydrochloride (2-Prøpanol, 1-[4-[2 (cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-, hydrochloride CAS RN 63659-19-8); buiøprozine hydrochloride (Methanone, [4- [3(dibutytemino)propoxy]phenyl](2-ethyl-3-indoiizinyl)-, monohydrochioride CAS RN 62134-34-3); cinepazet maleatei-Piperazineacetic acid, 4-[1-oxo-3-(3»4,5- trimethoxyphenyl)-2-propenyl]-, ethyl ester, (2Z)-2~butenedioate (1 :1) CAS RN 50679-07- 7); tosifen (Benzenesuifonamide, 4-methyl-N-[[[(1S)-1-methyl-2- phenylethyl]amino]carbonyl]- CAS RN 32295-18-4); verapamilhydrochloride (Benzeneacetonitrile, .alpha. -[3-[[2-(3,4-dimethoxyphenyl)ethyl3methylamino]propyl]-3,4- dimethoxy-.alpha.-(1-methylethyl)-, monohydrochioride CAS RN 152-11 -4); moisidomine (1 ,2,3-Oxadiazolium, 5-[(ethoxycarbonyl)amtno]-3-(4-morpholinyl)-, inner salt CAS RN 25717-80-0); ranoiazine hydrochloride (1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4- [2-hydroxy-3-(2-methoxyphenoxy)propyl]-, dihydrochloride CAS RN 95635-56-6); tosifen (Benzenesuifonamide, 4-methyl-N-[[[(1S)-1-methyf-2-phenylethyI]amino]carbonyf]- CAS RN 32295-18-4).
"Coronary vasodilators" may act to reduce angina systems by increasing the oxygen supply to the heart. Coronary vasodilators useful in the present invention include, but are not limited to, diltiazem hydrochloride (such as 1 ,5-Benzothiazepin- 4(5H)-one,3-(acetyloxy)-5[2-(dimethylamino)ethyl]-2!-3-dihydro-2(4-methoxyphenyl)-! monohydrochioride, (+)-cis, for example, TIAZAC® Capsules available from Forest); isosorbide dinitrate (such as 1 ,4:3,6-dianhydro-D-glucitol 2,5-dinitrate, for example, iSORDIL® TITRADOSE® Tablets available from Wyeth-Ayerst); sosorbide mononitrate (such as 1 ,4:3,6-dianhydro-D-glucitol,5-nitrate, an organic nitrate, for example, Ismo® Tablets available from Wyeth-Ayerst); nitroglycerin (such as 2,3 propanetriol trinitrate, for example, NiTROSTAT® Tablets available from Parke-Davis); verapamil hydrochloride (such as benzeneacetonitrile, (±)-(alpha)[3[[2-(3,4 dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-(alpha)- ( 1 -methylethyl) hydrochloride, for example, COVERA HS® Extended-Release Tablets available from Searle); chromonar (which may be prepared as disclosed in US Patent No. 3,282,938); clonitate (Annalen 1870 155); droprenilamine (which may be prepared as disclosed in German Patent No. 2,521 ,113); lidoflazine (which may be prepared as disclosed in US Patent No, 3,267,104); prenylamine (which may be prepared as disclosed in US Patent No. 3152173); propatyl nitrate (which may be prepared as disclosed in French Patent No. 1 ,103,113): miσflazine hydrochloride (1 - Piperazineacetamide, 3~(aminocarbonyl)-4-[4,4-b!s(4~fluorophenyl)butyt]-N-(2,6- dichlorophenyl)-, dihydrochSoride CAS RN 83898-67-3); mixidine (Benzeneethanamine, 3,4-dimethoxy-N-(1 -methyl-2-pyrrolidϊnylidene)- Pyrrolidine, 2- [(3,4-dimethoxyphenethyl)imino]-1 -methyl- 1 -Methyl-2-[(3,4~ dimethoxyphenethyl)imino]pyrrolidine CAS RN 27737-38-8); molsidomine (1 ,2,3- Oxadiazolium, 5-[(ethoxycarbonyl)amino]-3-(4-rnorphoiinyl)-, inner salt CAS RN 25717-80-0); isosorbide mononitrate (D-Giucitol, 1 Λ^δ-dianhydro-, 5-nitrate CAS RN 16051 -77-7); erythrityl tetranitrate (1 ,2,3,4-Butanetetrol, tetranϊtrate, (2R,3S)-rel- CAS RN 7297-25-8); clonitrate(1 ,2-Propanediol, 3-chioro-, dinitrate (7Cl1 8Cl, 9Cl) CAS RN 2612-33-1 ); dipyridamole Ethanoi, 2,2',2",2"'-[(4,8-CIi-I - piperidinylpyrimidofδ^-djpyrimidine^.β-diyOdinitrϋoltetrakis- CAS RN 58-32-2); nicorandil (CAS RN 65141 -46-0 3-); pyridinecarboxamide (N-[2-(nitrooxy)ethyl]- Nisoldipine3,5-Pyridinedicarboxylic acid, 1 ,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-t methyl 2-methylpropyl ester CAS RN 63675-72-9); nifedipine3,5-Pyridinedicarboxylic acid, 1 )4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester CAS RN 21829-25- 4); perhexiline maleate (Piperidine, 2-(2,2-dicyciohexylethyl)-, (2Z)-2-butenedioate (1 :1 ) CAS RN 6724-53-4); oxprenolol hydrochloride2-Propanol1 1 -[(1 - methylethyl)amino]-3-t2-(2-propenyloxy)phenoxy]-! hydrochloride CAS RN 6452-73- 9); pentrinitrol (1 ,3-Propanediol, 2!2-bis[(nitrooxy)methyl]-, mononitrate (ester) CAS RN 1607-17-6); verapamil (Benzeneacetonitriie, ,aIpha.-[3-[[2-(3,4- dimethoxyphenyI)ethyl]methylamino]propyl]-3, 4-dimethoxy-. alpha. -(1-methylethyl)- CAS RN 52-53-9),
The term "diuretic" includes compounds that increase the excretion of solutes (mainly NaCI) and water. In general, the primary goal of diuretic therapy is to reduce extracellular fluid volume in order to lower blood pressure or rid the body of excess interstitial fluid (edema). Non-limiting examples of diuretics which may be used within the scope of this invention include althiazide (which may be prepared as disclosed in British Patent No. 902,658); benzthiazide (which may be prepared as disclosed in U.S. Patent No. 3,108,097); buthiazide (which may be prepared as disclosed in British Patent Nos. 861,367): chlorothiazide (which may be prepared as disclosed in U.S. 2,809,194); spironolactone (CAS Number 52-01-7); and triamterene (CAS Number 396-01-0).
"Adrenergic stimulants" useful as cardiovascular agents in the present invention include, but are not limited to, guanfacine hydrochloride (such as N-amk-ino-2-(2»6- dlchlorophenyl) acetamϊde hydrochlondes for example, TENEX® Tablets available from Robins); methyldopa-hydrochtorothiazide (such as levo-3-(3,4-dihydroxyphenyl)-2~ methylalanine ) combined with Hydrochlorothiazide (such as 6-chloro-3,4~dihydro-2 H - 1 ,2f4-benzothiadiazine~7- sulfonamide 1 ,1 -dioxide, for example, the combination as, for example, ALDORIL® Tablets avaiiable from Merck); methyldopa-chlorothiazide (such as 6- chloro-2 H -1 » 2, 4-benzothiadiazine-7-suffonamide 1 , 1 -dioxide and methyldopa as described above, for example, ALDOClORr® Tablets available from Merck) ; clonidine hydrochloride (such as 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride and chlorthalidone (such as 2-chloro-5-(1-hydroxy-3-oxo-1-isoindoIinyl) benzenesulfonamide), for example, COMBIPRES® Tablets avaiiable from Boehringer Ingelheim); cionidine hydrochloride (such as 2-(2,6-dichJorophenylarrtino)-2-imidazoline hydrochloride, for example, CATAPRES® Tablets available from Boehringer Ingelheim); clonidine (1H- imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- CAS RN 4205-90-7).
The anti-PCSK9 antibodies and antigen-binding fragments thereof and EGF-A polypeptides may also be administered in association with any azetidinone which inhibits intestinal cholesterol absorption. Such azetidinones include ezetimibe
Figure imgf000047_0001
Further chemotherapeutic agents that may be administered in association with an anti-PCSK9 antibody or antigen-binding fragment thereof or EGF-A polypeptide include fish oil, eicosaepenanoic acid, docosahexanoic acid, linoleic acid, niacin, fibrates such as fenofibrate, gemfibrozil and bile add sequestrants such as cholestyramine, colestipol and colesevelam.
Other chemofherapeutic agents include althiazϊde (2H-1 ,2,4-Benzothiadiazine-7- sulfonamide, 6-chloro-3,4-dihydro-3-[(2-propenylthio)methyl]-, 1 ,1 -dioxide CAS RN 5588- 16-9); benzthiazide (2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chIoro-3- [[(phenylmethyl)thio]methyl]-. 1 ,1 -dioxide CAS RIM 91-33-8); captopriI (L-Proline, 1-[(2S)- 3-mercapto-2-methyl-1-oxopropyl]- CAS RN 62571-86-2); carvedilol (2-Propanot. 1-(9H- carbazot-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amrno]- CAS RN 72958-09-3), chlorothiazide (sodium 2~Propanol, 1-(9H~carbazol-4-ytoxy}-3-[[2-(2- methoxyphenoxy)ethyl]amino]- CAS RN 72956-09-3); clonidine hydrochloride (1 H-lmidazoS-2-amine, N-{2,6-dichiorophenyI)-4,5-dihydro-, monohydrochloride CAS RN 4205-91-8); cyclothtazide (2H-1 ,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept- 5-en-2-yl-6-chioro-3,4-dihydro-, 1 ,1 -dioxide CAS RN 2259-96-3); delapril hydrochloride (2H-1 ,2,4-Benzothsadiazine-7-suifonamide, 3-bicyclo[2.2.1 ]hept-5-en-2-yl-6-chloro-3,4- dihydro-, 1,1 -dioxide CAS RN 2259-96-3); dilevalol hydrochloride (2H-1 ,2,4- Benzothiadtazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en2-yl-6-chloro-3,4-dihydro-, 1 ,1- dioxide CAS RN 2259-96-3); delapril hydrochloride (Glycine, N-[(1S)-1-(ethoxycarbonyl)- 3-phenylpropyl]-L-aIanyl-N-(2,3-dihydro-1H-inden-2-yl)-, monohydrochloride CAS RN 83435-67-0); doxazosin mesylate (Piperazine, 1-(4-amino-6,7-dimethoxy-2~quinazolinyl)- 4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-, rnonornethanesulfonate CAS RN 77883- 43-3); fosinopril sodium (L-Proline, 4-cyclohexyl-1-[[(R)-[(1S)-2-methyl-1 -(1- oxopropoxy)propox); moexipril hydrochloride (3-isoquinolinecarboxylic acid, 2-[(2S)-2~ [[(1 S)-1 -(ethoxycarbonyl)-3-phenylpropyl]amino]-1 -oxopropyl]-1 ,2,3,4-tetrahydro-6,7" dimethoxy-, monohydrochloride, (3S)- CAS RN 82586-52-5); monatepil maleate
(1-Piperazinebutanamide, N-(6,11-dihydrodibenzo(b,e)thiepin-11 -yl)-4-(4-fluorophenyl)-, (±)-, (Z)-2-butenedioate (1 :1) (±)-N-(6,11-Dihydrodibenzo(b,e)thiepin-11 -yl)-4-(ρ- fluorophenyl)-1-piperazinebutyramide maieate (1 :1) CAS RN 132046-06-1), Metoproloi succinate (Butanedioic acid, compd. with 1-[4-(2-methoxyethyl)phenoxy]-3-[(1- methylethyl)amino]-2-propanol (1 :2) CAS RN 98418-47-4); guanfacine hydrochloride (Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride CAS RN 29110-48-3; methyldopa (L-Tyrosine, 3-hydroxy-.aipha.-methyI- CAS RN 555-30-6); quinaprifat (3-lsoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-carboxy-3- phenylpropyl]amino3-1-oxopropyl]-1 ,2,3,4-tetrahydro-t (3S)- CAS RN 82768-85-2); quinapril hydrochloride (3-isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyI)- 3-phenylpropyl]amino]-1-oxopropyl]-1 ,2,3,4-tetrahydro-, monohydrochloride, (3S)- CAS RN 82586-55-8); Primidotol (2,4(1H,3H)-Pyrimidinedione, 1 -[2-[[2-hydroxy-3-(2- methy)phenoxy)propyl]amino]ethylj-5-methyl- CAS RN 67227-55-8); prazosin hydrochloride (Piperazine, 1 -(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2- furanylcarbonyl)-, monohydrochloride CAS RN 19237-84-4); pelanserin hydrochloride 2,4(1H,3H)-Quinazoltnedione, 3-[3-(4-phenyl-1-piperazinyl)propyl]-, monohydrochloride CAS RN 42877-18-9); phenoxybenzamine hydrochloride (Benzenemethanamine, N-(2- chloroethyl)-N-(1-methyl-2-phenoxyethyl)-, hydrochloride CAS RN 63-92-3); candesartan cilexetil (IH-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1 ,1'- biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester CAS RN 145040-37- 5); telmisartan (t,1'-Biphenyl]-2-carboxylic acid, 44(1 ,4'-dfmethyl-21-propyI[2t6'-bi-1H- benzimidazof]-1'-yl)methyl]- CAS RN 144701-48*4); candesartan1H-Benzimidazoie-7- carboxylic acid, 2-ethoxy-1 -[[Z-(I H-tetrazol-5-yl)t1 ,1'-biphenyt}-4-yt]methyl]- CAS RN 139481-59-7); amlodipine besylate3,5-Pyridinedicarboxylic acid, 2-[(2- aminoethoxy)methyl]~4-(2-chlorophenyl)-1 ,4-dihydro-6-methyh 3-ethyf 5-methyl ester, monobenzenesulfonate CAS RN 111470-99-6 Amlodipine maleate 3,5- Pyridinedicarboxylic acid, 2-[{2-aminoethoxy)methyl]-4-{2-chlorophenyl)-1 »4-dihydro-6- methyl-, 3-ethyl 5-methyl ester, (2Z)-2-buienediσate (1 :1) CAS RN 88150-47-4); terazosin hydrochloride (Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4- [(tetrahydro-2-furanyl)carbonyl]-, monohydrochtoride CAS RN 63074-08-8); bevantolol hydrochloride (2-Propanoi, 1 -[[2-(3,4-dirnethoxyphenyl)ethyl]aminol-3-{3-methylphenoxy)-, hydrochloride CAS RN 42864-78-8); ramipril (Cyclopenta[b]pyrrole-2-carboxylic acid, 1- [{2S}-2-[[(1S)-1 -(ethoxycarbonyl)-3-phenylpropyl]amtno]-1-oxopropyl]octahydro-f (2S,3aS,6aS)- CAS RN 87333-19-5).
Screening Assays
The present invention further provides a method for identifylng a substance which is a PCSK9 inhibitor or an inhibitor of PCSK9/LDL receptor binding or an inhibitor of PCSK9/EGF-A domain binding; or a substance which reduces total cholesterol level, low density lipoprotein cholesterol ievei, apolipoprotein B level, total cholesterol/high density lipoprotein ratio or low density lipoprotein/high density lipoprotein ratio; or a substance which treats or prevents hypercholesterolemia, hyperlipidemia, hypertriglyceridaemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma in a subject comprising contacting PCSK9 polypeptide or a functional fragment thereof and a polypeptide comprising LDL receptor EGF-A domain (e.g., SEQ ID NO; 3) and a sample to be tested for the presence of said substance; wherein said substance is identified if less binding of PCSK9 and the polypeptide comprising LDL receptor EGF-A domain is observed in the presence of the sample than in the absence of the sample. Any such substance identified in such an assay also forms part of the present invention.
An embodiment of the invention further comprises a negative-control assay wherein said PCSK9 and EGF-A polypeptides are contacted with a substance known not to inhibit binding of PCSK9 and LDL receptor or EGF-A domain thereof wherein the assay is determined to be operating property if more binding of the PCSK9 and LDL receptor or EGF-A domain thereof is observed than in the present of an inhibitor of said binding. An embodiment of the invention further comprises a positive-control assay wherein said PCSK9 and EGF-A polypeptides are contacted with a substance known to inhibit binding of PCSK9 and LDL receptor or EGF-A domain thereof wherein the assay is determined to be operating properly if less binding of the PCSK9 and LDL receptor or EGF-A domain thereof is observed than in the present of an inhibitor of said binding.
Binding of the substance can be determined using any of several methods known in the art.
Examples The following information is provided for more clearly describing the present invention and should not be construed to limit the present invention. Any and all of the compositions and methods described below fall within the scope of the present invention.
Example 1 : Soluble EGF-A domain of the LDL receptor or anti-PCSK9 antibody blocks the LDLR-PCSK9 interaction,
In this example, a soluble peptide encoding the EGF-A domain of the human LDL receptor as well as various anti-PCSK9 antibodies are shown to block interactions between PCSK9 and the receptor.
The following are the AlphaScreen methods and materials for the antibody and EGF-A inhibition of PCSK9-LDLR interaction experiments:
Purified PCSK9 carrylng a C-terminal FLAG tag was purified from HEK293 cells stably expressing PCSK9. Purity was estimated, by silver staining, at greater than >90%. Anti-PCSK9-catalytic domain antibody was purchased from Cayman Chemical (Rabbit anti-murine-PCSK9 polyclonal antibody, Cayman Chemical; Ann Arbor, Mi; Cat.# 10008811). This rabbit anti-mouse/human PCSK9-catalytic domain antibody recognizes an epitope with the following amino acid sequence: VFAQSiPWNLER (SEQ ID NO: 8). A rabbit anti- human PCSK9 C-terminal domain antibody (which binds specifically to SRSGKRRGERMEA (amino acids 490-502 of SEQ ID NO: 4)) and a rabbit anti-human PCSK9 whole protein antibody were also used. Soluble EGF-A domain peptide was synthetically generated using standard methods. 2.5 ng of purified, C-terminaliy FLAG tagged PCSK9 (2.5 ng/2.5 ul/well of a ProxiPlate-384 Plus (Perkϊn-Eimer; Waitham, Mass) in 2.5 microliters of buffer (25 mM HEPES. 0.1 M NaCL 0.1% 8SA, pH 7.5) was pre-incubated with 2.5 microliters of either anti-PCSK9 antibody or EGF-A domain pepitde at the indicated concentrations for 30 minutes at room temperature. Next, 5 ul buffer containing 2.5 ng purified HlS-tagged soluble LDLR (R&D Systems; Minneapolis, MN; Cat.# 2148-LD/CF; SEQ ID NO: 2) and 5 ng biotinylated anti-FLAG antibody (BioM2 monoclonal antibody, Sigma; St, Louis, MO; Cat.# F 9291 ), and the mixture, was incubated at room temperature for a further 30 minutes. Finally, under iow tight conditions, 5 ul of a donor/acceptor bead mixture (AlphaScreen Histidine Detection Kit, Perkin-Elmer; Waitharn, Mass.; Cat. #6760619C) was added and alphaScreen signal was detected using the 2103 En Vision Multilabel Plate Reader (Perkin-Elmer; Waltham, Mass). The donor/acceptor bead mixture was prepared in dark conditions by adding 10 ul Nickel-Acceptor bead and 10 ui SA-Donor bead to 2.2 ml buffer for one 384-well piate and incubated in dark at room temperature for at least 2 hours,
The data generated in these experiments is set forth below in Tables 1-3. Table 1. Inhibition of PCSK9-LDLR interaction by soluble LDLR-EGF-A domain in the presence or absence of added calcium*. Values are the mean of three replicates.
Figure imgf000051_0001
*A lower number of counts represents less observed PCSK9/LDL receptor binding.
These data indicate that the PCSK9-LDLR interaction is inhibited by soluble EGF-A domain in the presence or absence of calcium. A slightly greater level of inhibition was observed in the presence of calcium than in the absence of calcium, in the presence of calcium, the 1C50 was about 3 micromoiar and in the absence of calcium the 1C50 was about 12 micromoiar. Table 2. Inhibition of PCSK9-LDLR interaction by anti-PCSK9 antibodies (catalytic domain (Cat) and C-terminai domain (CT))
Figure imgf000052_0001
These data demonstrate that an anti-PCSK9 catalytic domain antibody and an anti- PCSK9 C-terminal domain antibody inhibits the interaction between PCSK9 and LDL receptor. The antt-PCSK9 raised against a C-terminal domain was less effective at inhibiting the interaction. A non-specific IgG control was ineffective at inhibiting the interaction and is shown for comparison. Values in this table are the mean of three replicates.
Table 3. inhibition of PCSK9-LDLR interaction by anti-PCSK9 antibodies (catalytic domain (Cat) and whole protein (whole))
Figure imgf000052_0002
These data demonstrate that the PCSK9-LDLR interaction is inhibited by antibodies that bind the PCSK9 catalytic domain peptide and antibodies raised against the whole PCSK9 protein, A non-specific IgG control was ineffective at inhibiting the interaction and is shown for comparison. These values are mean of three replicates.
Example 2: Arttϊ-PCSKi antibody treatment of cells leads to enhanced LDL uptake. Incubation of cells with soluble PCSK9 leads to a decrease in the ability of the cells to absorb and clear low density lipoprotein (LDL) from the medium. This example demonstrates that inhibition of PCSK9 with an anti-PCSK9 antibody antagonizes this effect of PCSK9 and leads to increased levels of LDL uptake and clearance. The uptake assays were performed as follows: HepG2 ceils at 10,000 cells/well in
384 Collagen I coated plate were seeded and grown overnight. On the next day. a serial dilution of bacu~PCSK9-WT in MEM-1% BSA was made, mixing with a fixed concentration of anti-mouse-cat domain PCSK9 polyclonal antibody (Cayman Chemical: Ann Arbor, Ml; cat# 10008811 ; raised against mouse PCSK9 antigen VFAGSIPWNLER (SEQ ID NO: 8) and cross reacts with human PCSK9) or anti-human PCSK9 polyclonal antibody (R&D Systems, Minneapolis, MN; cat# AF3888) at a final concentration of 100 ug/ml respectively. These mixtures were incubated for 1 hour at 40C, then medium was aspirated out from the HepG2 cells and 25 ui/weil of the mixtures was added to HepG2 cells in 384 plate and incubated for 6 hours and 18 hours, respectively. After the indicated incubation time, the mixture was removed from the HepG2 cells, washed 1 X with PBS, then DiI-LDL (DiI label is i .t-dioctadecyl-S^^S^etramethylindocarbocyanine perchlorate) was added at 10 ug/ml in MEM-1% BSA to the cells, then incubation followed at room temperature for 90 minutes. DiI-LDL was removed afterwards, the cells were fixed with Prefer fixative (glyoxal, ethanol, buffer; Anatech LTD.; Hayward, CA; cat# 414) for 20 minutes, then the cells were washed with PBS two times and DiI-LDL uptake into the cells was read using a fluorescence intensity reader Analyst. The data generated in these assays are set forth below in Table 4.
Table 4. UDL uptake in the presence of PCSK9 and antϊ-PCSK9 antibodies. 6 hour incubation
Figure imgf000053_0001
13 hour incubation
[PCSK9] ug/ml control anti-CAT
15 20163100 21843043 17106209
5 24214957 25921384 27741479
1.67 27777510 32018111 29054521
0 31232393 32526668 28127286
Table 4 sliσwiTuptake of dit-labeted LDL by human HepG2 liver ceils treated with the indicated amounts of purified, recombinant PCSK9 (control) or PCSK9 in the presence of either polyclonal antibody raised against the catalytic domain peptide (anti-CAT) or antibody raised against the whole protein (anti-all). PCSK9-deρendent uptake of LDL by the cells increased in a manner dependent upon the presence of anti-PCSK9 antibody in the mixture. Higher numbers indicated greater LDL uptake and preservation of LDLR despite the presence of PCSK9.
Example 3: Characterization of anti-PCSK9 antibodies.
The 75B9, 77D10, 11B5, 22D11, 1F11/1G11 and 29C 10 anti-PCSK9 antibodies were characterized. The antibodies were found to effectively inhibit interaction between PCSK9 and the LDL receptor as well as inhibit PCSK9-mediated LDL receptor degradation. In vivo, the antibodies were found to inhibit PCSK9 and, thereby increase the levels of LDL receptor present. Moreover, the antibodies neutralized the in vivo cholesterol increase observed when exogenous PCSK9 was added.
inhibition of PCSK9-mediated LDLR degradation with anti-PCSK9 antibodies.
The 75B9, 77D10, 1165, 22011, 1F11/1G11 and 29C10 antibodies were evaluated in an in-cell western assay for their ability to inhibit the degradation of the LDL receptor by PCSK9 in HepG2 ceils.
In-cell western was performed to quantitate anti-PCSK9 antibody inhibition of PCSK9-mediated LDLR degradation. HepG2 cells were seeded in 384-well collagen I coated plates and treated with anti-PCSK9 antibody and/or PCSK9 (100 nM) for 18 hours.
Detection of LDLR and β-actin was performed according to the manufacturer's protocol
(Li-Cor Biosciences; Lincoln, Nebraska) using the antibodies described above in conjunction with IRDye 800CW goat anti-rabbit (Li-Cor) and IRDye 680 goat anti-mouse (Li-Cor). The assay was read on an Odyssey infrared imaging system (Li-Cor) and the signal for LDLR protein in each well normalized to β-actin content. The data from these experiments are set forth below in Table 5. Table 5. Level of inhibition of each anti-PCSK9 antibody observed in in-ceil western assay
Figure imgf000055_0001
* Greater number of + symbols indicates a greater level of inhibition relative to other treatments.
Relative to the "÷PCSK9/no antibody" control, the antibodies tested inhibited PCSK9~mediated degradation of LDL receptor with various potencies in the HepG2 cells,
Alphascreen binding assays An Amplified Luminescent Proximity Homogeneous Assay (ALPHA, Perkin-Elmer;
Waltham, Massachusetts) capable of directly determining the interaction between PCSK9- FLAG and a putative binding partner was used to determine the effect of anti-PCSK9 antibodies on this interaction. This technique required that "donor" and "acceptor" beads be brought into proximity via protein-protein interaction, resulting in increased luminescence (Ulirnan et ai.t Proc. Nat. Acad. Sci. (1994) 91 :5426-5430). In the basic assay, LDL receptor binding to PCSK9 was determined as follows: 5 μl of recombinant receptor at the appropriate concentrations was incubated with 2.5 μl PCSK9-FLAG (1.4 μg/rnl, 30 min). About 2.5 μl of biotinylated anti-Flag-M2 antibody (1.8 μg/ml) was added and the mixture incubated for 1 hour. Afterward 5 μl of streptavidin donor bead and nickel chelate acceptor bead (1 :1 mixture) was added and the assay incubated overnight. AlphaScreen signal (counts per second) was analyzed using an Envision microplate reader (Perkin-ESmer). All data points were determined in triplicate. Assays were carried out at 23°C in buffer containing 25 my HEPES1 0.1 M NaCI5 pH 7.4, 0.1% BSA. The inhibition assays were determined similarty with slight adjustments to assay volumes and protein concentrations. Briefly, 5 μl of 1.25 μg/mi of PGSK9-Fiag and 1.25 μg/rrsl of His- tagged LDL receptor was incubated with 2.5 μl of antibody at the appropriate concentrations for 30 minutes followed by the addition of 2.5 μl of anti-Fiag-BioM2 (1.8 μg/mi) and a 1 hour incubation. The data from these assays are set forth below in Table 6.
Table 6. Level of anti-PCSK9 antibody mediated inhibition of PCSK9/LDLR interaction
Figure imgf000056_0001
* Average of two measurements.
The antibodies tested inhibited PCSK9/LDL receptor interaction with various potencies (expressed in terms of IC5G and % inhibition relative to the assay performed with no antibody added).
Effect of anti-PCSK9 on in vivo inhibition of LDLR degradation and plasma cholesterol
The ability of an anti-PCSK9 antibody (1 F11/1G11) to inhibit LDL receptor degration in mice was evaluated in these assays along with the ability of the antibodies to modulate cholesterol levels.
In vivo Procedure:
Time-G: Male C57BL/6] mice were injected, intraperitoneal, with 400μg of anti- human PCSK9 Antibody, 1 F11/1 G11.
Tϊme-2 hours: Mice were then injected, intravenously, with 10μg of human PCSK9
Protein.
Time-4 hours: Mice were terminated and plasma and liver samples were collected.
Analysis: Plasma lipoprotein profiles of individual mice (0.1 mL plasma) were determined by fast protein liquid chromatography (FPLC) with a Pharmacia Superose 6 column. FPLC fraction cholesterol levels were determined using Wako Cholesterol Enzymatic colorimetric method.
Protein levels of Liver LDL Receptor were determined by Western Blot. 40μg of each liver homogenate was separated on an Invitrogen 4-12% NuPAGE geis transferred to PVDF membrane and incubated with goat anti-mouse LDL receptor antibody (rabbit anti-GAPDH antibody was used as a control for equal loading). Membranes were then incubated with corresponding HRP-linked antibodies and visualization was accomplished with high performance chemiluminescence film. Band intensities were quantified using tmageQuant 5.2 software.
LDL receptor levels were expressed in Arbitrary Units (AU) as a ratio of LDL receptor band intensity to GAPDH band intensity. The results of the LDL receptor measurements are set forth in tables 7 and 8 below. Two separate analyses of the data are presented.
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000058_0002
*************************** The present invention is not to be limited in scope by the specific embodiments described herein, indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. Patents, patent applications, publications, product descriptions, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for aif purposes.

Claims

We claim;
1. An isolated antibody or antigen-binding fragment thereof comprising one or more members selected from the group consisting of: (i) CDR-H 1 , CDR-H2 and CDR-H3 of the variable region the 11 B5 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 10; (ϋ) CDR-H 1 , CDR-H2 and CDR-H3 of the variable region the 75B9 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 18; (iti) CDR-M1 CDR-H2 and CDR-H3 of the variable region the 77D10 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 26;
(iv) CDR-H 1 , CDR-H2 and CDR-H3 of the variable region the 29C10 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 34; (v) CDR-H 1 , CDR-H2 and CDR-H3 of the variable region the 22D11 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 42; (vi) CDR-H1 , CDR-H2 and CDR-H3 of the variable region the 1 F11/1G11 heavy chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 50; (vii) CDR-L1 , CDR-L2 and CDR-L3 of the variable region the 11 B5 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 14; (viii) CDR-L1 , CDR-L2 and CDR-L3 of the variable region the 7589 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 22; (ix) CDR-L1 , CDR-L2 and CDR-L3 of the variable region the 77D10 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 30; (x) CDR-L1 , CDR-L2 and CDR-L3 of the variable region the 29C10 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 38; (xi) CDR-L1 , CDR-L2 and CDR-L3 of the variable region the 22D11 light chain immunoglobulin which comprises the amino acid sequence of SEQ ID NO: 46; and (xii) CDR-Li, CDR-L2 and CDR-L3 of the variable region the 1 F11/1G11 light chain immunogtobufin which comprises the amino acid sequence of SEQ ID NO: 54.
2. A composition comprising the antibody or antigen-binding fragment thereof of ciaim 1 in association with a further chemotherapeutic agent,
3, The composition of claim 2 wherein the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor.
4. The composition of claim 2 wherein the further chemotherapeutic agent is ezetimibe, iovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin, simvastatin, an azetidinone, bunolol hydrochloride, acebutoloi, alprenolol hydrochloride, atenolol, carteolol hydrochloride, ceiiprolol hydrochloride; cetamolol hydrochloride, labetaiol hydrochloride, esmolol hydrochloride, ievobetaxoloi hydrochloride, levobunolol hydrochloride, nadolol, practolol, propranolol hydrochloride, sotaloi hydrochloride, timolol, timolol maleate, bisoprolol; bisoprolol fumarate, nebivaiol, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetoiol hydrochloride, dilevalol hydrochloride, exaproiol hydrochloride, flestolol sulfate, metalol hydrochloride, metoprolol 2-Propanot, metoprolol tartrate, pamatolol sulfate, penbυtoiol sulfate, practolol, tiprenolol hydrochloride or tolamolol.
5. The composition of claim 4 wherein the further chemotherapeutic agent is ezetimibe optionally in association with simvastatin.
6. The antibody or antigen-binding fragment thereof of claim 1 , which is a humanized antibody.
7. The antibody or antigen-binding fragment thereof of claim 1 , which is an antibody which is a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti-idiotypic antibody, a humanized antibody or a bispecific antibody,
8. The antibody or antigen-binding fragment thereof of claim 1 , which is an antigen- binding fragment which is a cameiized single domain antibody, a diabody, an scfv, an scfv dimer, a dsfv, a (dsfv}2, a dsFv-dsfv', a bispecific ds diabody, an Fv, an Fab, an Fab', art F(ab')2, or a domain antibody.
9. The antibody or antigen-binding fragment thereof of claim 1 which is linked to an immunoglobulin constant region.
10. The antibody or antigen-binding fragment thereof of cfaim 9 wherein the constant region is a K fight chain, γ1 heavy chain, γ2 heavy chain, -β heavy chain or γ4 heavy chain.
1 1. A pharmaceutical composition comprising the antibody or fragment of claim 1 in association with a pharmaceutically acceptable carrier.
12. An isolated antibody or antigen-binding fragment thereof comprising one or more members selected from the group consisting of:
Figure imgf000061_0001
Figure imgf000062_0001
13. A composition comprising the antibody or antigen-binding fragment thereof of claim 12 in association with a further chemotherapeutic agent.
14. The composition of claim 13 wherein the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor.
15. The composition of claim 13 wherein the further chemotherapeutic agent is ezetimibe, tovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin, simvastatin, an azetidinone, bunolol hydrochloride, acebutolol, alprenotol hydrochloride, atenolol, carteotoi hydrochloride, ceiϊproloi hydrochloride; cetamolol hydrochloride, iabetafoi hydrochloride, esmolol hydrochloride, levobetaxoloi hydrochloride, ievobunoioi hydrochloride, nadolol, practoioi, propranolol hydrochloride, sotaloi hydrochloride, timolol, timolol maleate, bisoprolol; bisoproloi fumarate, nebivalol, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetoiol hydrochloride, dilevalol hydrochloride, exaprolol hydrochloride, ftestoloi sulfate, metatol hydrochloride, metoprolot 2-Propanol, metoprolol tartrate, pamatoiol sulfate, penbutolol sulfate, practolol, tiprenolol hydrochloride, tolamoiot fenspiride hydrochloride, proroxan, atfuzosin hydrochloride, labetatol hydrochloride, bretylium tosylate, dihydroergtamine mesylate, carvedϊlol, labetaSoi, bretylium tosylate. phentoiamine mesylate, solypertine tartrate, zolertine hydrochloride, candesartan cilexetil, telmisartan, candesartan; losartan potassium, benazepril hydrochloride, captopril, fosinoprii, moexipril hydrochloride, perindopril erbumine, quinapril, ramipril, enalapril maleate, lisinoprii, delapril, spirapril, deiapril hydrochloride, libenzapril, pentoprii, perindoprii 1 H-I ndole-2-carboxylic acid, quinaprilat, spiraprii hydrochloride, spiraprilat, teprotide, zofenopril, amlodipine besylate, clentiazem maleate, isradipine, nimodipine, felodipine, nilvadipine; diltiazem hydrochloride, verapamil hydrochloride, teludipine hydrochloride, belfosdil, fostedil, ranoiazine, butoprozine hydrochloride, tosifen, molsidomine, ranoiazine hydrochloride, tosifen, diltiazem hydrochloride, isosorbide dinitrate, sosorbide mononitrate, nitroglycerin, verapamil hydrochloride, chromonar, clonitate, droprenilamine, lidoflazine, prenylamine, propatyl nitrate, mioflazine hydrochloride, mixidine, molsidomine, isosorbide mononitrate, erythrityl tetranitrate, clonttrate, dipyridamole; nicorandil, pyridinecarboxamide, nifedipine; perhexiline maleate; oxprenolol, pentrinitrol, verapamil, althiazide, benzthiazide, buthiazide, chlorothiazide, spironolactone, triamterene, guanfacine hydrochloride, methyldopa-hydrochlorothiazide combined with Hydrochlorothiazide, methyldopa-chlorothiazide, clonidine hydrochloride, chlorthalidone, clonidine hydrochloride, clonidine, aithiazide, benzthiazide, captopril, carvedilol, chlorothiazide, clonidine hydrochloride, cyclothiazide, deiapril hydrochloride, dilevalol hydrochloride, deSapril hydrochloride, doxazosin mesylate, fosinopril sodium, moexipril hydrochloride, monatepil maleate, metoprolol succinate, guanfacine hydrochloride, methyldopa, quinaprilat, quinapril hydrochloride, prsmtdotol, prazosin hydrochloride, pelanserin hydrochloride, phenoxybenzamϊne hydrochloride, candesartan citexθtil, teimisartan, candesartan, amlodipine maieate, terazosin hydrochloride, bevantolol hydrochloride or ramipril.
16. The composition of claim 15 wherein the further chemotherapeutic agent is ezetirnϊfae optionally in association with simvastatin.
17. The antibody or antigen-binding fragment thereof of claim 12, which is a humanized antibody.
18. The antibody or antigen-binding fragment thereof of claim 12, which is a humanized antibody.
19. The antibody or antigen-binding fragment thereof of claim 12, which is an antibody which is a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti- idiotypic antibody, a humanized antibody or a bispecific antibody.
20. The antibody or antigen-binding fragment thereof of claim 12, which is an antigen- binding fragment which is a camelized single domain antibody, a diabody, an scfv, an scfv dimer, a dsfv, a (dsfv)2, a dsFv-dsfv', a bispecific ds diabody, an Fv, an Fab, an Fab!, an F(ab')2, or a domain antibody.
21. The antibody or antigen-binding fragment thereof of claim 12 which is linked to an immunoglobulin constant region.
22. The antibody or antigen-binding fragment thereof of claim 21 wherein the constant region is a K light chain, γ1 heavy chain, γ2 heavy chain, γ3 heavy chain or γ4 heavy chain.
23. A pharmaceutical composition comprising the antibody or fragment of claim 12 in association with a pharmaceutically acceptable carrier.
24, The isolated antibody or antigen-binding fragment thereof of claim 12 comprising one or more members selected from the group consisting of:
(a) an immunoglobulin heavy chain comprising the amino acid sequence:
E V Q L Q Q S G A E L V K P G A 8 V T L S C T A S G P N I K D T Y M H W V N Q R P E Q G L V W I G R I D P A K G H T E Y D P K F Q D K A T I T T D T S S N T A Y L H L S S L T 3 G D T A V Y Y C A R S Y F G S I F A Y W G Q G T L V T V S A (SEGIDNO: 10);
(b) an immunoglobulin light chain comprising the amino acid sequence:
Figure imgf000065_0001
Figure imgf000066_0001
25. A composition comprising the antibody or antigen-binding fragment thereof of claim 24 in association with a further chemotrierapeutic agent.
26. The composition of claim 25 wherein the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor.
27. The composition of claim 25 wherein the further chemotherapeutic agent is ezetimibe, lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin, simvastatin, an azetidinone, bunolol hydrochloride, acebutoloi, alprenolol hydrochloride, atenolol, carteolol hydrochloride, celiproloi hydrochloride; cetamolol hydrochloride, labetalol hydrochloride, esmolol hydrochloride, levobetaxoiol hydrochloride, levobunoloi hydrochloride, nadolol, practoiol, propranolol hydrochloride, sotaiol hydrochloride, timolol, timolol maleate, bisoprolol; bisoprolol fumarate, nebivalol, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetolol hydrochloride, dilevalol hydrochloride, exaproloi hydrochloride, flestolol sulfate, metaiol hydrochloride, metoprolol 2-PropanoS, metoprolol tartrate, pamatolol sulfate, penbutolot sulfate, practolol, tiprenolol hydrochloride, tolamolol fenspiride hydrochloride, proroxan, alfuzosin hydrochloride, labetaiol hydrochloride, bretylium tosylate, dihydroergtamine mesylate, carvedilol, labetalol, bretylium tosylate, phentolamine mesylate, solypertine tartrate, zolertine hydrochloride, candesartan cilexetil, teimisartan, candesartan; losartan potassium, benazepril hydrochloride, captoprϋ, fosinopril, moexiprii hydrochloride, perindopril erbumine, quinapril, ramiprϋ, enalapril maleate, lisinoprϋ, delaprϋ, spirapril, delapril hydrochloride, libenzapril, pentopril, perindoprii 1H-lndoie-2-carboxylic acid, quinaprilat, spirapril hydrochloride, spiraprilat, teprotide, zofenopril, amlodipine besylate, clentiazem maleate, isradipine, nimodipine, felodipine, niivadipine; dϋtiazem hydrochloride, verapamil hydrochloride, teludipine hydrochloride, belfosdil, fostedii, ranoiazine, butoprozine hydrochloride, tosifen, molsidomine, ranoiazine hydrochloride, tosifen, diltiazem hydrochloride, isosorbide dinitrate, sosorbide mononitrate, nitroglycerin, verapamil hydrochloride, chromonar, ctonitate, droprβniiamine, lidoflazine, prenylamϊne, propatyl nitrate, mioffazsne hydrochloride, mixidine, molsidomine, isosorbide mononitrate, erythrityf tetranitrate, clonitrate, dipyridamole; nicorandil, pyridinecarboxamide, nifedipine; perhexiline maleate; oxprenolol, pentrinitroi, verapamil, althiazide, benzthiazide, buthiazide, chlorothiazide, spironolactone, triamterene, guanfacine hydrochloride, methyldopa-hydrochlorothiazide combined with Hydrochlorothiazide, methyldopa-chlorothiazide, cionϊdine hydrochloride, chlorthalidone, clonidine hydrochloride, ctonidsne, althiazide, benzthiazide, captoprii, carvedifσi, chlorothiazide, clonidine hydrochloride, cydothiazide, delapril hydrochloride, dϋevalol hydrochloride, delapril hydrochloride, doxazosin mesylate, fosinopril sodium, moexipril hydrochloride, monatepil maleate, metoprolol succinate, guanfacine hydrochloride, methyldopa, quinaprilat, quinapril hydrochloride, primidolol, prazosin hydrochloride, pelanserin hydrochloride, phenoxybenzamine hydrochloride, candesartan cilexetil, teimisartan, candesartan, amlodspine maleate, terazosin hydrochloride, bevantolol hydrochloride or ramiprii.
28. The composition of claim 27 wherein the further chernotherapeutic agent is ezetimibe optionally in association with simvastatin.
29. The antibody or antigen-binding fragment thereof of claim 24, which is a humanized antibody.
30. The antibody or antigen-binding fragment thereof of claim 24, which is a humanized antibody.
31. The antibody or antigen-binding fragment thereof of ciaim 24, which is an antibody which is a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti- idiotypic antibody, a humanized antibody or a bispecific antibody.
32. The antibody or antigen-binding fragment thereof of claim 24, which is an antigen- binding fragment which is a camelized single domain antibody, a diabody, an scfv, an scfv dimer, a dsfv, a (dsfv)2, a dsFv-dsfv!, a bispecific ds diabody, an Fv, an Fab, an Fab', an F(ab')2l or a domain antibody.
33. The antibody or antigen-binding fragment thereof of claim 24 which is linked to an immunoglobulin constant region.
34. The antibody or antigen-binding fragment thereof of claim 33 wherein the constant region is a K light chain, γ1 heavy chain, γ2 heavy chain, γ3 heavy chain or γ4 heavy chain.
35. A pharmaceutscal composition comprising the antibody or fragment of ctatm 24 in association with a pharmaceutically acceptable carrier.
36. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof or isolated EGF-A polypeptide which binds specifically to PCSK9, which antibody or fragment or polypeptide inhibits binding between PCSK9 and LDL receptor; and a pharmaceutically acceptable carrier.
37. The pharmaceutical composition of claim 36 wherein the antibody binds specifically to a PCSK9 catalytic domain or to a domain of PCSK9 which interacts with an LDL receptor EGF-A domain.
38. An isolated polypeptide comprising an amino acid sequence comprising about 90% or more amino acid sequence similarity to a fragment of the human LDL receptor which fragment consists of amino acids beginning at about amino acid position 314 and ending at about amino acid position 355 of said receptor; wherein said polypeptide optionally comprises one or more properties selected from the group consisting of: (i) binds to PCSK9;
(ii) competes with LDL receptor or an anti-PCSK9 antibody or antigen-binding fragment thereof for binding to PCSK9;
(iii) reduces total cholesterol level when administered to an animal;
(iv) reduces low density lipoprotein cholesterol level when administered to an animal; (v) reduces apolipoprotein B level when administered to an animal;
(vt) reduces total cholesterol/high density lipoprotein ratio when administered to an animal; and
(vii) reduces low density lipoprotein/high density lipoprotein ratio when administered to an animal; or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier.
39. The polypeptide of claim 38 which consists of the amino acid sequence of SEQ ID NO: 3; or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier.
40. A method for reducing: total cholesterol levef; low density lipoprotein cholesterol levei: apolipoprotθϊn B feveJ: total cholesterol/high density lipoprotein ratio; or low density lipoprotein/high density lipoprotein ratio; in a subject, comprising administering, to said subject, a therapeutically effective amount of a PCSK9 antagonist EGF-A polypeptide; or an antibody or antigen-binding fragment thereof that binds specifically to PCSK9; which antibody or fragment or EGF-A polypeptide inhibits binding between PCSK9 and LDL receptor; optionally in association with a further chemotherapeutic agent.
41. The method of claim 40 wherein the antibody or fragment binds specifically to a PCSK9 catalytic domain or to a domain of PCSK9 which interacts with an LDL receptor EGF-A domain.
42. A method for treating or preventing hypercholesterolemia, hyperlipidemia, hypertrigiyceridaemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, vascular inflammation or xanthoma, in an subject, comprising administering, to said subject, a therapeuticaliy effective amount of an EGF-A polypeptide or an antibody or antigen-binding fragment thereof that binds specifically to PCSK9, which antibody or fragment or EGF-A polypeptide inhibits binding between PCSK9 and LDL receptor; optionally in association with a further chemotherapeutic agent.
43. The method of claim 42 wherein the antibody binds specifically to a PCSK9 catalytic domain or to a domain of PCSK9 which interacts with an LDL receptor EGF-A domain.
44. A method for reducing; total cholesterol level; low density lipoprotein cholesterol level; apolipoprotein B level; lotal cholesterol/high density lipoprotein ratio; or
Sow density iipoprotein/high density lipoprotein ratio; or for treating: hyperchoiesterolem ia; hyperiipidernia; hypertrigtycericSaemia; sitosterotemia; atherosclerosis, arteriosclerosis; coronary heart disease; vascular inflammation; or xanthoma, in a subject, comprising administering, to said subject, a therapeutically effective amount of the antibody or antigen-binding fragment thereof of claim 1.
45. The method of claim 44 wherein the antibody or antigen-binding fragment thereof of claim 1 in administered in association with a further chemotherapeutic agent.
46. The method of claim 45 wherein the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor.
47. The method of claim 46 wherein the further chemotherapeutic agent is ezetimibe, lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin, simvastatin, an azetidinone, bunoloi hydrochloride, acebutolol, alprenolol hydrochloride, atenolol, carteolol hydrochloride, celiprolol hydrochloride; cetamolol hydrochloride, iabetalot hydrochloride, esmolol hydrochloride, levobetaxoioi hydrochloride, ievobunolol hydrochloride, nadolol, practoloi, propranolol hydrochloride, sotalol hydrochloride, timolol, timolol maleate, bisoprolot; bisoprolol fumarate, nebivalol, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacefolol hydrochloride, dilevalol hydrochloride, exaprolol hydrochloride, fiestoloi sulfate, metalol hydrochloride, metoprolol 2-Propanol, metoprolol tartrate, pamatolol sulfate, penbutoloi sulfate, practoiol, tiprenolol hydrochloride, tolamoiol fenspiride hydrochloride, proroxan, alfuzosin hydrochloride, iabetaloi hydrochloride, bretySium tosylate, dihydroergtamine mesylate, carvedϊfof, labetaSol, bretylium tosylate. phentoiamine mesylate, soiypertine tartrate, zolertine hydrochloride, candesartan ctlexetil, telmisartans candesartan; losartan potassium, benazepril hydrochloride, captopril, fosinoprii, moexipril hydrochloride, perindoprii erbumine, quinapril, ramipril, enalapril maleate, lisinopril, delapril, spirapril, detapril hydrochloride, libenzapril, pentopril, perindoprii 1 H-lndole-2-carboxylie acid, qumaprϋai spirapril hydrochloride, spiraprilat. tβprotide, zofenopril, amtodpne besySate, cJentiazem mateate, ssradipine, nimodipine, felodipine, nilvadipine; diltiazern hydrochforide! verapamil hydrochloride, teiudipine hydrochloride, beifosdil, fostedii, ranolazine, butoproztne hydrochloride, tosifen, molsidomine, ranolazine hydrochloride, tosifen, diltiazem hydrochloride, isosorbide dinitrate, sosorbide mononitrate, nitroglycerin, verapamil hydrochloride, chromonar, clonitate, droprenilamine, iidofiazine, prenylamine, propatyl nitrate, mioflazine hydrochloride, mixidine, molsidomine, isosorbide mononitrate, erythfityl tetranitrate, clonitrate, dipyridamole; nicorandil, pyhdinecarboxamide, nifedipine; perhexiline maleate; oxprenoloi, pentrinitroi, verapamil, althiazide, benzthiazide, buthiazide, chlorothiazide, spironolactone, triamterene, guanfacine hydrochloride, methyldopa- hydrochlorothiazide combined with Hydrochlorothiazide, methyldopa-chlorothiazide, clonidine hydrochloride, chlorthalidone, clonidine hydrochloride, clonidine, althiazide, benzthiazide, captoprii, carvediioi, chlorothiazide, clonidine hydrochloride, cyclothiazide, delapril hydrochloride, dilevalol hydrochloride, delapril hydrochloride, doxazosin mesylate, fostnopril sodium, moexipril hydrochloride, monatepϋ maleate, metoprolol succinate, guanfacine hydrochloride, methyldopa, quinaprilat, quinapril hydrochloride, primidolol, prazosin hydrochloride, pelanserin hydrochloride, phenoxybenzamine hydrochloride, candesartan cilexetil, telmisartan, candesartan, amlodipine maleate, terazosin hydrochloride, bevantolol hydrochloride or ramipril.
48. The method of claim 47 wherein the further chemotherapeutic agent is ezetimibe and, optionally, simvastatin.
49. The method of claim 44 wherein the antibody or antigen-binding fragment thereof is a humanized antibody.
50. A method for reducing: total cholesterol level; tow density lipoprotein cholesterol tevel; apoHpoprotein B level; total cholesterol/high density lipoprotein ratio; or low density lipoprotein/high density lipoprotein ratio; or for treating: hypercholesterolem ia; hyperlipictemia; hypertriglyceridaemia; sitosteroiemia, atherosclerosis; arteriosclerosis; coronary heart disease; vascular inflammation; or xanthoma, in a subject, comprising administering, to said subject, a therapeutically effective amount of the antibody or antigen-binding fragment thereof of claim 24.
51. The method of claim 50 wherein the antibody or antigen-binding fragment thereof of claim 1 in administered in association with a further chemotherapeutic agent.
52. The method of claim 51 wherein the further chemotherapeutic agent is a cardiovascular agent, an adrenergic blocker, an antihypertensive agent, an angiotensin system inhibitor, an angiotensin-converting enzyme inhibitor, a coronary vasodilator, a diuretic, an adrenergic stimulant or an HMG-CoA reductase inhibitor.
53. The method of claim 51 wherein the further chemotherapeutic agent is ezetimibe, lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, rivastatin, simvastatin, an azetidinone, bunofol hydrochloride, acebutoloi, alprenolol hydrochloride, atenolol, carteolol hydrochloride, celiprolol hydrochloride; cetamoiol hydrochloride, labetalol hydrochloride, esmolol hydrochloride, levobetaxolol hydrochloride, levobunolol hydrochloride, nadolol, practolol, propranolol hydrochloride, sotaloi hydrochloride, timolol, timolol maleate, bisoprolol; bisoprolol fumarate, nebivaloi, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetolol hydrochloride, dilevalol hydrochloride, exaproiol hydrochloride, flestotol sulfate, metalol hydrochloride, metoprolol 2-Propanol, metoprolol tartrate, pamatolol sulfate, penbutolol sulfate, practoloi, tiprenolol hydrochloride, toiamoioi fenspiride hydrochloride, proroxan, alfuzosin hydrochloride, labetaloS hydrochloride, bretylϊum tosylate, dshydroergtamine mesylate, carvedilol, labetaioi, bretylium tosylate, phentolamine mesylate, solypertine tartrate, zolertine hydrochloride, candesartan cilexetiL telmisartan, candesartan; losartan potassium, benazepril hydrochloride, captopril, fosinopril, moexipril hydrochloride, perindopril erbumine, quinapril, ramiprϊl, enalapril mateate, feϊnoprϋ, deiaprϊl, spiraprii, delaprii hydrochloride, litoenzaprif, pentopril, perindoprii 1 H-lndole-2-carboxyiic add, quϊnaprϊlai spsrapril hydrochloride, spiraprilat, teprofide, zofenopril, amtodtpine besylate, clentiazem snaleatβ, isradipine, nsmodipine, feiodipine, nϋvadipine; diitiazem hydrochloride, verapamil hydrochloride, teluclipine hydrochloride, belfosdil, fostedil, ranolazine, butoprozine hydrochloride, tosifen, molsidomine, ranolazine hydrochloride, tosifen, diltiazem hydrochloride, isosorbide dinitratβ, sosorbide mononitrate, nitroglycerin verapamil hydrochloride, chromonar, clonitate, droprenilamine, lidofiazine, prenylamine, propatyl nitrate, mioflazine hydrochloride, mtxidine, molsidomine, isosorbide mononitrate, erythrityl tetranitrate, cionitrate, dipyridamole; nicorandil, pyridinecarboxamide, nifedipine; perhexiline mateate; oxprenolol, pentrinitrol, verapamil, althiazide, benzthiazide, buthiazide, chlorothiazide, spironolactone, triamterene, guanfacine hydrochloride, methyldopa- hydrochlorothiazide combined with Hydrochlorothiazide, methyldopa-chlorothiazide, cfonidine hydrochloride, chlorthalidone, clonidine hydrochloride, clonidine, althiazide, benzthiazide, captoprii, carvedilol, chlorothiazide, clonidine hydrochloride, cyclothiazide, delapril hydrochloride, dilevalol hydrochloride, deiapril hydrochloride, doxazosin mesylate, fosinopril sodium, moexipril hydrochloride, monatepil maleate, metoprolol succinate, guanfacine hydrochloride, methytdopa, quinaprilat, quinapril hydrochloride, primidolol, prazosin hydrochloride, pelanserin hydrochloride, phenoxybenzamine hydrochloride, candesartan ciiexetil, telmisartan, candesartan, amlodipine maleate, terazosin hydrochloride, bevantoioi hydrochloride or ramipril.
54. The method of claim 53 wherein the further chemotherapeutic agent is ezetimibe and, optionally, simvastatin.
55. The method of claim 50 wherein the antibody or antigen-binding fragment thereof is a humanized antibody.
56. A method for producing an antibody or antigen-binding fragment therof of claim 1 comprising introducing one or more polynucleotides into one or more host cells; which polynucleotides encodes and direct expression of said heavy and/or fight chain immunoglobulins; and growing said host cells under conditions whereby said heavy and light chain immunoglobulins are expressed.
57. The method of claim 56 wherein said polynucleotide encoding and directing expression of said light chain and said polynucleotide encoding and directing expression of said heavy chain are in separate host cells.
PCT/US2008/081311 2007-10-26 2008-10-27 Anti-pcsk9 and methods for treating lipid and cholesterol disorders WO2009055783A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2010004454A MX2010004454A (en) 2007-10-26 2008-10-27 Anti-pcsk9 and methods for treating lipid and cholesterol disorders.
CN2008801235736A CN102232088A (en) 2007-10-26 2008-10-27 Anti-PCSK9 and methods for treating lipid and cholesterol disorders
EP08841231.7A EP2205639B1 (en) 2007-10-26 2008-10-27 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
JP2010531314A JP2011501952A (en) 2007-10-26 2008-10-27 Anti-PCSK9 and methods for treating lipid and cholesterol disorders
AU2008316587A AU2008316587B2 (en) 2007-10-26 2008-10-27 Anti-PCSK9 and methods for treating lipid and cholesterol disorders
US12/739,761 US8598320B2 (en) 2007-10-26 2008-10-27 Anti-PCSK9 and methods for treating lipid and cholesterol disorders
CA2703712A CA2703712A1 (en) 2007-10-26 2008-10-27 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
BRPI0818765A BRPI0818765A8 (en) 2007-10-26 2008-10-27 POLYPEPTIDE, ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, POLYNUCLEOTIDE, HOST CELL, VECTOR, COMPOSITION, USE AND METHOD FOR PRODUCING POLYPEPTIDE
NZ584902A NZ584902A (en) 2007-10-26 2008-10-27 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
IL205323A IL205323A0 (en) 2007-10-26 2010-04-25 Anti - pcsk9 and methods for treating lipid and cholesterol disorders
US14/094,560 US20140161798A1 (en) 2007-10-26 2013-12-02 Anti-pcsk9 and methods for treating lipid and cholesterol disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98292207P 2007-10-26 2007-10-26
US60/982,922 2007-10-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/739,761 A-371-Of-International US8598320B2 (en) 2007-10-26 2008-10-27 Anti-PCSK9 and methods for treating lipid and cholesterol disorders
US14/094,560 Continuation US20140161798A1 (en) 2007-10-26 2013-12-02 Anti-pcsk9 and methods for treating lipid and cholesterol disorders

Publications (2)

Publication Number Publication Date
WO2009055783A2 true WO2009055783A2 (en) 2009-04-30
WO2009055783A3 WO2009055783A3 (en) 2009-09-17

Family

ID=40261953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/081311 WO2009055783A2 (en) 2007-10-26 2008-10-27 Anti-pcsk9 and methods for treating lipid and cholesterol disorders

Country Status (13)

Country Link
US (2) US8598320B2 (en)
EP (1) EP2205639B1 (en)
JP (3) JP2011501952A (en)
KR (1) KR20100091191A (en)
CN (1) CN102232088A (en)
AU (1) AU2008316587B2 (en)
BR (1) BRPI0818765A8 (en)
CA (1) CA2703712A1 (en)
IL (1) IL205323A0 (en)
MX (1) MX2010004454A (en)
NZ (1) NZ584902A (en)
SG (2) SG2013014352A (en)
WO (1) WO2009055783A2 (en)

Cited By (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143367A2 (en) * 2008-05-22 2009-11-26 Schering Corporation Egf-a domain-mediated modulation of pcsk9
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9
WO2010029513A3 (en) * 2008-09-12 2010-07-15 Rinat Neuroscience Corporation Pcsk9 antagonists
WO2011027257A3 (en) * 2009-09-03 2011-06-30 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011117401A1 (en) * 2010-03-25 2011-09-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Use of pcsk9 as a vaccine for lowering cholesterol
US8030457B2 (en) 2007-08-23 2011-10-04 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP2450382A1 (en) * 2010-11-04 2012-05-09 Affiris AG Immunogenic peptide
US8188233B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1B20 PCSK9 antagonists
US8188234B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1D05 PCSK9 antagonists
WO2012071372A2 (en) 2010-11-23 2012-05-31 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor
US8206943B1 (en) 2008-06-30 2012-06-26 Schering Corporation Assay for PCSK9 inhibitors
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
CN102576018A (en) * 2009-10-30 2012-07-11 默沙东公司 Pcsk9 immunoassay
CN102596249A (en) * 2009-10-30 2012-07-18 默沙东公司 AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (en) * 2009-10-30 2012-08-15 默沙东公司 AX213 and AX132 PCSK9 antagonists and variants
WO2012146776A1 (en) * 2011-04-29 2012-11-01 Sanofi Test systems and methods for identifying and characterising lipid lowering drugs
WO2012101252A3 (en) * 2011-01-28 2012-11-15 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
WO2012154999A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders
US8344114B2 (en) 2006-11-07 2013-01-01 Merck Sharp & Dohme Corp. Antagonists of PCSK9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
US8530414B2 (en) 2011-09-16 2013-09-10 Eli Lilly And Company Antibodies to PCSK9 and uses thereof
WO2013166448A1 (en) * 2012-05-03 2013-11-07 Amgen Inc. Stable formulations containing anti-pcsk9 antibodies
EP2615113A3 (en) * 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP2667197A1 (en) 2012-05-25 2013-11-27 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
WO2013188855A1 (en) * 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
CN103562227A (en) * 2011-02-11 2014-02-05 Irm责任有限公司 Pcsk9 antagonists
EP2703009A1 (en) * 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
WO2014081780A1 (en) 2012-11-21 2014-05-30 Amgen Inc. Drug delivery device
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2014143770A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Body contour adaptable autoinjector device
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
WO2014150983A2 (en) * 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
AU2013200743B2 (en) * 2008-09-12 2014-10-30 Pfizer Inc. PCSK9 antagonists
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
WO2015054441A1 (en) * 2013-10-09 2015-04-16 Research Development Foundation Monoclonal olfml-3 antibodies and uses thereof
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015061386A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Injector and method of assembly
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
DE202014010499U1 (en) 2013-12-17 2015-10-20 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
WO2015187793A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Drug delivery system and method of use
EP2975059A1 (en) 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
WO2016008899A1 (en) 2014-07-15 2016-01-21 Kymab Limited Targeting human pcsk9 for cholesterol treatment
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016044337A1 (en) 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
DE202015009002U1 (en) 2014-07-15 2016-08-18 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
AU2015200427B2 (en) * 2008-09-12 2016-11-10 Pfizer Inc. PCSK9 antagonists
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US9724411B2 (en) 2008-12-15 2017-08-08 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
US10076571B2 (en) 2011-09-16 2018-09-18 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
WO2018183039A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
WO2019040548A1 (en) 2017-08-22 2019-02-28 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US10472425B2 (en) 2011-07-28 2019-11-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
WO2019231582A1 (en) 2018-05-30 2019-12-05 Amgen Inc. Thermal spring release mechanism for a drug delivery device
WO2019231618A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
WO2020081479A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020150474A1 (en) * 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2020150473A3 (en) * 2019-01-18 2021-02-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP4467563A1 (en) * 2023-05-23 2024-11-27 JLP Health GmbH Ldlr derived polypeptides for anti-viral uses
WO2024240848A1 (en) * 2023-05-23 2024-11-28 Jlp Health Gmbh Ldlr derived polypeptides for anti-viral uses
US12209128B2 (en) 2016-06-20 2025-01-28 Kymab Limited Anti-PD-L1 antibodies

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442868B2 (en) 2013-03-14 2019-10-15 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis B virus infections by administering receptor associated protein (RAP)
US20150037816A1 (en) * 2013-08-01 2015-02-05 Atherotech, Inc. PCSK9 Function Assay
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
CN104558199B (en) * 2014-09-05 2018-07-06 成都康弘生物科技有限公司 A kind of fusion protein preparation for treating hypercholesterolemia and application thereof
BR112017020091A2 (en) * 2015-03-20 2018-11-06 Aarhus Universitet pcsk9 inhibitors for treatment of lipoprotein metabolism disorders
CN106589127A (en) * 2015-10-16 2017-04-26 钜川生物医药 PCSK9 antibody, preparation method and application thereof
CN105214087B (en) * 2015-10-29 2017-12-26 陈敏 PCSK9 monoclonal antibodies are preparing the application in treating inflammatory-immune diseases medicine
WO2018052789A1 (en) * 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
CN109897110B (en) * 2017-12-08 2022-05-17 深圳华大生命科学研究院 Nano antibody and preparation method thereof
JP6639463B2 (en) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド Methods of treating homozygous familial hypercholesterolemia
CA3093469A1 (en) * 2018-03-09 2019-09-12 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
JP2023501745A (en) * 2019-11-18 2023-01-18 エーディー ファーマシューティカルズ カンパニー，リミティド Anti-PCSK9 antibody and uses thereof
KR20210158693A (en) * 2020-06-24 2021-12-31 바이오스트림테크놀러지스(주) Anti pcsk9 antibody and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057459A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057457A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057458A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008125623A2 (en) * 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057459A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057457A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057458A2 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008125623A2 (en) * 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENJANNET SUZANNE ET AL: "The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 281, no. 41, 13 October 2006 (2006-10-13), pages 30561-30572, XP002508324 ISSN: 0021-9258 [retrieved on 2006-08-15] *
CAYMAN CHEMICAL COMPANY: "Material Safety Data Sheet PCSK9 (human) Polyclonal Antibody" INTERNET CITATION 26 July 2007 (2007-07-26), pages 1-3, XP002517276 Retrieved from the Internet: URL:http://www.caymaneurope.com/msdss/10007185m.pdf> [retrieved on 2009-02-27] *
CAYMAN CHEMICAL COMPANY: "Material Safety Data Sheet PCSK9 (murine) Polyclonal Antibody" INTERNET CITATION 5 September 2007 (2007-09-05), pages 1-4, XP002517275 Retrieved from the Internet: URL:http://www.caymaneurope.com/msdss/10008811m.pdf> [retrieved on 2009-02-27] *
CAYMAN CHEMICAL COMPANY: "Product Information PCSK9 (murine) Polyclonal Antibody Catalog No. 10008811" INTERNET CITATION 12 December 2007 (2007-12-12), pages 1-2, XP002517273 Retrieved from the Internet: URL:http://www.caymaneurope.com/pdfs/10008811.pdf> [retrieved on 2009-02-27] *
CAYMAN CHEMICAL COMPANY: "Product Information PCSK9 Polyclonal Antibody Catalog No. 10007185" INTERNET CITATION 10 December 2007 (2007-12-10), pages 1-2, XP002517274 Retrieved from the Internet: URL:http://www.caymaneurope.com/pdfs/10007185.pdf> [retrieved on 2009-02-27] *
HORTON ET AL: "Molecular biology of PCSK9: its role in LDL metabolism" TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, vol. 32, no. 2, 6 February 2007 (2007-02-06), pages 71-77, XP005876225 ISSN: 0968-0004 *
LAGACE THOMAS A ET AL: "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 116, no. 11, 1 November 2006 (2006-11-01), pages 2995-3005, XP002493243 ISSN: 0021-9738 *
See also references of EP2205639A2 *

Cited By (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8344114B2 (en) 2006-11-07 2013-01-01 Merck Sharp & Dohme Corp. Antagonists of PCSK9
US9920134B2 (en) 2007-08-23 2018-03-20 Amgen Inc. Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en) 2007-08-23 2014-11-11 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8563698B2 (en) 2007-08-23 2013-10-22 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en) 2007-08-23 2015-03-17 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP2615114A3 (en) * 2007-08-23 2013-11-20 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8889834B2 (en) 2007-08-23 2014-11-18 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8030457B2 (en) 2007-08-23 2011-10-04 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP2615113A3 (en) * 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8168762B2 (en) 2007-08-23 2012-05-01 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP2215124B1 (en) 2007-08-23 2016-02-24 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US9056915B2 (en) 2007-08-23 2015-06-16 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
EP3666797B1 (en) 2007-08-23 2023-05-17 Amgen, Inc Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
US8871914B2 (en) 2007-08-23 2014-10-28 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9045547B2 (en) 2007-08-23 2015-06-02 Amgen Inc. Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en) 2007-08-23 2016-11-15 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8957194B2 (en) 2008-02-07 2015-02-17 Merck Sharpe & Dohme Corp. 1B20 PCSK9 antagonists
US8188234B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1D05 PCSK9 antagonists
US8188233B2 (en) 2008-02-07 2012-05-29 Merck Sharp & Dohme Corp. 1B20 PCSK9 antagonists
US8697070B2 (en) 2008-02-07 2014-04-15 Merck Sharp & Dohme Corp. 1D05 PCSK9 antagonists
US9089522B2 (en) 2008-05-22 2015-07-28 Merck Sharp & Dohme Corp. Method of reducing total cholesterol level by administering matrilin-2 polypeptide
WO2009143367A2 (en) * 2008-05-22 2009-11-26 Schering Corporation Egf-a domain-mediated modulation of pcsk9
US20110150875A1 (en) * 2008-05-22 2011-06-23 Qing Zhang Egf-a domain-mediated modulation of pcks9 for treating lipid disorders
WO2009143367A3 (en) * 2008-05-22 2010-08-12 Schering Corporation Egf-a domain-mediated modulation of pcsk9 for treating lipid disorders
US8206943B1 (en) 2008-06-30 2012-06-26 Schering Corporation Assay for PCSK9 inhibitors
AU2013200743B2 (en) * 2008-09-12 2014-10-30 Pfizer Inc. PCSK9 antagonists
US9175093B2 (en) 2008-09-12 2015-11-03 Rinat Neuroscience Corp. PCSK9 antagonists
KR101230675B1 (en) * 2008-09-12 2013-02-13 화이자 인코포레이티드 Pcsk9 antagonists
US8399646B2 (en) 2008-09-12 2013-03-19 Rinat Neuroscience Corp. Isolated nucleic acid encoding an antibody which specifically binds to PCSK9 and a host cell that produces the antibody
US8426363B2 (en) 2008-09-12 2013-04-23 Rinat Neuroscience Corp. Method for reducing a level of LDL-cholesterol by an antibody that specifically binds to PCSK9
US8080243B2 (en) 2008-09-12 2011-12-20 Rinat Neuroscience Corp. Isolated antibody which specifically binds to PCSK9
WO2010029513A3 (en) * 2008-09-12 2010-07-15 Rinat Neuroscience Corporation Pcsk9 antagonists
RU2618869C2 (en) * 2008-09-12 2017-05-11 Ринат Ньюросайенс Корпорейшн Pcsk9 antagonists
AU2015200427B2 (en) * 2008-09-12 2016-11-10 Pfizer Inc. PCSK9 antagonists
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9
US9550837B2 (en) 2008-12-15 2017-01-24 Regeneron Pharmaceuticals, Inc. Therapeutic uses of anti-PCSK9 antibodies
EP2358756B1 (en) 2008-12-15 2017-01-11 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to pcsk9
US8501184B2 (en) 2008-12-15 2013-08-06 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to PCSK9
EP3156422A3 (en) * 2008-12-15 2017-07-05 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to pcsk9
US9724411B2 (en) 2008-12-15 2017-08-08 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
US8062640B2 (en) 2008-12-15 2011-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to PCSK9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US10941210B2 (en) 2008-12-15 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
EP3943510A3 (en) * 2008-12-15 2022-04-20 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to pcsk9
US10023654B2 (en) 2008-12-15 2018-07-17 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
AU2010290931B2 (en) * 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
KR101660578B1 (en) * 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 PCSK9 vaccine
KR101512053B1 (en) * 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Pcsk9 vaccine
WO2011027257A3 (en) * 2009-09-03 2011-06-30 Pfizer Vaccines Llc Pcsk9 vaccine
KR20140004263A (en) * 2009-09-03 2014-01-10 화이자 백신스 엘엘씨 Pcsk9 vaccine
EP2865752A1 (en) * 2009-09-03 2015-04-29 Pfizer Vaccines LLC PCSK9 vaccine
US9481875B2 (en) 2009-09-03 2016-11-01 Pfizer Vaccines Llc PCSK9 vaccine
US8889144B2 (en) 2009-09-03 2014-11-18 Pfizer Vaccines Llc PCSK9 vaccine
US9987341B2 (en) 2009-09-03 2018-06-05 Pfizer Vaccines Llc PCSK9 vaccine
EP3358008A1 (en) * 2009-09-03 2018-08-08 Pfizer Vaccines LLC Pcsk9 vaccine
EP2493505A4 (en) * 2009-10-30 2013-06-12 Merck Sharp & Dohme ANTAGONISTS OF PCSK9 WITH FAB AX189 AND AX1 ANTIBODIES AND VARIANTS THEREOF
EP2493505A1 (en) * 2009-10-30 2012-09-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
EP2493507A4 (en) * 2009-10-30 2013-11-20 Merck Sharp & Dohme ANTAGONISTS AND VARIANTS AX213 AND AX132 PCSK9
CN102596249A (en) * 2009-10-30 2012-07-18 默沙东公司 AX1 and AX189 PCSK9 antagonists and variants
EP2493507A2 (en) * 2009-10-30 2012-09-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
US8877900B2 (en) 2009-10-30 2014-11-04 Merck Sharp & Dohme Corp. AX132 PCSK9 antagonists
CN102576018A (en) * 2009-10-30 2012-07-11 默沙东公司 Pcsk9 immunoassay
CN102639150A (en) * 2009-10-30 2012-08-15 默沙东公司 AX213 and AX132 PCSK9 antagonists and variants
WO2011117401A1 (en) * 2010-03-25 2011-09-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Use of pcsk9 as a vaccine for lowering cholesterol
EP2450382A1 (en) * 2010-11-04 2012-05-09 Affiris AG Immunogenic peptide
WO2012059573A1 (en) * 2010-11-04 2012-05-10 Affiris Ag Immunogenic peptide
CN103314011A (en) * 2010-11-23 2013-09-18 瑞泽恩制药公司 Human antibodies to the glucagon receptor
EA029669B1 (en) * 2010-11-23 2018-04-30 Регенерон Фармасьютикалс, Инк. Human antibodies to the glucagon receptor
US11498970B2 (en) 2010-11-23 2022-11-15 Regeneron Pharmaceuticals, Inc. Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels
EP3608338A1 (en) 2010-11-23 2020-02-12 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor
WO2012071372A3 (en) * 2010-11-23 2013-01-03 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor
WO2012071372A2 (en) 2010-11-23 2012-05-31 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor
CN103314011B (en) * 2010-11-23 2015-11-25 瑞泽恩制药公司 People's antibody of glucagon receptor
AU2011331998B2 (en) * 2010-11-23 2016-07-21 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor
US9127068B2 (en) 2010-11-23 2015-09-08 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding human glucagon receptor antibodies
US10233250B2 (en) 2010-11-23 2019-03-19 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels
US8545847B2 (en) 2010-11-23 2013-10-01 Regeneron Pharmaceuticals, Inc. Human antibodies to the human glucagon receptor and methods of use thereof
US9358287B2 (en) 2010-11-23 2016-06-07 Regeneron Pharmaceuticals, Inc. Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US9587029B2 (en) 2010-11-23 2017-03-07 Regeneron Pharmaceuticals, Inc. Human antibodies to the glucagon receptor and methods of use thereof
JP2014511106A (en) * 2010-12-22 2014-05-08 ジェネンテック， インコーポレイテッド Anti-PCSK9 antibody and method of use
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EP3395836A1 (en) * 2011-01-28 2018-10-31 Sanofi Biotechnology Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
AU2012210480B2 (en) * 2011-01-28 2017-05-18 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US11246925B2 (en) 2011-01-28 2022-02-15 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US9682013B2 (en) 2011-01-28 2017-06-20 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to PCSK9
WO2012101252A3 (en) * 2011-01-28 2012-11-15 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US9561155B2 (en) 2011-01-28 2017-02-07 Sanofi Biotechnology Method of reducing cholesterol levels using a human anti-PCSK9 antibody
CN103562227A (en) * 2011-02-11 2014-02-05 Irm责任有限公司 Pcsk9 antagonists
WO2012146776A1 (en) * 2011-04-29 2012-11-01 Sanofi Test systems and methods for identifying and characterising lipid lowering drugs
IL288048B1 (en) * 2011-05-10 2024-05-01 Amgen Inc Methods of treating or preventing cholesterol related disorders
AU2012253434B2 (en) * 2011-05-10 2017-07-06 Amgen Inc. Methods of treating or preventing cholesterol related disorders
EP3597218A1 (en) * 2011-05-10 2020-01-22 Amgen, Inc Methods of treating or preventing cholesterol related disorders
EA031228B1 (en) * 2011-05-10 2018-12-28 Амген Инк. Stable formulation comprising pcsk9 antibodies and the use thereof for treating or preventing cholesterol related disorders
IL288048B2 (en) * 2011-05-10 2024-09-01 Amgen Inc Methods for treating or preventing cholesterol-related disorders
WO2012154999A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders
CN103841992B (en) * 2011-05-10 2021-08-13 美国安进公司 Methods of treating or preventing cholesterol-related diseases
CN103841992A (en) * 2011-05-10 2014-06-04 安姆根有限公司 Methods of treating or preventing cholesterol related disorders
CN113786482A (en) * 2011-05-10 2021-12-14 美国安进公司 Methods of treating or preventing cholesterol-related disorders
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10472425B2 (en) 2011-07-28 2019-11-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10752701B2 (en) 2011-07-28 2020-08-25 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10076571B2 (en) 2011-09-16 2018-09-18 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US11116839B2 (en) 2011-09-16 2021-09-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US8530414B2 (en) 2011-09-16 2013-09-10 Eli Lilly And Company Antibodies to PCSK9 and uses thereof
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
CN104169304A (en) * 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 Single domain antibodies as inhibitors of PCSK9
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
EP3656399A1 (en) * 2012-05-03 2020-05-27 Amgen, Inc Stable formulations containing anti-pcsk9 antibodies
CN112390888A (en) * 2012-05-03 2021-02-23 安姆根有限公司 Stable formulations containing anti-PCSK 9 antibodies
WO2013166448A1 (en) * 2012-05-03 2013-11-07 Amgen Inc. Stable formulations containing anti-pcsk9 antibodies
US10259885B2 (en) 2012-05-08 2019-04-16 Alderbio Holdings Llc Anti-PCSK9 antibodies and use thereof
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2844673A4 (en) * 2012-05-08 2016-04-20 Alderbio Holdings Llc Anti-pcsk9 antibodies and use thereof
CN104508488A (en) * 2012-05-25 2015-04-08 佐拉生物科学公司 Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibition
WO2013175016A1 (en) 2012-05-25 2013-11-28 Zora Biosciences Oy Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibition
EP2667197A1 (en) 2012-05-25 2013-11-27 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
WO2013188855A1 (en) * 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
CN104364266A (en) * 2012-06-15 2015-02-18 霍夫曼-拉罗奇有限公司 Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
EP2703009A1 (en) * 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
US11458247B2 (en) 2012-11-21 2022-10-04 Amgen Inc. Drug delivery device
US11439745B2 (en) 2012-11-21 2022-09-13 Amgen Inc. Drug delivery device
EP4234694A2 (en) 2012-11-21 2023-08-30 Amgen Inc. Drug delivery device
US11344681B2 (en) 2012-11-21 2022-05-31 Amgen Inc. Drug delivery device
EP3072548A1 (en) 2012-11-21 2016-09-28 Amgen, Inc Drug delivery device
US10682474B2 (en) 2012-11-21 2020-06-16 Amgen Inc. Drug delivery device
EP3656426A1 (en) 2012-11-21 2020-05-27 Amgen, Inc Drug delivery device
US12115341B2 (en) 2012-11-21 2024-10-15 Amgen Inc. Drug delivery device
WO2014081780A1 (en) 2012-11-21 2014-05-30 Amgen Inc. Drug delivery device
EP3081249A1 (en) 2012-11-21 2016-10-19 Amgen, Inc Drug delivery device
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
WO2014150983A3 (en) * 2013-03-15 2014-12-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014143770A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Body contour adaptable autoinjector device
WO2014150983A2 (en) * 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP3831427A1 (en) 2013-03-22 2021-06-09 Amgen Inc. Injector and method of assembly
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10995150B2 (en) 2013-06-07 2021-05-04 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US10808026B2 (en) 2013-10-09 2020-10-20 Research Development Foundation Monoclonal Olfml-3 antibodies and uses thereof
WO2015054441A1 (en) * 2013-10-09 2015-04-16 Research Development Foundation Monoclonal olfml-3 antibodies and uses thereof
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3501575A1 (en) 2013-10-24 2019-06-26 Amgen, Inc Drug delivery system with temperature-sensitive-control
EP3421066A1 (en) 2013-10-24 2019-01-02 Amgen, Inc Injector and method of assembly
EP3789064A1 (en) 2013-10-24 2021-03-10 Amgen, Inc Injector and method of assembly
WO2015061386A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Injector and method of assembly
EP3957345A1 (en) 2013-10-24 2022-02-23 Amgen, Inc Drug delivery system with temperature-sensitive control
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US10611849B2 (en) 2013-12-17 2020-04-07 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US10618971B2 (en) 2013-12-17 2020-04-14 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9040052B1 (en) 2013-12-17 2015-05-26 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8951523B1 (en) 2013-12-17 2015-02-10 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
DE202014010421U1 (en) 2013-12-17 2015-11-12 Kymab Limited Human goals
US11434305B2 (en) 2013-12-17 2022-09-06 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
DE202014010499U1 (en) 2013-12-17 2015-10-20 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US11773175B2 (en) 2014-03-04 2023-10-03 Kymab Limited Antibodies, uses and methods
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
EP3785749A1 (en) 2014-05-07 2021-03-03 Amgen Inc. Autoinjector with shock reducing elements
EP4036924A1 (en) 2014-06-03 2022-08-03 Amgen, Inc Devices and methods for assisting a user of a drug delivery device
WO2015187793A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Drug delivery system and method of use
WO2015187797A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Controllable drug delivery system and method of use
WO2015187799A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Systems and methods for remotely processing data collected by a drug delivery device
US11992659B2 (en) 2014-06-03 2024-05-28 Amgen Inc. Controllable drug delivery system and method of use
EP4362039A2 (en) 2014-06-03 2024-05-01 Amgen Inc. Controllable drug delivery system and method of use
US11738146B2 (en) 2014-06-03 2023-08-29 Amgen Inc. Drug delivery system and method of use
US11213624B2 (en) 2014-06-03 2022-01-04 Amgen Inc. Controllable drug delivery system and method of use
DE202015009002U1 (en) 2014-07-15 2016-08-18 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
US9068012B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
DE202015009007U1 (en) 2014-07-15 2016-08-19 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
DE202015009006U1 (en) 2014-07-15 2016-08-19 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9394568B2 (en) 2014-07-15 2016-07-19 Kymab Limited Methods of treating anaemia
DE202015008988U1 (en) 2014-07-15 2016-06-30 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
DE202015008974U1 (en) 2014-07-15 2016-06-30 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9303089B2 (en) 2014-07-15 2016-04-05 Kymab Limited Methods of treating anaemia
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia
US10711059B2 (en) 2014-07-15 2020-07-14 Kymab Limited Methods for treating neurodegenerative diseases using anti-PD-L1 antibodies
US11555066B2 (en) 2014-07-15 2023-01-17 Kymab Limited Precision medicine for cholesterol treatment
WO2016008899A1 (en) 2014-07-15 2016-01-21 Kymab Limited Targeting human pcsk9 for cholesterol treatment
EP2975059A1 (en) 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US10618955B2 (en) 2014-07-15 2020-04-14 Kymab Limited Methods for treating neurodegenerative disease using anti-PD-1 antibodies
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
WO2016044337A1 (en) 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
EP3943135A2 (en) 2014-10-14 2022-01-26 Amgen Inc. Drug injection device with visual and audible indicators
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
US10765801B2 (en) 2014-12-19 2020-09-08 Amgen Inc. Drug delivery device with proximity sensor
US11944794B2 (en) 2014-12-19 2024-04-02 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3556411A1 (en) 2015-02-17 2019-10-23 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
EP3721922A1 (en) 2016-03-15 2020-10-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US12209128B2 (en) 2016-06-20 2025-01-28 Kymab Limited Anti-PD-L1 antibodies
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
EP4241807A2 (en) 2017-03-28 2023-09-13 Amgen Inc. Plunger rod and syringe assembly system and method
WO2018183039A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
EP4512445A2 (en) 2017-03-28 2025-02-26 Amgen Inc. Plunger rod and syringe assembly system
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
EP4292576A2 (en) 2017-07-21 2023-12-20 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
WO2019040548A1 (en) 2017-08-22 2019-02-28 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP4257164A2 (en) 2017-10-06 2023-10-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
WO2019231582A1 (en) 2018-05-30 2019-12-05 Amgen Inc. Thermal spring release mechanism for a drug delivery device
WO2019231618A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
WO2020081479A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020150474A1 (en) * 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
WO2020150473A3 (en) * 2019-01-18 2021-02-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN113574055A (en) * 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 PCSK9 inhibitors and methods of use
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
EP4467563A1 (en) * 2023-05-23 2024-11-27 JLP Health GmbH Ldlr derived polypeptides for anti-viral uses
WO2024240848A1 (en) * 2023-05-23 2024-11-28 Jlp Health Gmbh Ldlr derived polypeptides for anti-viral uses

Also Published As

Publication number Publication date
CA2703712A1 (en) 2009-04-30
NZ584902A (en) 2012-03-30
WO2009055783A3 (en) 2009-09-17
SG2013014352A (en) 2014-09-26
US8598320B2 (en) 2013-12-03
CN102232088A (en) 2011-11-02
SG188814A1 (en) 2013-04-30
KR20100091191A (en) 2010-08-18
MX2010004454A (en) 2010-07-28
JP5692867B2 (en) 2015-04-01
AU2008316587A1 (en) 2009-04-30
EP2205639B1 (en) 2015-12-23
IL205323A0 (en) 2010-12-30
JP2013091655A (en) 2013-05-16
AU2008316587B2 (en) 2014-07-17
JP2013213057A (en) 2013-10-17
BRPI0818765A8 (en) 2016-02-10
US20110033465A1 (en) 2011-02-10
JP2011501952A (en) 2011-01-20
EP2205639A2 (en) 2010-07-14
BRPI0818765A2 (en) 2015-04-22
US20140161798A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
EP2205639B1 (en) Anti-pcsk9 and methods for treating lipid and cholesterol disorders
US20210047434A1 (en) Methods of treating or preventing cholesterol related disorders
US8883983B2 (en) Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
WO2012054438A1 (en) Anti-pcsk9
US20140030270A1 (en) Methods of treating or preventing cholesterol related disorders
US20150004174A1 (en) Methods for treating homozygous familial hypercholesterolemia
US9089522B2 (en) Method of reducing total cholesterol level by administering matrilin-2 polypeptide
JP2015519050A5 (en)
US20140004122A1 (en) Methods for treating or preventing cholesterol related disorders
AU2020201012A1 (en) Methods for treating homozygous familial hypercholesterolemia
EP3560961A1 (en) Anti-pcsk9 antibody and application thereof
JP2020015731A (en) Human lcat antigen binding proteins and their use in therapeutic methods
EP2615114B1 (en) Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8257921B1 (en) NRIP1 regulation of apolipoprotein A1
WO2021142253A1 (en) Anti-angiotensin ii type 1 receptor (agtr1) binding proteins
NZ734570B2 (en) Methods of treating or preventing cholesterol related disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880123573.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841231

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2349/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2703712

Country of ref document: CA

Ref document number: 2010531314

Country of ref document: JP

Ref document number: MX/A/2010/004454

Country of ref document: MX

Ref document number: 12010500897

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 205323

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 584902

Country of ref document: NZ

Ref document number: 2008841231

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107011280

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008316587

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008316587

Country of ref document: AU

Date of ref document: 20081027

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12739761

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0818765

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100427